take a position here for a mid term plat at least.iIts in the Bio tech sector and priced right right now under .05. and with the new Avian flu issue on the rise this may be a good player. Hard as hell to buy though.
the Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates.
HEADLINES Change Display [ hide $$ edit ] • CalbaTech Advisory Member Contributes Stem Cell Intellectual Property, Ranging From Banking of Stem Cells to Regeneration of Tissues PR Newswire (Thu 5:00am) • CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of Stem Cell Collection and Storage Service PR Newswire (Wed 5:00am) • CALBATECH INC Financials EDGAR Online Financials (Tue, Sep 20) • CALBATECH INC Files SEC form 10KSB/A, Annual Report EDGAR Online (Tue, Sep 13) • CalbaTech Announces Significant Six-Month Revenue Increase, Details the Company's Expectations for LifeStem Inc., Its Adult Stem Cell Subsidiary PR Newswire (Fri, Aug 12) • CalbaTech Announces Expansion At K-D Medical, Leading Manufacturer of Microbiological and Cell Culture Media, Allowing it to Significantly Grow the Business PR Newswire (Thu, Aug 11) • CalbaTech, Inc. Retains AGORACOM.Com to Expand Investor Awareness PR Newswire (Tue, Aug 2) • CALBATECH INC Files SEC form 8-K/A, Entry into Material Agreement, Financial Statements and Exhibits EDGAR Online (Tue, Jun 2 • CALBATECH INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online (Fri, Jun 3) • CALBATECH INC Files SEC form 10KSB/A, Annual Report EDGAR Online (Mon, May 23)
Posted by QuestSolver on :
the Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates.
had to move my buy up 3 times already and still only got a partial fill,guess because of the low low float!
Posted by permanentjaun on :
You missed the play on it yesterday. It showed up on one of dardadogs morning runners after it gapped. Matt
Posted by QuestSolver on :
GREAT bio play under .05 so far,look at the chart history,this is a all time low pretty much and watching the news on the Avian flu I think many bio's are getting jiggy soon.The Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates.
About CalbaTech
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board, that intend to contribute innovation in areas of biological discovery.
Contact: Paul Knopick (949) 707-5365 pknopick*eandecommunications.com
Posted by QuestSolver on :
yes perm but I take all the time neede to DD each investment for a mid to long term play,not into flipping.
Posted by Superbee383 on :
With everything going on about stem cell research and the scare of the Avian flu, this definitely sounds interesting.
CalbaTech Advisory Member Contributes Stem Cell Intellectual Property, Ranging From Banking of Stem Cells to Regeneration of Tissues PR Newswire - October 06, 2005 05:00
IRVINE, Calif., Oct 06, 2005 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced that Dr. Jason Van Tassel has provided three pieces of stem cell related intellectual property to CalbaTech's wholly owned subsidiary LifeStem, Inc. Earlier this week, LifeStem announced that it is finalizing plans to offer a stem cell collection and storage service in selected markets.
"We're pleased to have the support and contribution of Dr. Van Tassel," said CalbaTech CEO James DeOlden. "All three pieces of intellectual property complement our efforts in the stem cell arena and we're focused on developing them through our stem cell subsidiary LifeStem," Mr. DeOlden added.
The three pieces of intellectual property contributed by Dr. Van Tassel are related to therapeutic uses of autologous adult stem cells, and range from intellectual property related to the banking of stem cells to regeneration of tissue through the use of stem cells. The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office.
Dr. Van Tassel previously developed a novel method of injecting stem cells into diseased tissue through the use of a modified endoscope for which the company has filed for patent protection.
About CalbaTech
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. It is concentrating on acquiring, incubating and developing early stage life science based companies that are developing next generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute breakthrough innovation in areas of biological discovery.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc.
Posted by permanentjaun on :
Gotcha, best of luck with it. Matt
Posted by QuestSolver on :
15375 Barranca Parkway, Suite I101, Irvine, California 92618 (Address of principal executive offices) (Zip Code)
Company's telephone number: (949) 450-9910
Posted by QuestSolver on :
for you chart specialist,check out this 3 year chart....does this have recovery spike all over it or what!
overall average is about .175
Posted by prefect on :
I still feel the same way about this as I did when I posted it yesterday...guess the thread got buried.
Posted by QuestSolver on :
Deciphering Stem-Cell Semantics
THE STEM-CELL LEGISLATION that has sparked controversy in Washington and rekindled the debate about when life begins also presents a puzzle to investors. Put your money in a company that could benefit from additional federal funding, and you run the risk of President Bush fulfilling his promise to veto any bill that would finance the related research. But sit this one out, and the legislation could eventually push through in one form or another, allowing public companies that conduct such research to capitalize on the government's deep coffers. What's a biotech investor to do? The answer may be to toe the line between the controversial and the ground-breaking. By investing in companies that conduct stem-cell research not involving contentious embryonic stem cells, investors can hedge their bets, taking advantage of the added attention to the field while relying on a more conventional capital model: One that doesn't depend on the president's signature.
Aastrom Biosciences (ASTM) is such a company. It's conducting adult stem-cell research that doesn't require the destruction of the human embryo, thus insulating itself from the debates over which research deserves federal funding. Perhaps more importantly to investors, the 14-year-old company has begun to make progress on commercial products and has successfully treated patients with at least one of them in midstage clinical trials. Although these aren't the miracle cures for paralysis or Alzheimer's disease that many expected stem-cell research to deliver — most scientists agree treatments for those conditions will require embryonic stem cells — Aastrom has come up with some promising solutions for lesser maladies such as bone fractures and vascular damage.
With no drugs on the market yet — and approvals from the Food and Drug Administration still likely years away — revenues remain scarce. For its fiscal third quarter ended March 31, Aastrom pulled in just $252,000 from grants and sales of therapy kits to other researchers. The company's loss for the period added up to $3.3 million, or three cents a share. At quarter's end the company was sitting on $35.4 million in cash and short-term investments.
SmartMoney.com sat down with Aastrom Chief Executive Doug Armstrong to discuss how the company got started, what its products may soon do for patients, how its fundamentals measure up to its peers', and what in blazes its name means. Here's what he had to say.
SmartMoney.com: How did the company get started and become involved in stem-cell research?
Doug Armstrong: A team at the University of Michigan had developed an approach to be able to take a small amount of human tissue, particularly human bone marrow, and to culture it outside of the body so that it would grow in a normal way. And as part of that process, the stem cells that are found in bone marrow would replicate and grow as well. And that was pretty unique because there were a host of companies, even in the early '90s, that were trying to figure out how to grow stem cells found in the body, and there were a variety of approaches taken. Out of all of those companies in the '90s... we're the only ones with our doors open. They all shut down. And that was, I believe, fundamentally because the approach that was in that founding technology worked. In other words, it actually allowed us to grow these normal human cells and produce them in a way that they retained their functionality as tissue-forming cells, so that when you put them back into patients, they would function. They would form tissue. In all the other approaches that were employed where cells were put back into patients, they didn't grow tissues.
That's an interesting perspective which serves to illustrate a couple things. One is, it's not easy to grow these normal cells and have them retain their functionality when you want to use them for a therapeutic reason. And secondly, it's why stem cells from bone marrow got such a bad name — because there were all of these failures in trying to be able to access them, grow them and then utilize them clinically.
SM: Where do you get the stem cells that you use for patient treatments?
DA: They all come from the patient. Now, they could be regulated by the FDA and by EMEA in Europe as drug. They're biologics — biologic drugs — so they will have approvals. They will have labeling. They will have reimbursement codes — all of those things identical to drugs. There's one big difference, and that's the manufacturing, and this has been a real barrier to entry for many groups. It comes down to this: Usually if you're going to treat 100,000 patients with a drug, one lot of drug is manufactured and put in 100,000 vials and shipped out. In our case, we have 100,000 manufacturing runs, not one, because every manufacturing run is patient-specific.
We have worked hard to have a fully automated manufacturing process. And with that automation, we've built into modularity, so that we can go anywhere in the world right now and do pilot manufacturing locations for trials. Then, as we go into larger trials, and then into commercialization, manufacturing will actually be brought back into centralized manufacturing facilities, where we'll have the same platform automation technology.
So, the process works where the physician would write a prescription for cells. When the patient is going around for the blood test and the urine test and things like that, a small amount of marrow would be aspirated in an outpatient procedure [and] dropped in a shipping container that goes right to the manufacturing facility. The manufacturing facility provides it back to the hospital pharmacy, and it's available at that hospital when it needs to be used by the patient.
Part of the difficulty in seeing the vision is that there are certain things that aren't done today that will be done when this becomes a product. It's just like the central labs for pulling blood. In the old days, each physician did it. Now, they just go to a lab. That would just be part of our business — either integrating one of those labs or clinics, or we would hope to work with hospitals to help expand that need. So, there are certain things that are new here. You can't just plug-and-play.
SM: How long does that process take?
DA: It's a 12-day process. We have over the years worked it out so that it is the same process for every patient, and we have worked out the procedure so that every patient will have the product. That's been another big, big hurdle in our field, is how do you productize these cells? It's one thing to show that you have cells that can in a laboratory do this or that or have the capability to perform in a certain way. It's a whole other thing to turn that into a standard medical product that's going to be used for patients all over the world. And that's been a very difficult hurdle to clear for many groups, and it was for us early on, but we've had a number of years to be able to work that out. And part of that hurdle is that if it's going to be like a drug — in other words, a physician can write a prescription for it and the patient's going to get a reliable treatment — that drug's got to be there every time they write the prescription. So, that means the manufacturing process for the cells has to be very reliable. The cells that come out of that manufacturing process have to be very reliable in their numbers, in their function. It's no good if you get a million cells for one patient and a billion cells for another patient.
SM: So what's your estimate for an annual patient population for the bone-fracture treatment?
DA: For the fractures, we think the segment that's available to us is about 175,000 to 250,000. The number of fractures, of course, is much higher than that. This is the area of severe fractures that would be candidates for our indication. And the market for spine applications is approximately 400,000.
SM: And vasculature? DA: The patients in the United States that go to amputation are in the 200,000 to 250,000 range. The patients who are at the stage of getting these interventional procedures to hopefully stem that tide are more in the 500,000 range. And then you go to European and Japanese markets — that's a big, big market, and there is no effective therapeutic there...
There's been a series of clinical trials that have come out that show that if you take about a quart of bone marrow, concentrate it and inject it into that tissue, it can stimulate and regenerate that vascular tissue. And the link for us is that we've been able to show that we can effectively substitute for large volumes of bone marrow. So, that's partially the drive to be able to move into this indication.
SM: So, it seems as if embryonic stem cells would have no particular place in your business model.
DA: Yeah, our focus is on products and being in the clinic and starting to generate revenue. And we have our hands full with what we have in-house. We are very interested in what's happening in that area, of course, particularly with any research that begins to provide what's called effective instruction to the cells that can be a benefit to a tissue. As I was mentioning earlier, there are certain tissues that aren't normally replaced everyday in our bodies, like nerves. So, there needs to be some additional biology, I think, to help effectively solve that problem. And if some of that additional biology can be identified through the embryonic stem-cell work, we would immediately apply that to our own stem cells.
With bone marrow stem cells, there's a big difference here, in that you can't isolate, purify and put bone marrow stem cells in front of you. There are too few. No one's been able to do that. Our Tissue Repair Cells — they're not pure stem cells — are a real mixture of cells. If you destroy the integrity of that, you can't grow the stem cells anymore. Embryonic stem cells are different. They're pure. If you want to do research as a biologist, that's just what you need. They're all right there. They're pure. They're all the same. You can actually do research that you can't do with bone marrow stem cells. But it doesn't mean that some of the things you learn can't be applicable. So, we're very interested in seeing what is learned, so we can then apply it to our cells.
But do we see anything going into the clinics soon there? No. I think you're going to hear and will see the anecdotal amazing story come out, which is going to be good. But even from that point, getting to something that's going to be productized is going to take a while.
SM: Where did the company get its name?
DA: The company, Aastrom, is in Ann Arbor, Mich. The A-A is for Ann Arbor; the S-T-R-O-M is for stromal cell. It's a key part of the early and current technology. The company began operations in 1991. We'll call it an old-style biotech spinoff out of the University of Michigan with venture-capital backing and a pretty traditional format. The lead investors at that time actually brought me to lead the company, so I've been with the company since 1991, a pretty long stint. A very long stint. It was supposed to be two years. It didn't work out that way.
SM: There's been a lot of press recently about Big Pharma absorbing or collaborating with smaller-cap biotechs to augment their thinning pipelines. Is Aastrom is a good candidate for that kind of relationship?
DA: Pharma has not been active in the cell-therapy area because that's not what they do. That stated, they also haven't been engaged because of a lot of the failures that have occurred with cells over the past 10 years. They are waiting for, I think, unequivocal clinical results to show that these results work and a business model to show that they can make money. Those are our objectives. With that, we think partnering will begin to unfold in a more positive way. Part of our business model is to pursue at least marketing partners for the different indications of use.
SM: What about the reverse relationship, taking a smaller company on? DA: We have such a long list of applications ourselves, we probably would not be looking for someone who has a new application. What we might be looking for is someone that adds either critical mass or a related application in the marketplace, someone that could be otherwise supportive or synergistic with what we're doing. If our market cap continues to grow, we will put that capital to work and look to bring in additional components that would allow us to the either get to market sooner or in a larger way.
SM: Thomson First Call projects negative earnings per share for Aastrom into 2006. Can you account for those numbers, or do they concern you?
DA: Yes, and I think it's fine. We'll be investing in our clinical activities and research activities for a few years. Investors should look for value in the company, not from our revenues, but from definable clinical results from our clinical trials. Even though we're only spending money and raising money, we've shown steady growth in our market cap and in our share price, and we will continue that model for the next couple years. In May of 2003, we had a market cap of $24 million and share price of approximately 40 cents. So, this year, at the end of May, our share price was over $2.20, and our market cap was over $225 million.
SM: Why else should someone invest in Aastrom?
DA: I think it comes down to a couple of pretty important, basic things. One is this is a company that's not focused on cool technology. It's focused on cool products. The products are now in the clinic in trials. There should be a continuous flow of clinical milestones coming out of this company from now until we get into revenues. And, talking about tissue regeneration, you either grow tissue or you don't. So, you're not running a 200,000-patient trial to get a statistic like a 10% difference in five-year survivals. We're really looking at pretty definitive, early-term types of indicators to show that things are working.
News flow will be pretty continuous out of these clinical pathways. So, there should be, we think, the opportunity to value growth in measurable ways. You're also going to be able to begin to track, with each month that goes by as we work through this process, the real timeline until revenues will be there, where they're going to come from and how that's going to work out. The business model will begin to firm up with announceable events. One of our milestones for the next six months is to establish our first pilot commercial manufacturing facility in Europe.
So, we've already mitigated a lot of the technology risk for the investor. The cells are safe when we put them in patients. We know that they can generate healthy, normal tissue. We know that they're functional. So, it really comes down to what's the specific indication, the product, and when do we get to revenue. And that's what you can begin to track with this company. In the space, there's no one else close to being able to have that type of story
Posted by QuestSolver on :
just got back in,seems I missed 2 calls from the southwest...LOL....yeah Texas...I'll let ya'll kow what is said if I can reach them back!!
Did anyone try to buy CLBE? I only got several partials up to .049, see how hard buying low floaters are! they move quick though once they start.I contacted a friend to let him in on this but he already took a position yesterday,figured I would return the favor since he turned me on to BIPH at .09,I tried giving him AMEP at .013's but he only plays the Biotechs!!! I told his butt to step out of the box for once...I know he regrets it now I bet!
Posted by QuestSolver on :
all the good pennies require patience and some stocks are just right in your face screaming STRONG BUY like this one,hell all the financials are in order and their business plan is excellent from everything I have read so far and look at the filings,simply flawless...this alone tells me they mean REAL business and also in a great sector second only to energy. Logged
Posted by redneck woman on :
Here's my email response from Joe Christopher re: Berlin Exchange Cathy:
We have had several investors inquire this morning about the impact the Berlin exchange has had on our stock. We have requested in the past to be de-listed on that exchange. They have not responded. In reality there is not really much that we can do.
The real question is how much trading is taking place on the Berlin exchange? This morning when we had traded over 14 million shares only 116 thousand had traded on that exchange.
I believe the real problem lies with our own stockholders who bought recently in the quick run up. They didn’t have a real understand on the company. They were only buying because a computer program drew their attention to it due to price movement, volume and momentum. They are now selling for the same reason. The heard mentality is rarely right.
My advice, as always, is to put your AMEP stock into a nice clean envelope and slip it between your mattresses.
Take it out in a year and I believe you will be pleasantly surprised.
If you have any questions please call me at (800) 417-3670 Joe Christopher
Posted by redneck woman on :
Sorry - wrong thread - will repost on AMEP - I don't post much - can you tell?
Posted by QuestSolver on :
thanx redneck!!! CB is actually a pretty decent guy!
Posted by Superbee383 on :
quote:Originally posted by QuestSolver:
Did anyone try to buy CLBE? I only got several partials up to .049, see how hard buying low floaters are! they move quick though once they start.I contacted a friend to let him in on this but he already took a position yesterday,figured I would return the favor since he turned me on to BIPH at .09,I tried giving him AMEP at .013's but he only plays the Biotechs!!! I told his butt to step out of the box for once...I know he regrets it now I bet!
Yes, I'm in too. I'm averaged at .044, so hopefully this keeps on going!
Posted by QuestSolver on :
Superbee...what a tough one to accumulate though,I did not get all my fill but got most,I will try again tomorrow but may raise my buy point!
winter is here soon...natural gas and flu,two prime issues this year!!
Posted by Superbee383 on :
At this point, Quest, I'm not sure which one has more national attention. I THOUGHT it was oil and natural gas, but with the attention that this Avian Flu is getting, and what it could do if it spread here, is way beyond what I want to think about. I see in the AMEP thread where Bmax said to be careful. I plan to be. I used to have ASTM when it was under 1.00.. LOL, and sold it because I thought it was garbage. I am NOT making that mistake again. Stem research isn't going away.
Posted by mmalone on :
Quest: I got a few hundred dollars in CLBE this afternoon. Reading the 10K right now. I'll let you know my thoughts later.
Does your bio-tech friend know anything about Hana Bioscience (HBX)? I got into it a few weeks ago. They have a few products in the pipeline. Really low volume, a fair amount of institutional holding, and the price moves very easily. Analyst valued the company at between $8 and $12 a share, they're currently trading around $4. Just wondering if you or anyone else has any thoughts.
Posted by prefect on :
Yesterday, I got 15K (all that would fill) at 54.
Down now (obviously) but I think this is solid so will hold for the next few weeks.
Posted by QuestSolver on :
mmalone...I will ask him in an e-mail but he may not return an answer until afternoon tomorrow.
SuperBee....Stem cell research is not going away at all imo,they have already been looking for back doors around the issue.CLBE is into more then that though,they are postionaing themselves to cover a wide spectrum in the Biotech sectors,way under valued imo and with such a ridiculus low float and OS its no wonder why even a 15k buy will bump up the B/A so quick.
Posted by QuestSolver on :
I posted today that the RSI was very bearish for CLBE but all these indicators are setting up for a reversal.Do you remember way back then when I first started posting AMEP? I clearly stated on this board and others that I try to enter when everyone wants out and it looks to be on the declince (as long as I know its a good company),I post to everyone when I feel a good entry is set and its time to get in early which is now for CLBE.Maybe CLBE is not your choice but seriously watch for the Avion (bird)Flu stocks to really wake up,this epidemic could easily kill 100's of millions per Fox news.Many Biotechs I believe will be looking into the flu issue especially those like CLBE that has a wide spectrum other then stem cell research.I see a thread was started specifically for the Avian Flu...thats a great idea,not only does it give us many good ideas for investment but in the DD process many will get educated on just how bad this Flu can be!
Posted by kywee on :
maybe we will be part of the 100's of millions
Posted by QuestSolver on :
kywee.....I have no doubt that there will be Americans killed due to this,we are not indistructable and with the way people travel hell anyone sick could just hang out at an airport and infect many people going all over the country or world....its some scary CHIT to say the least!
Posted by QuestSolver on :
CalbaTech now looks to build a portfolio by buying companies that develop new technologies to sell or license; it also targets universities that are planning to license technology developed in academic labs. The firm is interested in products that will generate sales or licensing revenue within two years and need less than $1 million. Among its acquisitions are MolecularWare and iStem Technologies
MoleculareWare helps scientists have the wherewithal to keep their As, Cs, Gs, and Ts straight. The firm, a subsidiary of CalbaTech, offers bioinformatics software and other products to integrate the volumes of data produced from high throughput screening, combinatorial synthesis, and other methods of genomics research. Its DigitalGENOME suite consists of three software programs. DesignerDG can configure microplates and track the liquids used in the microplate wells. AnalyzerDG analyzes images and manages data from microarrays; the software can be used as part of DigitalGENOME or on its own. IntegratorDG can integrate data stored in a variety of database platforms, including platforms from Oracle and Microsoft.
Drug Week, 09/15/2005 07:18:31 PM EDT) CalbaTech, Inc., announced that revenues for the 6 months ended June 30, 2005, totaled $625,345, up from $58,217 for the same period in 2004. Revenues for the second quarter totaled $310,525, compared to revenues of $40,941 for the same period in 2004.
(Biotech Week, 09/15/2005 07:08:23 PM EDT)
(Medical Devices & Surgical Technology Week)
Biotech Week
CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).
The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.
Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
Posted by QuestSolver on :
CalbaTech Advisory Member Contributes Stem Cell Intellectual Property, Ranging From Banking of Stem Cells to Regeneration of Tissues
CalbaTech, Inc., an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced that Dr. Jason Van Tassel has provided three pieces of stem cell related intellectual property to CalbaTech's wholly owned subsidiary LifeStem, Inc. Earlier this week, LifeStem announced that it is finalizing plans to offer a stem cell collection and storage service in selected markets.
"We're pleased to have the support and contribution of Dr. Van Tassel," said CalbaTech CEO James DeOlden. "All three pieces of intellectual property complement our efforts in the stem cell arena and we're focused on developing them through our stem cell subsidiary LifeStem," Mr. DeOlden added.
The three pieces of intellectual property contributed by Dr. Van Tassel are related to therapeutic uses of autologous adult stem cells, and range from intellectual property related to the banking of stem cells to regeneration of tissue through the use of stem cells. The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office.
Dr. Van Tassel previously developed a novel method of injecting stem cells into diseased tissue through the use of a modified endoscope for which the company has filed for patent protection. Posted by kywee on :
didnt a group just run this? so wouldnt it come down some?
Posted by QuestSolver on :
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., is close to completion of its plans to offer a stem cell collection and storage service in selected markets.
The stem cell market has developed sufficiently to a point that now offers vast opportunities. Potential consumers are becoming more knowledgeable about the possible benefits of stem cells and are more ready than ever to embrace new stem cell related services.
"LifeStem has researched this market and believes that it has developed a novel approach to serve this rapidly growing market. We are anticipating launching our collection service no later than the first quarter of 2006, and possibly as soon as the fourth quarter of this year," said Dan Fulkerson, President of LifeStem Inc. LifeStem continues to maintain a focus on developing a novel approach to providing quality stem cells to researchers in California and believes that both its services will work in tandem. Future details will be provided after LifeStem completes patent and trademark protection.
LifeStem is solely concentrating its efforts on autologous adult stem cells. Stem cells are the body's "master" cells that have the ability to grow into new healthy tissue. As a result, stem cells may have the potential to cure diabetes, heart disease, Alzheimer's disease, spinal cord injuries and many other medical conditions. Adult stem cells have shown great promise as a regenerative therapy and are free of the issues that complicate the use of embryonic stem cells. Posted by QuestSolver on :
CLBE--filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
this is good because all the controversy over harvesting stem cells from embryos may be over,CLBE has found a way to harvest from adults,this is just one thing they are involved in,look for PR's soon imo on the others.
Posted by QuestSolver on :
CalbaTech is focused on providing products and platforms to the life sciences research market, both for biotech and pharmaceutical companies, as well as academic and government institutions. CalbaTech is pursuing a classic "roll-up" strategy of growth by acquisition. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that CalbaTech believes will contribute breakthrough innovation in areas of biological discovery. Currently, CalbaTech contains four wholly owned subsidiaries, Molecula Research Laboratories, LLC. ("Molecula"), KD Medical, Inc. ("KD"), LifeStem, Inc. ("LifeStem") and Molecularware, Inc. ("Molecularware") that serve niche markets in the life sciences research market. Molecula and Molecularware were acquired by CTI in 2003, KD was acquired in November 2004, and LifeStem was incorporated in September 2004 to pursue opportunities in the rapidly expanding stem cell market.
In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
CTI's business strategy is establish shareholder value by creating a significant new provider of research reagents, equipment and services to the life sciences market, primarily through acquisition of life science companies that share two or more of the following attributes: 1) They will be generating revenues; 2)They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
Posted by QuestSolver on :
good Morning all
as for this one CLBE...the more I was digging the last few days the better it looked for a mid to long term investment,if they announce the patent approval for stem cell recovery from adults this will go crazy especially since all the controversy over embryonic cells is not going away easy!CLBE has a wide spectrum of R&D going on and not just stem cell research,one of these Bio's are going to nail the golden goose with an Avian flu vaccine you watch!!
Posted by QuestSolver on :
for all who have L2 access....simply look at the line up for CLBE! I don't think I need to say anymore.
Posted by QuestSolver on :
there are only 3 MM's in the .04's.
ETRD NITE and SHWB .045,.046 and .049
6 MM's from .05 to .069
2 in the .07's and all the rest are .12 and above!!
Posted by QuestSolver on :
brief recap.
OS of under 37 mill and float at 770k
CalbaTech is focused on providing products and platforms to the life sciences research market, both for biotech and pharmaceutical companies, as well as academic and government institutions. CalbaTech is pursuing a classic "roll-up" strategy of growth by acquisition. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that CalbaTech believes will contribute breakthrough innovation in areas of biological discovery. Currently, CalbaTech contains four wholly owned subsidiaries, Molecula Research Laboratories, LLC. ("Molecula"), KD Medical, Inc. ("KD"), LifeStem, Inc. ("LifeStem") and Molecularware, Inc. ("Molecularware") that serve niche markets in the life sciences research market. Molecula and Molecularware were acquired by CTI in 2003, KD was acquired in November 2004, and LifeStem was incorporated in September 2004 to pursue opportunities in the rapidly expanding stem cell market.
In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
CTI's business strategy is establish shareholder value by creating a significant new provider of research reagents, equipment and services to the life sciences market, primarily through acquisition of life science companies that share two or more of the following attributes: 1) They will be generating revenues; 2)They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
been looking at the chart for this lil puppy again this morning and still cannot believe I missed this one so long,this one should carry an average of .175 PPS with a few high spikes based on normal operations alone.
2 in the .07's and all the rest are .12 and above!!
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service.
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., is close to completion of its plans to offer a stem cell collection and storage service in selected markets.
The stem cell market has developed sufficiently to a point that now offers vast opportunities. Potential consumers are becoming more knowledgeable about the possible benefits of stem cells and are more ready than ever to embrace new stem cell related services.
"LifeStem has researched this market and believes that it has developed a novel approach to serve this rapidly growing market. We are anticipating launching our collection service no later than the first quarter of 2006, and possibly as soon as the fourth quarter of this year," said Dan Fulkerson, President of LifeStem Inc. LifeStem continues to maintain a focus on developing a novel approach to providing quality stem cells to researchers in California and believes that both its services will work in tandem. Future details will be provided after LifeStem completes patent and trademark protection.
LifeStem is solely concentrating its efforts on autologous adult stem cells. Stem cells are the body's "master" cells that have the ability to grow into new healthy tissue. As a result, stem cells may have the potential to cure diabetes, heart disease, Alzheimer's disease, spinal cord injuries and many other medical conditions. Adult stem cells have shown great promise as a regenerative therapy and are free of the issues that complicate the use of embryonic stem cells.
Posted by QuestSolver on :
I have a 25k buy sitting on the ask at .045 and got nothing yet...told ya these shares are tight!
Posted by QuestSolver on :
just got two partials for 5k each so far! and the damn ask jumps to .049!
Posted by QuestSolver on :
man this is moving fast and with such a low float and OS it will hold ground,right now it should be leveling above .125,looks like it just took a typical OTC dip just like AMEP did.
Posted by QuestSolver on :
I am almost willing to wager that this will be at .125 to .17 next week.
people will be chasing this because they don't have enough shares at each ask level
Posted by Superbee383 on :
I just got filled partially on the bid but wow.. it's a tough one to get!
Posted by QuestSolver on :
heres the first AM dip!! this one is starting to get more liquid now!
Posted by QuestSolver on :
bid and ask getting tight,looks like its going to move up steady soon.Check out L2 again...WOW is all I can say between .07 and .125...no resistance at all.
Posted by QuestSolver on :
can't wait to hear about the patent eceptance!! That will stop a lot of controversy over the embryo extraction and now adult extraction is possible!
Posted by mmalone on :
Just thought I'd clarify that the Bush administration's objection to embryonic stem cell research should NOT hurt this company. In fact, it could help. I have read this administration's report on stem cell research (had to for class last year), and one of their objections to embryonic stem cells is that they feel adult stem cells offer similar advantages without the moral problems related to embryonic stem cells. In other words, the Bush administration supports the use of adult stem cells.
Posted by QuestSolver on :
mmalone I agree but the new method under development here is for living adult stem cell extraction!!I had to move my buy ask up but I think this is going to launch much higher soon and if any news leaks get out on the patent concerning the adult stem cell extraction method this will go nuts,most people don't like the embryo extraction methods and controversy and this patent will remove that issue altogether!! Posted by QuestSolver on :
this is getting some well deserved attention!!
Posted by QuestSolver on :
the Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates.
HEADLINES Change Display [ hide $$ edit ] • CalbaTech Advisory Member Contributes Stem Cell Intellectual Property, Ranging From Banking of Stem Cells to Regeneration of Tissues PR Newswire (Thu 5:00am) • CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of Stem Cell Collection and Storage Service PR Newswire (Wed 5:00am) • CALBATECH INC Financials EDGAR Online Financials (Tue, Sep 20) • CALBATECH INC Files SEC form 10KSB/A, Annual Report EDGAR Online (Tue, Sep 13) • CalbaTech Announces Significant Six-Month Revenue Increase, Details the Company's Expectations for LifeStem Inc., Its Adult Stem Cell Subsidiary PR Newswire (Fri, Aug 12) • CalbaTech Announces Expansion At K-D Medical, Leading Manufacturer of Microbiological and Cell Culture Media, Allowing it to Significantly Grow the Business PR Newswire (Thu, Aug 11) • CalbaTech, Inc. Retains AGORACOM.Com to Expand Investor Awareness PR Newswire (Tue, Aug 2) • CALBATECH INC Files SEC form 8-K/A, Entry into Material Agreement, Financial Statements and Exhibits EDGAR Online (Tue, Jun 2 • CALBATECH INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online (Fri, Jun 3) • CALBATECH INC Files SEC form 10KSB/A, Annual Report EDGAR Online (Mon, May 23)
Posted by QuestSolver on :
new HOD again
Posted by Superbee383 on :
I'm assuming there'll be some profit taking this afternoon, but as hard as it was to get these shares, I'm not letting go.
Posted by QuestSolver on :
get in under .07 or you won't be able to until .125 or so imo.
Posted by QuestSolver on :
lil dip for some back fill but its not much at all,look for the normal lunchtime lull to kick in soon to but this is going to another new HOD a few more times today imo.
Posted by QuestSolver on :
be back in a few,calling a contact in CA for Biotech plays! also just got my last partial fill..what a pain that was!
Posted by Jerm on :
SCHB sitting on bid and ask... seems you are right... shares are hard to get.
Posted by Forrestgump on :
CLBE gonna be a good winner just like CTUM and CNCN.
Posted by Persia on :
Volume suddenly stopped.
Posted by Superbee383 on :
Nite on both the bid and ask?? And look at that spread..
Posted by QuestSolver on :
just got back in and apparently this has some substantial institutional holdings,that intertest me alot,I am looking for details
CNBC now talking about the bird flu and smaller biotech companies!!
Posted by QuestSolver on :
This is a candidate for a future forward split imo!!
37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates.
do the math
37,561,205 minus 21,772,737 equals 15,788,468
not many shares to play with is it!! Posted by mmalone on :
Been reading the most recent 10K, thought I'd share some of my favorite quotes:
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
3. Officers and Directors:
James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.
Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.
John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.
4. Scientific Advisory Board:
Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.
Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.
Do your own DD, but I like it.
Posted by QuestSolver on :
thats what attracted me right off the bat and the more I dug into it the better it looks!
Posted by Superbee383 on :
But of course it's going to be an upward battle with the MM's.
Posted by mmalone on :
Yea, look at that spread. A full penny spread is rediculous... that's 20% in one tick.
Posted by Superbee383 on :
And look at NITE.. again on the bid AND the ask
Posted by QuestSolver on :
going to be hard to contain though once the buys flood in and chase the ask.
Posted by QuestSolver on :
lunch almost over,look for new HOD soon.
Posted by QuestSolver on :
man this looks so much like BIPH when it was .09's!! What a great flashback to!
Posted by QuestSolver on :
B/A GETTIN tight now!
Posted by QuestSolver on :
when this breaks out over .07 its getting wild imo.Look for low teens next week imo.
Posted by Forrestgump on :
MMs don't wnat to fill me at .063....?
Posted by QuestSolver on :
LOL..RUN FORRST RUN!!!!!lol...just had to do that because many will be chasin this one soon.
they are definitely getting more active no question about it,shares are not easily available and thats why we been getting quite a few mirror trades and moving up,but when there is no sell then the MM must use their inventory which is slowly declining...then guess what?
the bid will go over the ask often forcing upward movment.
GLTY and all here,this is a hold for sure.
Posted by Forrestgump on :
Thanks Quest for this lesson
Posted by prefect on :
Woke up this morning (slept through the opening...oops) to find my GTC went through at 60. Oh well...profit is profit (not matter how little).
check out the T/A chart now....this is a major reversal in the works.
MACD just went very bullish along with EMA bullish ST,RSI is still showing bearish signals but reversal has started imo!
Posted by QuestSolver on :
I doubt we see many EOD exits by DT's since the volume is so low still,imagine what would happen on a 10 mill day?
Posted by Jerm on :
Stochs and RSI bearish? Really? I'm pretty new to chart reading but I read them as bullish also (daily chart)... Slow Stochs shooting straight up about to cross 70... RSI also shooting straight up about to cross 60. Am I mis-reading something here?
Posted by Jerm on :
BTW Quest, this is not an attack... just trying to understand it all.
Also, the price is crossing the 50 day MA!
Posted by QuestSolver on :
Attack? LOL...we are all here for a continuing education...LOL....I am definitely included.
BRB checking out something else for this one!
on Today at 2:01pm, QuestSolver wrote:trying to figure out the dip cycle on this one,kinda hard so far.Might get a dip within the next 15 minutes or so but buy presuure is high just below bid.I doubt we get mamy DT exits near close today since volume is to low for most to play or flip.
damn called that dip almost to the minute!! lucky guess huh.....LOL....going back up already.
Posted by Forrestgump on :
At the moment MMs need shares. We MAY close strong. Chart looking good but market still bearish for all stock.
Posted by QuestSolver on :
been reading up on this Bird flu and man this could turn out to be some bad chit!! Hope vaccines get developed quick!
Posted by Persia on :
Scary stuff!!
By BETSY MCKAY Staff Reporter of THE WALL STREET JOURNAL October 5, 2005
Two teams of scientists reported that they re-created the influenza virus that killed as many as 50 million people in 1918 and 1919. The findings suggest that the threat of an avian-flu pandemic might be greater than previously thought.
Researchers from the Armed Forces Institute of Pathology, the Centers for Disease Control and Prevention and Mount Sinai School of Medicine said that the historic, killer flu-bug strain probably originated as an avian bug and then spread in humans without undergoing complicated changes that many experts had thought necessary for a human pandemic.
Their findings, published today in the journals Nature and Science, create "cause for concern" and make getting to the bottom of the 1918 flu outbreak far more than an historical exercise, said Jeffery Taubenberger, the Armed Forces Institute researcher who led one of the studies.
Fears are growing over the continuing spread of avian flu, which has become widespread in poultry flocks and is jumping to humans with increasing frequency. The lethal strain, known as H5N1, has claimed 60 lives in Indonesia, Vietnam, Thailand and Cambodia since late 2003.
Most of those cases were in people who had direct contact with infected poultry, but fears are growing that the highly contagious virus could mutate and begin spreading between humans. President Bush said on Tuesday that he would consider using the military to enforce quarantines in the event of an outbreak in the U.S.
The findings by Dr. Taubenberger and his team of researchers, published in Nature, follow a nine-year effort to decode the 1918 strain by sequencing its eight genes. The research concluded that the pandemic flu outbreak was most likely caused by an avian virus. The scientists also discovered 10 mutations that distinguish the 1918 virus from avian bugs, suggesting changes that the virus made to adapt to a human host, they said. They also noted that some of those mutations are also present in the currently circulating H5N1 virus, suggesting it could make the jump to humans in a similarly rapid and alarming way.
In the second study, published in Science, scientists from the CDC and Mount Sinai took the decoded virus and re-created it, using a process known as reverse genetics. The virus they created, in a secure CDC lab, was "exceptionally virulent," quickly killing embryonated chicken eggs and mice, said Terence Tumpey, a senior scientist at the CDC who led the effort. The team also found that the 1918 bug had an unusual ability to penetrate cells that flu bugs don't usually reach deep in the lungs, providing some clues as to why its symptoms were so severe.
While the research significantly advances scientists' understanding of the avian-flu threat, it also raises concerns about keeping the virus from escaping from the lab or into the hands of bioterrorists. Dr. Tumpey said the experiments were approved ahead of time by two CDC committees with internal and external experts, and were conducted under strict safety and security standards. <<
Posted by QuestSolver on :
might try to buy another small block at the bid or just above and see if I get lucky,along with AMEP I don't mind holding a good stock thru the weekends!
Posted by QuestSolver on :
still no luck,shares locked up I guess,won't even give me a tweener just under the ask!This is going to look much better in the upcoming weeks imo!
Posted by mmalone on :
Quest: Yesterday I bought a few hundred dollars AT the ask and it took several minutes for them to fill me. And that was a tiny order. Shares are incredibly tight on this one.
Posted by Jerm on :
Sounds like after we make our fortunes on AMEP and this stock... we all need to buy log cabins in the mountains!
Posted by QuestSolver on :
mmalone...no doubt about it,much differant then AMEP but when these low floaters take off MM's will scrounge and entice for shares and move the bid fast!
Posted by QuestSolver on :
AMEP best ONG otcbb play imo,CLBE best Biotech based on potential plus OS and PPS entry!
Posted by QuestSolver on :
trying to buy another 30k at .06 if there is any sellers here.
Posted by QuestSolver on :
they bumped it up again,should be a gapper Monday!
Posted by QuestSolver on :
looks like I will have 2 gappers Monday at open
AMEP and CLBE!!!
Posted by Persia on :
Looks like we had a last minute run... Posted by QuestSolver on :
only one way to go for this one imo,coming off an all time low this should be up in the teens soon.
have a great weekend all! great close
Q
Posted by bmaxingout on :
quest,great pick good luck bmax,
Posted by QuestSolver on :
Thanx Bmax,I think we now have two great stocks to be in and carry into the new year,AMEP and CLBE
as for CLBE
In the recent 10-q they clearly state they may be profitable THIS year and heck we are in the last quarter now.The potential for their new adult stem cell extraction is going to be the most and probably the only used method very soon and if we get the news on the patent approval for this its going to change the whole outlook for this company and its subs,even major religous leaders are now backing this method eliminating the controversal embryo issue altogether giving the new method a higher moral standing in our social system.CLBE is definitey not a flipper,its a strong BUY and HOLD in your long term or mid term portfolio.This is one I recommended directly to family members myself,with some contacts I have been dealing with out west in this sector they have clearly stated something very important is in the works in stem cell methods and reseach and may be released next week,this could effect all companies involved in stem cells I guess.
The Catholic Church in Korea has decided to donate money for adult stem cell research. The move comes amid strong Vatican opposition to embryonic stem cell research and is reflects support for research into an alternative. The Church has been among the most vocal opponents of embryonic stem cell research based on the belief that embryos are human beings. In Korea, a country leading that field of science, the Catholic Church is donating millions of dollars to aid research involving adult stem cells in the hope of reducing the increasing reliance on embryonic stem cells to treat hard-to-cure diseases.
"The research harms the integrity of life, and that's why we cannot accept the use of embryos," the church said. It wants to fund research on adult stem cells derived from bone marrow or umbilical cords that would otherwise be discarded after a baby is born. They say this is more practical and does not cause ethical controversy.
The Seoul Diocese set up a committee to donate W10 billion (US$10 million). The church said it will not assist the research of Korea's Dr. Hwang Woo-suk who grabbed the world's attention last year by announcing the successful cloning of a human embryo. Catholics have criticized Hwang since his work involved using human eggs and destroying embryos to harvest stem cell batches.
Embryonic stem cells have the potential to become any cell or tissue of a human body like bone, skin or blood. In contrast, adult stem cells, which can be harvested from adult patients, can only be used to create specific cell types like muscle tissue from muscle stem cells. The decision by the Seoul Diocese may still fuel an ongoing debate between religious and academic groups over the desired type of stem cell research.
Arirang News
Hank
Posted by QuestSolver on :
Pro-Life Congressman and Dr. J Seek Adult Stem Cell Research Bill
Washington, DC (LifeNews.com) -- A leading pro-life congressman and former Philadelphia 76ers basketball star Julius "Dr. J" Erving teamed up at a press conference Thursday to ask the Senate to pass a House-approved bill that would promote adult stem cell research using umbilical cord blood. The bill provides funding to use stem cells from umbilical cord blood, which have proven to be the most effective and the House approved HR 2520 434-1 in May.
The Senate has stalled on voting for the bill because it has gotten caught up in the divisive debate over using taxpayer funds for embryonic stem cell research. Smith asked that the Senate not delay any further on voting on the bill.
"Delay is denial, especially for the sick who will not benefit from cord blood transplantation because the Senate inexplicably delayed," Smith said. "Make no mistake, for these sick children and adults, this is a matter of life or death."
Dr. J, who is currently the Vice President of the Orlando Magic, said African American patients need the bill to be approved because they have a much lower chance to obtain a match within the current bone marrow and umbilical cord blood stem cell inventories.
"Each year, thousands of Americans die who could be saved if larger and more diverse inventories of umbilical cord stem cells were in existence," Erving noted. "I came today to join Congressman Smith in asking the Senate to finish the job and pass this legislation and provide doctors the resources they need to treat the thousands of courageous patients in desperate need of help."
Currently, some minorities have less than a 50% chance of obtaining a potentially life saving transplant
Umbilical cords are a rich, non-controversial source of stem cells. Currently hospitals throw millions of them away each year because the infrastructure required to properly collect and store them is not available.
Thousands havebeen successfully treated with cord blood stem cells for more than 67 diseases including Leukemia and Sickle Cell Anemia.
The infusion of federal funds will make this medical miracle available to thousands more and will ensure that research continues so that this source of stem cells can treat many other debilitating diseases.
Numerous doctors and patients who have been treated with umbilical cord stem cells also attended the press conference.
Posted by QuestSolver on :
Boswell backs adult stem cell research
Medical studies into embryonic stem cells have failed and it was time to get behind alternative research, Nationals Senate leader Ron Boswell says.
Three years ago, after a passionate debate, federal parliament passed laws giving scientists access to unwanted human embryos for research purposes.
Since then the national scientific regulator has issued nine licences for such research.
But Senator Boswell told parliament on Wednesday the research had come to nothing and support should now be given to alternative research on adult stem cells.
"The last debate was a very difficult one for many of us and led to deep searching over ethical issues involved," Senator Boswell told parliament.
"My point is that for all the pain we went through, for all the cost, we are not even close to the promised cures from embryo research.
"Yet there is true hope out there that medical research will tackle the most painful and debilitating diseases known to humanity and it will do it through adult stem cell technology.
"The only question is how long before the world wakes up to it.
"We have before us a sober opportunity to change direction to a zone of scientific research that is free of ethical dilemmas."
Senator Boswell said research had shown that adult stem cells provided a viable alternative to embryonic stem cells.
He said researchers at Queensland's Griffith University had successfully grown adult stem cells harvested from the olfactory mucosa, the organ of smell in the human nose.
They demonstrated the cells can give rise not only to nerve cells but also to heart, liver, kidney, and muscle cells.
The research team, led by Professor Alan Mackay-Sim has spent the past four years developing the research, particularly investigating the potential of stem cells in treating Parkinsons disease.
Senator Boswell's speech came as Industry Minister Ian Macfarlane was planning a forum for federal MPs next week to consider the issues surrounding stem-cell technologies.
Mr Macfarlane warned earlier this week that Australia's reputation as a global player in biotechnology could be undermined if conservative forces succeeded in banning embryonic stem-cell research.
Posted by QuestSolver on :
Date: Saturday, October 08, 2005 9:03:09 AM EST By STEVE MITCHELL, Senior Medical Correspondent
WASHINGTON, Oct. 8 (UPI) -- Researchers said Saturday they have used stem cells collected from the amniotic fluid surrounding fetal lambs to grow windpipes, and then implanted the tissue back into the fetuses while they were still in the womb -- a breakthrough that could lead to ways to repair congenital defects before birth.
Defects in the windpipe or trachea are rare in humans, but they can be life-threatening and are difficult to repair. Often, the fix -- involving surgery soon after birth -- can be fraught with complications, including brain damage.
Dr. Dario Fauza and colleagues at Children's Hospital in Boston hope their technique can offer a way around such problems by repairing the defect before the baby is born.
"The fetus doesn't need the trachea, so the repair would have time to heal in utero," Fauza said in a statement, "and fetal healing is very good -- it's better than adult healing."
The technique involves extracting amniotic fluid, which surrounds the fetus in the womb, to obtain a type of stem cells known as mesenchymal stem cells. These cells arise directly from embryonic stem cells and they can give rise to various cell types, so they could be used to regenerate damaged or diseased tissues.
Congradulation QuestSolver for this pick. Good one. It will raise like CBAI for sure. Meanwhile have a look on CTUM. Chart look very good and only 7 millions in the float. I have been playing with it all week. Each time I order 5000 shares the ask was moving up...So with some buying pressure, CTUM could hit .39 cent in one day.
Posted by QuestSolver on :
Thanx Forrest,was looking at that Friday but took no position,at least not yet,had no loose money because I was dumping as much as I could into CLBE.I still hold my AMEP for the ONG now.
the following companies are in stem cell research.
ASTM $2.20
STEM $5.04
GERN $9.86
VIAC $5.49
get an idea where CLBE could go now especially with the new adult stem cell extraction tech that is patent pending with no ethical or moral issues attached?
Posted by QuestSolver on :
by Whinny on HSM
I saw a show on the tube a short while back where they took the patients own stem cells from up in their nasal cavity and put the stem cells on the affected nerves. In this case there were three women and they were all paralyzed in the legs from accidents. They were like that for years, but after receiving the stemcells they actually had movement in their legs.
The prognosis was that in time they may walk again with this type of treatment. I was dumbfounded and had never seen anything like this before. The three women were very hopeful and you could tell that something great was happening. I think adult stem cells and cord blood offer the best hope at this time for any advances made in this kind of therapy. I'm loading up on Monday. Hope I'm right
my response...
Whinny...thats just the tip of the mountain for adult stem cell research,this is going to reveal unprecidented results in healing and CLBE with its patent pending on stem cell extraction from adults could easily become a top player so if your buying Monday at open,you will get hell even buying at the ask imo.
Posted by QuestSolver on :
I think soon many will realize how lucky they were when they made even a small entry at these levels,as for CLBE I believe the reason it took a drop in late July and early August from .20 to the single digits may be related to the PR on August 2 concerning the deal that was made with AGORA. AGORA has been retained by CalbaTech for a period of 12 months. AGORA will be compensated with both a monthly monetary fee and stock options, vesting 50,000 shares per quarter, at $.20 per share.This agreement has been negotiated entirely at arm's length. AGORA is located in Toronto, Ontario. I think it is only a temporary effect and I have and will continue to take advantage of this as much as I can because there is almost zero resistance between .07 to .125 and from there it should glide back into the .20's quick and any whisper of the patent approval then this will be a completely new ballgame.
QuestSolve continue to informe us. I do agree with you all the way because and I see what you mean with this stock. Alot of people on this board do prefere invest in Pink sheet than OTCBB. They like to buy million of shares instead of few one and trying to figure out how to make big buck quickly with stock like QBID, ICAN... They don't like when we suggest or promote other stock with more potential. They call us pumper....
Posted by Forrestgump on :
I recently suggest CTUM and CNCN. I have been describe as a pumper by clintoj. This guy promote GZFX and look now where this stock is... We all make mistake sometime...I use Chart and news. My play til december: CLBE, CTUM and CNCN. Except for CNCN, very very bullish chart.
Posted by QuestSolver on :
Thats what I don't understand either,face it..information changes every second in our world now.So by us putting out new DD or more detailed info on a company is called pumping? I always considered pumping as post that have CAPITOL ONE LINERS and GOING TO THE MOON! etc...but posting real verifiable info thats up to date I never considered pumping at all especially when providing links to the sources!
It was announced by CEO last year or early this year CLBE would be buying up some open shares. Now seems like a good time. Hope to read about it in future 10-Q's that they got some, is this still on the horizon?
Subject: CLBE buying shares From comtek PostID 426099 On Saturday, October 08, 2005 (EST) at 7:05:28 AM
Why would they need to buy back shares... I thought that their float is fairly low?
Posted by QuestSolver on :
Jerm...the float is low but the shares I believe they are speaking of the shares they used in the deal with AGORA this past August at .20 pps
Posted by Jerm on :
Ah, got ya... thanks.
Posted by QuestSolver on :
Jerm...the way I see it,since the deal has been pretty recent(August)and they set the deal at .20 a share,that tells me this dip is going to be quite temporary and should be taken advantage of.In order to create a more fluid PPS this stock is a great candidate for a forward split,it seems everything is in perfect order just for that.Now wouldn't that be nice...snatch up a couple 100k this week and then they file a pre14 requesting a FS of maybe 3 for 1 or maybe 5 for 1? Only speculating here and have no inside information to sustain this theory.
Posted by QuestSolver on :
recap for any new eyes....
CLBE--from the 10-q
the Company had 37,561,205 shares of common stock issued and outstanding, of which 21,772,737 were held by non-affiliates. (think about these low numbers!,this could take off like BIPH did! Been reading the most recent 10K, thought I'd share some of my favorite quotes:
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
3. Officers and Directors:
James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.
Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.
John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.
4. Scientific Advisory Board:
Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.
Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board, that intend to contribute innovation in areas of biological discovery.
Contact: Paul Knopick (949) 707-5365 pknopick*eandecommunications.com
CalbaTech now looks to build a portfolio by buying companies that develop new technologies to sell or license; it also targets universities that are planning to license technology developed in academic labs. The firm is interested in products that will generate sales or licensing revenue within two years and need less than $1 million. Among its acquisitions are MolecularWare and iStem Technologies
MoleculareWare helps scientists have the wherewithal to keep their As, Cs, Gs, and Ts straight. The firm, a subsidiary of CalbaTech, offers bioinformatics software and other products to integrate the volumes of data produced from high throughput screening, combinatorial synthesis, and other methods of genomics research. Its DigitalGENOME suite consists of three software programs. DesignerDG can configure microplates and track the liquids used in the microplate wells. AnalyzerDG analyzes images and manages data from microarrays; the software can be used as part of DigitalGENOME or on its own. IntegratorDG can integrate data stored in a variety of database platforms, including platforms from Oracle and Microsoft.
CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).
The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.
Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
Posted by QuestSolver on :
CalbaTech's business strategy is establish shareholder value by creating a significant new niche market by providing research reagents, equipment and services to the pharmaceutical research market, primarily through acquisition of life science companies that share the following attributes: 1) They will be generating revenues; 2) They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
"The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office".
Also the fact that the stock ran to .20 in july, expenses static around 1-mil, and this news out Thurs., is significiant, only it may take a few weeks for everyone to sort out.
Posted by QuestSolver on :
They have not openly pin pointed any specific virus or biological issue by name yet but take a good hard look at the divisions and with Avian on the top burner right now and the U.S. government announced last week that all companies including small biotechs will and should be researching a vaccine for this flu.
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. It is concentrating on acquiring, incubating and developing life science based companies that are developing current and future generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute innovation in areas of biological discovery.
on this thread I gave some phone numbers,its worth making a call.Take a look at this team,they have every bio angle covered.
Ph.D. Biochemistry, UC Berkeley
Dr. Mullis received the Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the 20th century, one that revolutionized genetic science and engineering. PCR has also been an enormous commercial success. The original patent was sold to Hoffman LaRoche for $300 million and has generated more than a billion dollars in revenue from royalties.
Paul Heaney, Ph.D. Ph.D. Medicinal Chemistry, Univ. of Glascow, Scotland
Dr. Heaney has held numerous positions within the life sciences industry, most recently as EVP of Research and Technology at Sequenom. Dr. Heaney's team was responsible for the development of the highly acclaimed and commercially successful chip-based MassARRAY™ Genotyping Platform and the MassARRAY™ 200K which can be multiplexed to more than one million DNA assays per day. While Head of Bioelectronics at the Sarnoff Corporation, Dr. Heaney's team was awarded a $12 million DARPA grant which led to the spin-out of Orchid BioSciences. Dr. Heaney holds more than 25 patents.
David O'Bryan, Ph.D. Ph.D. Medical Sciences/Biochemistry, BU Med School
Dr. O'Bryan is a former Senior VP at SmithKline Beecham Clinical Laboratories. He has more than 28 years experience in the clinical testing industry, including significant experience in developing new technologies. On behalf of SmithKline Beecham Clinical Laboratories he negotiated license agreements involving patented gene sequences used to diagnose diseases and secured the first license for nucleic acid testing. Dr. O'Bryan is also a recognized expert in laboratory instrumentation and automation in the commercial reference laboratory industry.
Gerald Huth, Ph.D. Ph.D. Physics/Electronics, Uppsala University, Sweden
In 1985, Dr. Huth founded Xsirius Scientific, Inc. Two subsidiaries, Xsirius Superconductivity, Inc. and Xsirius Photonics, Inc. had IPOs and traded on NASDAQ, with Xsirius Scientific having a market cap exceeding $100 million.
To learn more about Dr. Huth and his inventions visit www.ghuth.com[/b]
Jason Van Tassel, M.D. Dr. Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in Los Angeles, CA. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California at Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery. Prior to practicing medicine in LA, Dr. Van Tassel worked at Hybritech Inc., where he performed research investigating manufacturing processes related to monoclonal antibody test assays. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Dept. of Neurosciences at San Diego State.
John A. Drews, M.D., J.D. Dr. Drews was in the clinical practice of cardiothoracic surgery in CA, from 1976 through 1990 as a member of a medical group which performed cardiac, vascular, and thoracic surgery. During that time Dr. Drews was instrumental in the founding of the Orange Coast Heart Institute at Hoag Hospital, Newport Beach, in 1982 (now the Hoag Heart and Vascular Institute). Dr. Drews has contributed approximately 17 research articles to various prominent medical journals. He is a Fellow of the American College of Surgeons, as well as a member of many other medical surgical societies. Dr. Drews received his bachelor's degree from Duke University in 1963 and his M.D. from Yale University in 1967. He is board certified in both general surgery and cardiothoracic surgery having trained at both UCLA Hospital and Yale-New Haven Hospital in Connecticut. Dr. Drews received his law degree from Western State University College of Law in 1994 and has subsequently performed medico-legal consulting in many medical malpractice case
Posted by QuestSolver on :
stocks to watch before and be in at open imo,all are going to be actively in the green maybe all week.
AMEP....CLBE.....GCCP
Posted by QuestSolver on :
The way it looks it appears the biotech sector is about to heat up probably equal to the energy sector,between the great advances recently in adult stem cell research now its about to open doors without controversy following behind which really inhibited the same research when extracting embryonic cells and now with the Avian flu predictions that could be catastrophic to say the least I think many labs are working overtime now. I may try to visit one of the CalbaTech divisions in Maryland this week before I head to Florida,if not I'll have to check it out when I get back near the end of Month, its the K-D Medical site...
K-D Medical, Inc. 6935-A Oakland Mills Road Columbia, Maryland USA 21045 (410) 290-9690 (Phone) (410) 290-9691 (Fax)
a lot is going on in this sector and this specific industry so we can expect more PR's from the company imo keeping up us to date and so far fortunately I don't believe we are listed in any foreign markets like Berlin of Frankfurt.
GLTA Hank
Posted by Persia on :
Coming closer and closer...
ANKARA, Turkey -- Turkey and Romania culled thousands of birds and imposed quarantine zones on Sunday to try to stop the spread of avian flu as scientists worked to discover if the outbreaks could be the deadly H5N1 strain.
Reports of Turkey's outbreak only surfaced on Saturday night, but nearly 2,000 turkeys died at the affected farm near the Aegean Sea on Tuesday and Wednesday and hundreds more were culled overnight in the affected area, local media said.
Hurriyet newspaper quoted Mehmet Eksen, owner of the stricken farm, as saying he now feared for his own health. Authorities slapped a 3 km (1.8 mile) quarantine ring around the site.
"I cried when I witnessed the death of my turkeys. I cannot forget those moments ... But now I think of myself and what will happen to my health. I cannot go near my wife and children."
The state Anatolian news agency quoted local official Resul Celik as saying: "At the moment this is not a situation which should cause (ordinary citizens) any worry."
Romania's suspected outbreak was detected in poultry in the Danube delta, on the Black Sea, and the European Commission says the two cases are different but they have raised the specter of the disease reaching European Union countries.
If the Romanian cases did turn out to be the deadly H5N1 virus, they would be the first evidence the strain has spread to Europe from Asia, where it has killed more than 60 people and millions of birds since 2003.
Russia and Kazakhstan have already had outbreaks.
Experts fear H5N1 could mutate into a virus which spreads easily among humans, creating a pandemic that might kill millions. The so-called Spanish flu pandemic of 1918 killed between 20 and 40 million people worldwide.
Britain said it was sending a team of experts to Romania to help and was in touch with Turkey authorities. Romania said Britain, which has the European reference laboratory for avian influenza, would deliver "the final verdict" on the birds.
Posted by Persia on :
CalbaTech's Subsidiary, K-D Medical, Inc., Contracts With Independent Sales and Marketing Group to Increase Sales Monday October 10, 5:00 am ET
IRVINE, Calif. and COLUMBIA, Md., Oct. 10 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, has contracted with an independent sales and marketing group, Imgen Technologies, to bring its products to new customers with the intention of opening new accounts and increasing sales. ADVERTISEMENT
K-D Medical, a primary vendor of the National Institutes of Health, also currently sells its full line of molecular biology products to Universities, Research Centers and major Pharmaceutical companies nationwide.
Imgen Technologies is an independent sales and support company for innovative molecular biology and life science product manufacturers with extensive experience in increasing sales and locating new customers. The group includes five members who travel from North Carolina to New York to demonstrate and service these product lines. The contract is for two years.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About K-D Medical, Inc.
K-D Medical, located in the heart of the Maryland Biotech Corridor, is one of the nation's leading manufacturers of microbiological culture media and other research reagents. K-D Medical's products are used in drug discovery, microbiology labs and biopharmaceutical production. The company is headquartered in Columbia, Maryland.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
Posted by QuestSolver on :
outstanding!
Posted by QuestSolver on :
stem cell webcast starts at 10:15am
A two-day webcast begins Saturday, hosted by BayBio, Northern California's life science association, where the California Institute of Regenerative Medicine (CIRM) will hold its first scientific meeting featuring six scientific sessions with presentations by stem cell researchers and clinicians from the United States, Australia, Canada, Israel, Sweden and the United Kingdom.....link...baybio .org
this and the upcoming releases will play a big roll for CLBE and other stem cell and biotech companies and you can bet institutional interest is growing so if you think its hard to buy now just wait when the big boys step in.
Posted by QuestSolver on :
Stem Cell Cure for Peripheral Vascular Disease on the Horizon
Peripheral Vascular Disease is a near-pandemic condition that threatens millions with loss of limb; and also life. PVD is the result of narrowing arteries that deprive regions of the body—typically hands, feet, and limbs—of much-needed blood. Stem cell therapy enables patients’ own bodies to repair damaged blood vessels and grow new ones thus restoring blood flow and oxygen to damaged tissue.
If you have a professional interest in whether embryonic and other forms of stem cell research are supported at the state level, then you should subscribe to State Stem Cell Funding News.
October 2005 Cells From Amniotic Fluid Are Used To Tissue-Engineer A New Trachea Neural Stem Cells Are Long-Lived Hair-Raising Stem Cells Identified New Stem Cell Therapy Research Centers Are Established
How would stem cell therapy work? The goal of any stem cell therapy is to repair a damaged tissue that can't heal itself.
This might be accomplished by transplanting stem cells into the damaged area and directing them to grow new, healthy tissue.
It may also be possible to coax stem cells already in the body to work overtime and produce new tissue.
To date, researchers have found more success with the first method, stem cell transplants.
Posted by QuestSolver on :
the MM line is looking outstanding.
3 at .065
2 at .070
1 at .071
1 at .083
and all the rest at .115 to .51 and 1 out there at $1.01
I think once this breaks loose of the .07's it will take off and I only see the depth from .065 to .083 at 65,000 shares.
Posted by QuestSolver on :
looks like the real gap so far is with AMEP right now and CLBE and GCCP is small as of yet.
Posted by QuestSolver on :
ask now up to the .07's!
Posted by QuestSolver on :
MMs just retreated from that .065 ask. Just as I typed this, another one retreated.
No MMs anymore at the .065 ask!!!!!
Now it's 4 MMs at .07.
Must be a lot of demand for this, and this is gonna gap for sure.
I only wish that they'd filled more shares for me on Friday, but they didn't. I'll definitely have an order ready for .07 at the open. Maybe I'll get some more before this baby flies.
Posted by QuestSolver on :
WOW now at .085 and I am tellin ya its still a deal,this is going to be another BIPH imo and if you can gettem, gettem and holdem!
Posted by QuestSolver on :
I am tellin ya,this has another "BIPH" written all over it,just look at the other stem cell companies now! Don't be surprised to see this at .20 this week imo!
Posted by Persia on :
90 X 95
Posted by Persia on :
Maybe even today Quest... Posted by MoneyHolic on :
nice call quest! your up 55%!! Let's go AMEP!!!
Posted by QuestSolver on :
should be hittin .12 soon,hope we get a little dip to allow for some more entries under a dime but I don't see it coming anytime soon.
Posted by QuestSolver on :
many will see over the next month that this is heading north...far north imo.And once the IR firms kick in they are going to be targeted by institutional thats why most better buy asap because after the big boys step in the shares are gone!
Posted by QuestSolver on :
heres the profit takers that got in last week,I recommend you buy as much as they let you on this dip!
Posted by MoneyHolic on :
Quest; I would but all my money is tied up with AMEP... I'll keep an eye on it though.
Posted by QuestSolver on :
thats understandable,they both are good but if anyone can they really should take advantage of any dips here,looking at L2 you see what I mean.
Posted by STOCKMOVER on :
Questsolver,
I am looking at the L2 also. When it says "5 more" at the bottom, what does this mean?
Thanks,
Posted by QuestSolver on :
take advantage of these dips,many DT's made entries Friday and took profit exits this morning,doubt they get back in again unless they are going to pay higher.I possibly believe this could touch .20's this week before moving to even higher ground following weeks imo.
it means more MM's are involved but out of sight.
Posted by Forrestgump on :
I do agree QS
Posted by prefect on :
everyone seems to be holding thier shares tight!
Posted by Jerm on :
Nite sitting on ask and bid with big spread... must need shares.
Posted by QuestSolver on :
my computer decided to give me hell today!! switching to another one and looks like we are looking strong!
Posted by QuestSolver on :
looks like we may be in for a decent afternoon run the way its setting up now!
Posted by prefect on :
should have left my order at 8 in...
Posted by maumee river rat on :
put it back in prefect....It's not too late
I think it will test support one more time before it runs...
Posted by QuestSolver on :
L2 looks even better,tellin ya,hope your in now.
Posted by QuestSolver on :
simply put,only 4 MM's in the .09's,all others over .12 except 1 at .115
Posted by QuestSolver on :
this just gave me a good flashback,at .09's is where I started buying BIPH...LOL.....I rode that one into the dollars quick! I do believe we may have another ride with this one!
my advice is to grab a few shares and put them aside and come back later this year and be quite happy.See the new patent request? Adult stem cell extraction will be the only way to do this without any controversy over moral and ethical issues!
Posted by Persia on :
Only 1 left at 0.09 and that's Mr. Nite.
Posted by Superbee383 on :
Quest, what is the story with BIPH? That's before my time on here, and I'd like to hear about it. I see it's at 2.34 right now, but where did it start? And how long did it take to get to where it is now? Just curious! Thanks in advance :-)
Posted by QuestSolver on :
Nite is about to go imo! over 2 mill volume!
Posted by Persia on :
He's gone Quest.
Posted by prefect on :
I had in the order at 8 and saw it buys going through at 75...so I lowered my bid.
Of course by the time it queued up we were already back up.
I will leave it at 8 for now and see what happens.
GLTA!
Posted by QuestSolver on :
SuperBee...Its a company that makes MRI safe coatings,I started buying them at .09 and it took off to $3.60's all within a short time and has leveled off in the $2's.If I remeber correctly they even had a higher OS then CLBE does right now,I think they were at 80m.I see alot of similar attributes comparing the two,except CLBE has more avenues other then being focused on one like BIPH was.
Posted by Persia on :
Only 2 left in the 0.95's, people.
Posted by QuestSolver on :
yeah be careful trying to lower your buys to catch what appears to be an upcoming dip,they will pass you by,shares are scarce.
Posted by Persia on :
Only 1 left at 96 and that's again our dear friend, Mr Nite.
Posted by Persia on :
Help me on this Quest. You know why the ask from NITE went from 0.094 to 0.1, because volume didn't change at that moment.
Posted by QuestSolver on :
share consolidation I guess or someone trying to buy above the ask....looks like we get our lunchtime lull now,might be a good time to take an entry for any new eyes here,should start moving hard again around 2 or so.
Posted by QuestSolver on :
this is unreal!! I have a 25k buy sitting on the ask right now and not even biting!
Posted by prefect on :
Jeez, when I left for work we were flirting with 10!?
I got here about 2 min ago and logged in to 77? My buy at 8 went through at least...
Time to go back up!
Posted by j160e on :
Quest, I just got 10k more at .076 and NITE moved over to the bid. Do you rememebr seeing DOMS on the ask at all the last few days? Looks like he's unloading for somebody.
Posted by BULListic on :
I just got 25k at .077 and executed in less than 5 seconds....
Posted by buckstalker on :
Someone just dumped a boatload at .075
Posted by Jerm on :
Yeah, looks like after that 700K share dump we are moving back up... guess someone has the shares they wanted now. :-)
Posted by QuestSolver on :
check out the volume increase! Looks like they pulled it down to fill some big orders and trucking back up now! Look for real action near close today imo,we will probably close at a new HOD at close.
Posted by j160e on :
DOMS is gone, and here's ARCA to hold it down.
Posted by Forrestgump on :
MACD line about to break 0. If so we will run this afternoon. MMs may need some shares or preparing the field....
Posted by QuestSolver on :
got fills at .077 and .08's now.
Posted by Forrestgump on :
Quest if MMs fill you at the bid...thats means they manipulate the price to stay steady between 7 and 8 for some reason.
Posted by j160e on :
Grabbed another 10k at .080 after a partial fill of 500 and waiting about 5 minutes for the rest. ARCA's gone and DOMS is back. NITE is patiently sitting at .10
Posted by QuestSolver on :
trying to get 8,500 more shares at this level then its sit back and watch time,looks like they are taking advantage of the lunchtime dry spell and trying to work out some shares.Watch after 2 soon,they know this one is going to continue and when the institutional interest grows after the IR teams retained this stock will never look at the low pennies again imo.
Posted by Forrestgump on :
1/3 of the float had been traded so far
Posted by QuestSolver on :
I think we are getting inline for many announcements not only from CalbaTech but also more from the subs,they have a lot going on thats quite proprietory and once the patent protection is assigned this will be flirting with .50 to a buck sooner then we may think imo.
time to grab something to eat,be back soon!!
Posted by QuestSolver on :
had to step back in a minute and see my buy did not execute yet!!! hell its sitting above the ask let it go!
Posted by QuestSolver on :
looks like they are finally going to give it a shake!
Posted by QuestSolver on :
trying for another buy at .0741 and to believe this company is expecting to make profit this year per the CEO!
Posted by prefect on :
I wish I could figure these MMs out.
Had a buy in all morning at 75. Nothing...
Changed it to 80 and it went through, now 75s are going through like crazy.
Hrrrm.
Posted by QuestSolver on :
I wonder where we will be when they announce we are profitable this year? No doubt we will know the day before because the CEO made that projection that we will be profitable this year I am sure their will probably be a lot of volume before the announcement,the patent protection is what I am looking for,patents have a great effect on the PPS of a stock.
Posted by QuestSolver on :
prefect...happened to me twice today,they are scrambling I do believe and actually looking for sellers,round 2 is about to start,should be quite interesting in the last hour of trading!
Posted by Forrestgump on :
CBLE won't run before MACD line break 0 and if we get news in the same time...lock your hat on your head.
Posted by Forrestgump on :
www.MarketGainer.com: Market Gainer Issues Profile for Calbatech Inc. Monday , October 10, 2005 13:43 ET
Oct 10, 2005 (M2 PRESSWIRE via COMTEX) --MarketGainer.com strives to find dynamic issues that are unknown but because of their technology, approach, executive team, recent discoveries or other key factors, could advance in the market. MarketGainer.com has identified CalbaTech (CTI) (OTCBB:CLBE) a publicly-traded incubator which incubates smaller, life science-based companies that are developing next generation products and technologies.
Calbatech is having yet another day in the green today, trading up 28% as 2.5million shares trade hands. This wave of share price increase comes as a result of numerous public announcements adding to this company's financial success. CalbaTech is garnering investor interest as an emerging life sciences company, particularly with today's announcent that it's wholly owned subsidiary, K-D Medical, Inc., of Columbia, Maryland, has contracted with an independent sales and marketing group, Imgen Technologies, to bring its products to new customers with the intention of opening new accounts and increasing sales. K -D Medical currently sells its full line of molecular biology products to Universities, Research Centers and major Pharmaceutical companies nationwide
This move could push the company ahead as Imgen has extensive experience increasing sales and locating new customers. The group includes five members who travel from North Carolina to New York to demonstrate and service these product lines.
CalbaTech's timing of promotion could provide a competitive edge, especially after last week's double announcements that Dr. Jason Van Tassel has provided three pieces of stem cell related intellectual property to CalbaTech's wholly owned subsidiary LifeStem, Inc., and that CalbaTech's subsidiary, LifeStem announced that it is finalizing plans to offer a stem cell collection and storage service in selected markets.
The company's decision to attract sales and marketing expertise could be a key factor in this company's future. The field of stem cell research continues to fuel public interest, and the increased knowledge of consumers is moving them to consider using the stem cell related services.
Market Gainer will be watching Calbatech to see if the company can increase its market and tap into the new consumer awareness that could result in very healthy opportunities for financial gain.
To learn more about this company and others like it visit www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed. Market Gainer's team of market researchers, and industry professionals focus on doing one thing well - identifying companies with dramatic growth potential that you could profit from soon - sometimes within a few days of when we release information to our subscribers. To become a subscriber feel free to visit our site www.marketgainer.com.
The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.
All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Market Gainer may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Market Gainer's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market Gainer will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info*m2.com.
(C)1994-2005 M2 COMMUNICATIONS LTD
Posted by prefect on :
Averaged at 86...
Going to sit back and watch these last two hours.
Time to MOOOOOVE!
Posted by QuestSolver on :
great news!
Posted by Forrestgump on :
We may have a run tomorrow. Co preparing the field for patent and others news.
Posted by QuestSolver on :
this is well worth a strong hold imo!! I will not sell chit here!
Posted by Forrestgump on :
That might explain why with 1/3 of the float we still between 7 and 8. Creditor selling shares converted note.
Posted by prefect on :
So are they diluting this?
I mean 5 million shares in the last hour and we haven't moved up an inch!
Posted by QuestSolver on :
just got back in and see I got my other .078,cool,looks like the last dip of the day is upon us and should rebound quick imo!
Posted by QuestSolver on :
they are probably from the Agora deal I mentioned here,the shares will easily be absorbed and the .07's are the lowest level and the next level is .15 I believe,let me see if I can pull the details real quick.
Posted by QuestSolver on :
definitely going to be a gapper tomorrow and should bust .10 quicker then hitting it today
Posted by prefect on :
Let's see what's in store for the last 1/2 hour!
Posted by QuestSolver on :
buy pressure looks to be building and no matter what I don't care if we close here,just another green day for a killer long term play!!!
Posted by QuestSolver on :
I think this could be the very last chance to get in at the .07's if they let ya buy at all.
Posted by QuestSolver on :
rock n roll and no matter what we are in the GREEN another day!
Posted by QuestSolver on :
I have to believe that some of the shares today were from the SB2 filing and thats good,it will increase our liquidity and make buying and selling much easier.
Posted by prefect on :
Has anyone really had a problem buying?
I started playing this last week and never really had a problem.
Anticipating what the MMs were going to do that's another story.
Posted by QuestSolver on :
prefect...I have caught hell buying since Thursday! I put in a buy for a simple 25k and barely got it in 3 partials! I have been accumulating to get 500k from .039 up.
Posted by QuestSolver on :
since more MM's will get involved,take advantage of this while you can,at this point you and I and all other investors literally control this PPS by the MM's mirror trading...that to will change probably tomorrow or the next day,the MM's will take over since many more traders are actively getting involved now.
GLTA and I actually think I have a new pick to go with this one but refining the DD tonight,also in this sector!! I'll put it on this board when I think its a go so have some loose change ready.Have a good evening all!
Posted by Lucas Brachish on :
Alright Quest, I've gotta start following the threads you start earlier... you're right way too often. I didn't get in on this one when it was at it's low earlier in the month, but I think I'll to scrape together a few hundred $$ and see if I can get in now .... the chart is sooo pretty.
Does anyone think the MM's try to shake this one down soon, before it can run any more? And since it's gone up awful fast, I wonder if traders will begin to dump, grabbing the quick buck ... those are my only worries with CLBE....
Posted by Forrestgump on :
To me, between 7 and 8 seem solid...good resistance.
Posted by QuestSolver on :
LOL....Okay Lucas thats cool,as for this one I think its about to get a little more liquid therefore the MM's will close the Bid and Ask up more.I don't see this hiting the .06's again and should jump into the .08's just after open and the way it hit .10 this morning even caught me offguard but it will see it again just as quick imo.The chart says to me that this should idle down in the low .20's will retracement along the way up.(but this is an OTCbb and in this world anything can happen....LOL),thats why I press the issue that whenever you invest your first target must be to recover your principal funds back to ride free and totally put yourself in a riskfree position.(for newbies-example buy 100k at .02 and then sell 50k at .04 and you have 50k free shares and your money back,just one of many mathematical ways)
today I mentioned the SB2 filing.
whoever may be trying to understand the SB2 I mentioned that was filed back in July 22nd,I do believe some of the shares hitting the market today was from the filing.These shares are desiganted to be sold at differant levels up to .35 which is good for all of us who made entries way down here.I pulled sections out and posted them here along with the link,to all newbies you should read this filing fully for educational and future uses.The addition of these shares in full will still keep our OS under 97 mill total and this will help liquify the PPS where we can get buy or sell executions quicker and the bid and ask will get much tighter and we won't see penny spreads.The company obviously has the business plan on the right track (check use of proceeds)
This prospectus relates to the resale by the selling stockholders of up to 57,087,736 shares of our common stock, including up to 44,444,446 shares of common stock underlying secured convertible notes in a principal amount of $2,000,000 up to 12,143,290 shares of common stock issuable upon the exercise of common stock purchase warrants and 500,000 shares of commono stock The secured convertible notes are convertible into our common stock at the lower of $0.14 or 50% of the average of the three lowest intraday trading prices for the common stock on a principal market for the 20 trading days before but not including the conversion date. The selling stockholders may sell common stock from time to time in the principal market on which the stock is traded at the prevailing market price or in negotiated transactions. The selling stockholders may be deemed underwriters of the shares of common stock, which they are offering. We will pay the expenses of registering these shares.
up to 6,071,945 shares of common stock issuable upon the exercise of common stock purchase warrants at an exercise price of $.20 per share (includes a good faith estimate of the shares underlying warrants to account for antidilution protection adjustments);
- up to 6,071,945 shares of common stock issuable upon the exercise of common stock purchase warrants at an exercise price of $.35 per share (includes a good faith estimate of the shares underlying warrants to account for antidilution protection adjustments); and
- 500,000 shares of common stock
Common stock to be outstanding after the offering ................. Up to 96,517,476 shares Posted by Jerm on :
Quest... again, much thanks for the good work and sharing.
I totally agree with you... get free shares to ride! Ironically enough, this afternoon I was in the process of entering my sell order for half my shares (to get the rest free) when it took its dive! But I'm confident I'll be able to do just that before the week is up.
Posted by QuestSolver on :
Jerm,plenty of time left on this one imo to collect and convert to freebies. Right now I am in the DD process of another med sector pick that I was DD'ing along side of CLBE,near the final now and will post it probably before 10 or so once I make another verbal contact with the company for some other really non material details but it should complete the DD process for now.
Posted by QuestSolver on :
gotta feeling today is going to get active,we struck a lot of radars yesterday and will probably bring in more DT's which is fine with me,as much as some do not like flippers and DT's they do keep a stock fluid which is important,if your a tic by tic watcher you may want to consider Valeum or Prozac....LOL...I say we close another day in the green today but as we gradually increase the PPS we must settle down for a retrace before close Thursday so we can move up to the next higher level...don't freak out..all good stocks do it.
Q
p.s. I am trying to get final info for the next pick,I already confirmed the reversal is underway,need to make one more call that should take place before 10am Central time in this case,but maybe sooner,everyone on my two favorite boards will know first before I create a thread.
Posted by Forrestgump on :
I want a know for sure your next pick.
Posted by Forrestgump on :
Gapper this morning....
Posted by Persia on :
84 X 90
Posted by Forrestgump on :
Ready to explose upward
Posted by QuestSolver on :
off topic--one post only and sorry I could not PM anyone but time is important since I cannot mass PM everyone.Shares will be hard to buy here to.
PMED is my next pick after confirmation of a reversal on different levels, the previous issues are now settled and over and is about to get more attention. I am playing this as a short to mid term (under 3 months for now but that could change) only since I lack the info to confirm holding long as of yet. Same sector as CLBE but in another division. In no way do I see this as equal to CLBE but I speculate it should reach the upper single pennies fairly easy. They also have a smaller OS at approximately 28 mill but the AS eventually could reach 250m which is still modest but stocks like AMEP with almost 400m OS and 500AS easily shows you how they can move in the right sector and the energy and bio tech /med sectors are getting to be focused on throughout the season and thru the last quarter of this year. Looking at the chart for this you can easily see what I mean if your into charting. My opinion of a good entry here is anywhere from here to .03 to safely cover your double mark at my projected target of .06 (but that to can changed)
As you can see by the T/A chart it’s just beginning to start the reversal cycle and coming off an all time low now.
There’s also an alert going out now from Morning Star and just been rated a buy from American Bulls (if anyone cares about them at all…LOL) and also from another poster that has been pretty inquisitive.
“Revenue of over $3 million and they have over $1 million in cash. Just based on that, the company should be at $0.038. Only $2.5 million in debt, so it's not like they are grossly in debt or anything. Looks like the lawsuit has held this one down. Not much downside on this one”
As usual do your own DD on this as you have on the rest of my picks, do not buy off anyone else’s post or mine without verifying any info you may find and do not forget to target your principal first.
Q
Posted by prefect on :
what is with these MMs???
Posted by STOCKMOVER on :
I don't even want to watch my L2 screen now. This is looking bad. I hope we see a rise by late afternoon.
Posted by kywee on :
looks like quest started a sell off with his new pick lol
Posted by QuestSolver on :
got a small buy for 10k,take advantage of these dips,this will be setting up for the next level,this is a mid to long term play for CLBE not short.
Posted by QuestSolver on :
strong support above .065
Posted by QuestSolver on :
also PMED based out and is line for another upward move,should touch .03 today if all stays consistant
Posted by MB on :
boing...
Posted by rfggator on :
quest, .03 ??????????????
Posted by Persia on :
He means PMED, rfggator.
Posted by Persia on :
How can a bid/ask fall suddenly from 79 X 80 to 70 X 73?
Posted by MB on :
no volume, persia. I think once the volume comes back we will be above .08 again in no time. folks are distracted by PMED. wait til after lunch.
Posted by mmalone on :
MMs raising the ask on no volume... any theories on what's going on? Are they trying to get shares or are we just in a lull?
Posted by prefect on :
well this is sort of disappointing...
Posted by QuestSolver on :
I stated that this is a mid to long hold but will advise right now that if you cannot handle some negative movements then you may want to exit if your in the green.If this breaks the .0645 mark it may drop to .05 flat ut will be very short imo.I have bid support for 150k aon but they could pass right by me if they want to cause a panic.The reson I am saying this is for you newbies mainly,vets know the OTC's can get violant so always pretect your principal and try to hold free shares.Level 2 here looks fair at the moment and even the smallest buys can move it back up quick...but the smallest sells can also drop it.
Posted by prefect on :
like I said I am averaged at 86 so no green here...wondering if I should just take the lose and move on.
Posted by mmalone on :
quote:Originally posted by prefect: like I said I am averaged at 86 so no green here...wondering if I should just take the lose and move on.
Here's how I usually answer that question (if I don't have a pre-determined exit point):
If a stock goes down and I think 'I wish I could have gotten into this thing at this price' then I hold.
If a stock goes down and I think 'I was wrong about this' and am unwilling to put additional funds in then I sell.
Basically look at it as if you don't have any money in the stock right now. What would you do if that was the case?
GL
Posted by Persia on :
Hoping for some sort of virus outbreak in order to push this and other bio-tech stocks up... Posted by prefect on :
yeah it's tough...
I have learned not to trust these pennies whatsoever...get in get out.
I should have sold immediately this morning at 90 and switched to PMED...would have been a much nicer day. But now I am stuck and not really willing to take the 25% loss so I guess I will wait and see what happens.
I mean the fundamentals for the company haven't changed from when it was 23 cents, so I believe we could be right back at those levels. My exit is 10-12.
Posted by MB on :
still no volume. my guess is we go lower... .04 maybe then rebound on volume.
Posted by Persia on :
Last 2 days there was a last minute eod run, really last minute. See if it happens today.
Posted by Persia on :
L2's actually look good, 2 at 6 and 2 at 7. but the stock is moving no inch.
Posted by QuestSolver on :
for those in this above .065 take advantage of this and average down,looks like it may test .05 flat into late today and maybe tomorrow. Remember this is a mid to long play,not for flipping or scalping.
Posted by prefect on :
mid to long..meaning?
Couple weeks, months, years?
I don't believe in long in pennies...you will get burnt EVERY time.
Posted by Persia on :
Jeeez. I expected this stock to come down but not to the 40's actually.
Posted by MB on :
out at .058 trying for .042
Posted by mmalone on :
Careful, L2s show 5000x 0.049 on the ask then nothing til 15000x0.06 and 10000x0.07. Looks like a big shake to me. We'll see.
Posted by Persia on :
Come on boy or girl, a last minute run would be nice!
Posted by Superbee383 on :
From reading Quests messages, I've known since message #1 that this is a mid to long hold. I'm going to hold tight thru the dips, but holy moly! This one is the king of dips!!
Posted by QuestSolver on :
see that? I put in a 200k buy at .048 and they boosted the bid and ask up,this is typical in the pennies with low OS and float,they can duck over buys and sells quick if the MM's need inventory. > Posted by buckstalker on :
I just put one in at .054...no fill and they bumped it up immediately!
Posted by prefect on :
yeah my 45 buy didn't take but I got some at 49.
let's get some more buys at the ask, make her sail!
Posted by mmalone on :
Hah, saw that coming. Ask at 0.07 now.
Posted by tomktoo on :
Could someone please tell me when this stock ran to .09??? i had it covered all day & it started out at .083, & that was the highest. What time did it go to .09?
Posted by QuestSolver on :
gapped at open to .09 I believe,man some lucky ones actually too out the .04's quick!!!
Posted by Lucas Brachish on :
I just wish I'd either (a) waited for it to drop this low before buying or (b) sold it at today's high and then bought back in at this low. Instead I watched the stock turn greener and greener, and then drop until I was all red red red... depressing. But I'll keep holding. This one will work out well in the end, I think. Just not today. And by the time I've had my spare funds settle, it'll likely be too expensive to buy more (let's hope).
I've gotta learn how to wait for the real valley's and sell at the real peaks -- I'm always misjudging. I think 98% of the stocks I've owned where I've lost money (or at least haven't made nearly as much as I should have) were due to not knowing when to best hold and when to fold. I've rarely bought into a stock that was a complete dud -- they're just duds when I sell 'em.... Posted by QuestSolver on :
mid to long...don't get discouraged...we have been in the "WOULDA,COULDA,SHOULDA" position before.
Posted by Persia on :
Good morning people! Here's some news for ya.
CalbaTech Featured in Drug Discovery News Article Wednesday October 12, 5:00 am ET
IRVINE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, recently was featured in Drug Discovery News (http://www.drugdiscoverynews.com), which is a newspaper on the Internet for the pharmaceutical industry. The story follows in full: ADVERTISEMENT
In announcing plans by its Columbia, Md.-based subsidiary K-D Medical to acquire a new facility with two validated, class 100 clean rooms, CalbaTech not only had expanded manufacture of products on its mind, but also the opportunity to profit by leasing part of the new space to other companies -- some of whom could be engaged in drug discovery efforts.
Previously, K-D Medical's facilities consisted solely of a 7,000 square foot operation located between Baltimore and Washington, D.C., near the National Institutes of Health (NIH)-- for which K-D Medical is a "primary vendor," according to CalbaTech. That facility, like the new one, has two clean rooms for sterile production, as well as a room for contract medical packaging, a warehouse and a walk-in cold box.
Of direct and primary interest to K-D Medical and its parent company, CalbaTech, is that the additional space will provide for expanding the current custom product offerings and better serving the needs of both existing and new customers, including drug discovery companies, drug production operations, universities, government agencies and others in the pharmaceutical market.
K-D Medical's founder, John Powers, adds that the new clean rooms -- along with a complete quality control laboratory at the new facility -- will also allow the company to manufacture higher quality products.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers says.
In addition to expanding its manufacturing and client service capabilities, K-D Medical is also looking forward to leasing opportunities. One of the new clean rooms will be used solely by K-D, while the other one will be usable by contract customers.
"These new facilities allow K-D Medical to open new manufacturing and clean room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," says James DeOlden, chairman and chief executive officer of CalbaTech. "We are very bullish on our subsidiary's future."
"There are two types of potential customers for K-D through the new facility," Powers reports. "First, the incubator company who needs clean room operation capability and second, the large pharmaceutical company who may want to run prototype or small batch productions for research use only."
K-D will offer the opportunity for companies to utilize the approximately 1,000 square feet of available class 100 clean room, along with the adjacent 4,000 square feet of fully furnished and fitted laboratory space, Powers says, adding that the facility is ISO 9002 certified and FDA compliant.
"K-D is of the belief that a need exists for various companies who cannot afford the capital expense of approximately $100,000 to establish this type of high-end clean room and laboratory," Powers explains, "or who believe that such space rental at the K-D facility would allow them to maximize their existing production facilities, and to do so in our facility on a daily, monthly or annual basis."
CalbaTech provides products and platforms to the biotech and pharmaceutical research market and to academic institutions, while K-D Medical is focused on manufacturing bacterial and yeast growth media, microbiological biological buffers and reagents. As of the filing of its 10KSB documentation in May, K-D Medical's production was more than a half million liters of molecular biology reagents and buffers and nearly three quarters of a million bacterial and yeast biological media products yearly -- which were sold to "every major pharmaceutical company" in the United States, according to CalbaTech.
The announcement of the new facility acquisition was followed a day later by CalbaTech's announcement that its overall corporate revenues for the six months ended June 30 totaled $625,345, up from $58,217 for the same period in 2004.
That announcement also had good things to say about K-D Medical, particularly in relation to another CalbaTech subsidiary, Molecula, which provides antisense oligonucleotides to researchers worldwide.
"We are confident that Molecula and K-D Medical will continue to complement each other and that our cross-marketing plans will allow these two subsidiaries to generate $1.5 million in revenues in the current fiscal year," DeOlden noted in the revenue announcement.
Posted by Zygore on :
Lucas,
The best thing you can do to learn exit and entry points is to learn the charts and monitor the DD. If you follow discussion thread hype you will get burned every time.
I think part of the drop yesterday was due to PMED. Most people don't have money just laying around and is usually tied up in stocks. So with the PMED announcement alot of selling CLBE and AMEP was going on so they could get into PMED.
Just a day or two before the big hype on CLBE was that it was headed to .20 so people were chasing the stock trying to buy in and most likely bought high but the charts said it was about to take its normal dip and that's exactly what happened.
When that happens you can make a choice whether to try and average down or just hold and ride out the dip, both are a risk. Personally I like to average down if I have a lot of confidence in a stock and this one I do.
Amep on the other hand even according to the charts was primed for a run yesterday but didn't happen but then that was pretty much across the board so it looks to rebound especially with more news today.
Keep your chin up and take the necessary time to learn the charts is my advice.
Posted by QuestSolver on :
Zgore...CLBE will go to .20 and more imo and near term to.When I posted the pick I clearly stated mid to long play,this also makes allowances for flippers and DT's. This is just getting into the spot light as you can tell by todays PR and more to come.
Posted by Zygore on :
No doubt Quest I think it will even go higher mid to long term, I was just using that as an example of how most newbies mess up by following the discussion threads short term and up buying high and then are upset when the PPS falls on a dip.
Posted by QuestSolver on :
Zygore...thats probably a good point and your correct,its also a shame because most dump all their eggs in one basket...BIG BIG MISTAKE from my point of view! Always keep some loose change for any new picks!
Posted by Zygore on :
Now that's some advice I could have used yesterday! My pockets are empty at the moment:(
Posted by QuestSolver on :
not gapping yet but this is a late bloomer (within 5 minutes of open it shows)PMED gapping though.
Posted by Persia on :
LOL, only 900 in volume up to now
Posted by QuestSolver on :
I noticed that and they are not selling you any at bid,I got 50k sitting there now to buy.
Posted by Persia on :
Same volume for the last hour. Guess nobody is interested today.
Posted by Persia on :
Stock is sleeping!
I'm off, see you tomorrow, or better, read you tomorrow.
Posted by Lucas Brachish on :
Zygore, Quest... thanks guys. I know what you mean -- Newbie mistakes and all:
Before I joined this board I traded a lot less on a per-day basis, but I never experienced much turbulence -- I always had at least some idea of what to expect based on the charts and my own research, so I made nice, slow profits. But since I started following this board I've seen huge highs and massive, killer lows zooming by at warp speed, because the excitement of a good pick on a new thread does too often convince me to jump on a stock at a rather high point while it's moving up, and then it dips and crashes before I've had time to do much DD of my own -- stupid mistakes, I know, but, anyway, I'll be more careful in the future.
(Also, reading the charts of Pennies never works as well for me as reading charts for bigger stocks -- I'm very impressed by the people on this board who can make fast, accurate, and precise calls with the Pennies, even in the midst of a major change. That's tough stuff.)
And I wouldn't mind the ups and downs except that over the last two months the downs have outpaced the ups by an unseemly proportion, cutting me deep. But I trust CLBE, PMED, and AMEP to go back up to a decent number within a month ..... Everything looks good there. I just got on the rides at unideal points, like a few others here. But I'll hold on till we get the engine cranked back into gear....
Posted by QuestSolver on :
Wow...just got back in and see my .05 flat buy executed a partial but got nothing in the .04's at all yet.Down day all around today guys don't don't panic over it,we'll bee ok.
Posted by prefect on :
time for an eod push!
Posted by prefect on :
no chance I guess...
green day tomorrow please!
Posted by Zygore on :
Sell confirmed for CLBE and AMEP on American Bulls Dot Com DUUUHHHH! Even PMED had a SELL-IF.
I think you can type just about any stock symbol on their sight today and get a SELL. Sometimes the market can be just plain mean! Posted by kywee on :
not many people listen, or should listen to AB for pennies. AB doesnt know when a group is going to play a stock
Posted by QuestSolver on :
some on the other board have brought up the subject of Agora's involvement with CLBE and the SB filing so I will clarify it now.
Common stock to be outstanding after the offering ................. Up to 96,517,476 shares and thats the absolute maximum if they even use them at all and did you see the issue PPS level? .20's , .30's and you see that as bad?
and over 5 years yet?
50% of the warrants are exercisable until five years from the date of issuance at a purchase price of $0.20 per share. The other 50% of the warrants are exercisable until five years from the date of issuance at a purchase price of $0.35 per share.
here...look thru all the filings and read them all,I only deal in FACTS not BS as others do.
I plan on accumulating another good portion in the .04's and under for the next advancement. this is still a mid to long term play and will be worth holding free shares when the time comes.BIPH virtually did the same identical moves when it was trading in the .09's to .20's. If your interested you should really look out of the box into the Stem Cell issues as to whats going on and how we have advanced and see why its important and maybe you will get a better uderstanding as to why holding a position here or in any other good stem cell stock is worth the patience.
GLTA Q
p.s. my posting will be limited today and tomorrow,have a lot of running to do and heading out to Daytona Saturday for Biketoberfest all next week so I won't be around (unless I decide to bring my laptop on vacation with me which is likely...LOL)
Posted by QuestSolver on :
A draft paper by the Presidents Council on Bioethics surveys 4 ways to derive embryonic stem cells without destroying human embryos.The goal:Be practical but "ethically uncontroversial"
1 Alter embryonic stem cells
2 Rescue embryonic stem cells
3 Biopsy embryonic stem cells
4 Reprogram adult stem cells
further comment on this subject-"it would have zero ethical problems
info found on page 123 in the WIRED magazine.
Posted by bullish_pennystocks on :
what is the price target?
Posted by prefect on :
Anyone have any thoughts on this?
Down around 48% here wondering if I should just cut it loose...
Don't really want to wait for it to go to .01. Posted by Zygore on :
I am considering the same thing Prefect... Better to live to fight another day than to go down with this ship...
Posted by prefect on :
come one...do something!
Posted by QuestSolver on :
got 52,500 CLBE today at the low fortunately!
Posted by prefect on :
you're crazy...
Posted by STOCKMOVER on :
Prefect,
Same here, I am down 44%, this is painful to watch. I have never been down this low except a few months ago with JPHC, I was down about 74% but I held on and ended up with a 94% ROI. I am not so certain on this one, I feel like this can go to .01......I will give it another week and I am gone. Cut my losses and move on.
Posted by STOCKMOVER on :
Questsolver,
You said mid to long term, how long does that mean? I feel 3 months is a long term hold in these pennies. What is your angle?
Posted by kywee on :
long term in pennies is more then 3 days
Posted by prefect on :
quote:Originally posted by kywee: long term in pennies is more then 3 days
exactly the reason I am getting nervous.
was the move late last week and early this week a group or legitimate interest in the company?
Posted by prefect on :
looks like another great day...<rolls eyes>
Posted by QuestSolver on :
Good Morning all,
From the looks of level 2 trying to buy more in the .03's might be over.
Oct 17, 2005 (M2 PRESSWIRE via COMTEX) -- Today our stock watch alerts today include Featured Profile for VideoMovieHouse.com (OTCBB: VMHVF), SLS International, Inc. (AMEX: SLS) and stock alerts for Marmion Industries Corp. (OTCBB: MMIC), Hybrid Technologies Inc. (OTCBB: HYBT), CalbaTech, Inc. (OTCBB: CLBE), Lifestream Technologies, Inc. (OTCBB: LFTC)
CALBATECH, INC. (OTCBB: CLBE) "Up 26.32% in morning trading"
CalbaTech, Inc. (OTCBB: CLBE) is a publicly-traded incubator. CalbaTech incubates smaller, life science-based companies that are developing next generation products and technologies. The firm specifically sponsors companies that are capable of generating sales or licensing revenue within two years and require less than $1,000,000 to reach the market. It finances its acquisitions through a stock swap of a small percentage its own shares for 100% of the shares of the company being acquired.
Posted by QuestSolver on :
got the rest of my shares! I have a friend who was debating on which stock to buy on Friday,it was between GCCP and CLBE.....I think now she realized the mistake she made,she bought a boatload of GCCP in the .02's. I think our CLBE will be touching the .10's again soon,been in touch with Paul Knopick over the weekend and the outlook for CalbaTech is going to be great for all share holders!
Posted by QuestSolver on :
Thanx Zygore! This one is going to surprise many here when they look back at it in a month or two imo.
Oct 17, 2005 (M2 PRESSWIRE via COMTEX) -- Today our stock watch alerts today include Featured Profile for VideoMovieHouse.com (OTCBB: VMHVF), SLS International, Inc. (AMEX: SLS) and stock alerts for Marmion Industries Corp. (OTCBB: MMIC), Hybrid Technologies Inc. (OTCBB: HYBT), CalbaTech, Inc. (OTCBB: CLBE), Lifestream Technologies, Inc. (OTCBB: LFTC)
CALBATECH, INC. (OTCBB: CLBE) "Up 26.32% in morning trading"
CalbaTech, Inc. (OTCBB: CLBE) is a publicly-traded incubator. CalbaTech incubates smaller, life science-based companies that are developing next generation products and technologies. The firm specifically sponsors companies that are capable of generating sales or licensing revenue within two years and require less than $1,000,000 to reach the market. It finances its acquisitions through a stock swap of a small percentage its own shares for 100% of the shares of the company being acquired.
Posted by QuestSolver on :
check under Molecular applications division for the new DNA methods and the other sub catagories for just how much CalbaTech has going on.
check out the Cellular Therapy division for the iStem info.I am telling you they are connecting all the dots for one big outcome.
the research reagents is just icing on the cake!IMO buy and hold this and simply go away,let it sit and I think we all are in for a surprise in a month or two!
look under key personnel on the scientific advisory board,look at the credentials of these individuals,they are highly reckognized in their perspective fields and one even got a Nobel prize,these are highly motivated professionals in the field of success for biotechs!
Dr. Mullis received the Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the 20th century, one that revolutionized genetic science and engineering. PCR has also been an enormous commercial success. The original patent was sold to Hoffman LaRoche for $300 million and has generated more than a billion dollars in revenue from royalties.
Posted by MB on :
closed at .05 high of day...up 30%
Posted by hazel1401 on :
should hit .06 tomorrow maybe a good time to get out until the next dip
Posted by Lucas Brachish on :
quote:Originally posted by hazel1401: should hit .06 tomorrow maybe a good time to get out until the next dip
You think this will take another dip before making significant gains? I suppose it probably will.. I bought in at around 0.075, so I'd hate to sell at a loss, but if this is going to drop again it'd be more monetarily sound to sell at 6 and then buy back in at 4 and THEN wait for the long haul ...
But I'm not sure.... That kind of thing is always such a tough call. With my recent luck, if I sell at a loss the stock is sure to double in price before I ever get a chance to buy back in Posted by MB on :
I believe we will pass by .06 before another significant dip and .04 is history imo. If there is news then watch out..could be .1 before a pull back.
Posted by johnny14511 on :
SOMETIMES I FEEL LIKE YOU LUCAS.
BUT YOU KNOW WHAT IF YOU BUY A STOCK AND IT GOES DOWN ITS AMISTAKE JUST TAKE FAULT FOR IT AND WITH THAT MONEY THATS LEFT TRY TO MAKE A LITTLE SOMETHING
DONT JUST SELL WHEN IT HITS 6, MONITOR IT AND TRY TO SELL AT THE DAYS HIGH IF ITS GOING UP AND STARTS GOING DOWN A LITTLE DOSENT MEAN NOTHING IT MIGHT GO EVEN HIGHER,JUST GO WITH YOUR GUT
Posted by QuestSolver on :
Ain't nothing like coming home from the Boot Hill Saloon (Daytona) and seeing we closed at the high of day!
As for .06,the last time we broke out like that we hit .10 quick so selling at .06 is a "NO NO" for me.This one is acting just as BIPH did in its early stages from .09,once it broke the last time it stayed on the climb and yes,it did make its dips,but buying back in was quite hard as it will be here.I am tellin you,buy and hold this one and put it away,I have been in contact with the company as recent as this past Saturday (yes Saturday,they even work on the weekend!..LOL)CalbaTech has a lot more going for them then many will realize until its to late and they will be chasing it.
GLTA!
Q
Posted by QuestSolver on :
just bumpin some DD up front
Pro-Life Congressman and Dr. J Seek Adult Stem Cell Research Bill
Washington, DC (LifeNews.com) -- A leading pro-life congressman and former Philadelphia 76ers basketball star Julius "Dr. J" Erving teamed up at a press conference Thursday to ask the Senate to pass a House-approved bill that would promote adult stem cell research using umbilical cord blood. The bill provides funding to use stem cells from umbilical cord blood, which have proven to be the most effective and the House approved HR 2520 434-1 in May.
The Senate has stalled on voting for the bill because it has gotten caught up in the divisive debate over using taxpayer funds for embryonic stem cell research. Smith asked that the Senate not delay any further on voting on the bill.
"Delay is denial, especially for the sick who will not benefit from cord blood transplantation because the Senate inexplicably delayed," Smith said. "Make no mistake, for these sick children and adults, this is a matter of life or death."
Dr. J, who is currently the Vice President of the Orlando Magic, said African American patients need the bill to be approved because they have a much lower chance to obtain a match within the current bone marrow and umbilical cord blood stem cell inventories.
"Each year, thousands of Americans die who could be saved if larger and more diverse inventories of umbilical cord stem cells were in existence," Erving noted. "I came today to join Congressman Smith in asking the Senate to finish the job and pass this legislation and provide doctors the resources they need to treat the thousands of courageous patients in desperate need of help."
Currently, some minorities have less than a 50% chance of obtaining a potentially life saving transplant
Umbilical cords are a rich, non-controversial source of stem cells. Currently hospitals throw millions of them away each year because the infrastructure required to properly collect and store them is not available.
Thousands havebeen successfully treated with cord blood stem cells for more than 67 diseases including Leukemia and Sickle Cell Anemia.
The infusion of federal funds will make this medical miracle available to thousands more and will ensure that research continues so that this source of stem cells can treat many other debilitating diseases.
Numerous doctors and patients who have been treated with umbilical cord stem cells also attended the press conference.
Boswell backs adult stem cell research
Medical studies into embryonic stem cells have failed and it was time to get behind alternative research, Nationals Senate leader Ron Boswell says.
Three years ago, after a passionate debate, federal parliament passed laws giving scientists access to unwanted human embryos for research purposes.
Since then the national scientific regulator has issued nine licences for such research.
But Senator Boswell told parliament on Wednesday the research had come to nothing and support should now be given to alternative research on adult stem cells.
"The last debate was a very difficult one for many of us and led to deep searching over ethical issues involved," Senator Boswell told parliament.
"My point is that for all the pain we went through, for all the cost, we are not even close to the promised cures from embryo research.
"Yet there is true hope out there that medical research will tackle the most painful and debilitating diseases known to humanity and it will do it through adult stem cell technology.
"The only question is how long before the world wakes up to it.
"We have before us a sober opportunity to change direction to a zone of scientific research that is free of ethical dilemmas."
Senator Boswell said research had shown that adult stem cells provided a viable alternative to embryonic stem cells.
He said researchers at Queensland's Griffith University had successfully grown adult stem cells harvested from the olfactory mucosa, the organ of smell in the human nose.
They demonstrated the cells can give rise not only to nerve cells but also to heart, liver, kidney, and muscle cells.
The research team, led by Professor Alan Mackay-Sim has spent the past four years developing the research, particularly investigating the potential of stem cells in treating Parkinsons disease.
Senator Boswell's speech came as Industry Minister Ian Macfarlane was planning a forum for federal MPs next week to consider the issues surrounding stem-cell technologies.
Mr Macfarlane warned earlier this week that Australia's reputation as a global player in biotechnology could be undermined if conservative forces succeeded in banning embryonic stem-cell research.
Posted by QuestSolver on :
CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.
K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.
"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).
The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.
Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.
CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.
CalbaTech's business strategy is establish shareholder value by creating a significant new niche market by providing research reagents, equipment and services to the pharmaceutical research market, primarily through acquisition of life science companies that share the following attributes: 1) They will be generating revenues; 2) They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.
"The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office".
Also the fact that the stock ran to .20 in july, expenses static around 1-mil, and this news out Thurs., is significiant, only it may take a few weeks for everyone to sort out.
Posted by Jerm on :
Thanks again for the DD and hard work, Quest! All I ask is if you hear something negative you'll let us know that as well, as I believe you would.
Hope you are enjoying Daytona... wish I was there!
Posted by QuestSolver on :
wow, one decent buy and we jumped 4 points. I am buckling up. Bring on a little volume...
Posted by MB on :
.05x.057
Posted by Forrestgump on :
Reversal chart...MACD line need to break 0 first to run upward...Very interesting Chart because difficult to know where this stock is going in short term...need more buying pressure.
Posted by QuestSolver on :
looking good and I guess most already realize this is getting harder to buy any decent amount at a time without moving the B/A.This is going to be a great mid to long play.
Posted by QuestSolver on :
looking pretty strong now....a close over .06 would be nice,all it would take is a few small buys by investors who want to accumulate and hold mid to long.
Posted by QuestSolver on :
only 38,000 shares until it hits .06 and only 15k more to hit .07
Posted by Forrestgump on :
Quest do you still in PMED?
Posted by prefect on :
how do you know that?
Posted by QuestSolver on :
holding free PMED forrest and bought 50k today at these lows
prefect...look at the depth on L2
Posted by prefect on :
quote:Originally posted by QuestSolver: look at the depth on L2
Ok... I see three MMs sitting at .057 with a total size of 150. How does that translate to 38,000 shares?
Thanks.
Posted by QuestSolver on :
who all wants to buy 10k each? lets push this up over .06
Posted by QuestSolver on :
0.057 3000 OBB 0.057 10000 OBB 0.057 25000 OBB
15k at .06 but somehting is going on now,looks like they are tightening up the B/A
Posted by prefect on :
Am I missing something?
Posted by QuestSolver on :
getting jiggy now,going to be flip flopping and and may help bring in the EOD rush.
Posted by QuestSolver on :
going for another 10k buy right now at ask.
Posted by MB on :
closed at .055. I will be watching this one the rest of the week. I believe we could jump over .08 again before fri.
Posted by prefect on :
quote:Originally posted by MB: I believe we could jump over .08 again before fri.
That would be nice Posted by QuestSolver on :
not HOD but still a great close just have a feeling we get a PR tomorrow but really have nothing to base that on.Someone jumped over me on the last by at .056 but thats OK,this will be looking real good soon. I can see .08's as an easy target,just look at the share depth from .059 to .125,sure isn;t going to take much buying to bust the .08 and higher imo. This is a rock solid investment for a biotech play!
Posted by johnny14511 on :
if just more people can get into this the will make themselves some money
hey quest besides this one whats another good one your keeping an eye on?
Posted by QuestSolver on :
johnny...right now I am slowly loading up on PMED and also already loaded with AMEP for the winter months.CLBE is by far the most undervalued of the lot right now and should be heading back to the high teens or low .20's where it normally trades and then much higher over the next 3 to 6 months. I think its clearly going to be another BIPH type move in the making.I am currently on vacation in Florida for Biketoberfest and have not done any real DD on anything worth talking about yet ut will finish up a few when I get back on the 24th or 25th.
Posted by Forrestgump on :
I do agree with you about CBLE and PMED. PMED should be remove from SHO list tomorrow...If si this stock will run. SYCI is a very good play too because still unknow from investor communauty...I like this king of stock before they tend to run fast after their discovery...
Posted by QuestSolver on :
Scientists in separate experiments have obtained embryonic stem cells from mice without destroying an embryo. This could remove moral and ethical objections to using embryonic stem cells for medical research toward possible cures for Alzheimer's, diabetes, Parkinson's spinal injuries and other health problems. Embryonic stem cells are master cells that can develop into any part of the body: skin, bone, muscle, brain. However, when the cells are extracted, the embryo dies. Opponents of embryonic stem-cell research call it murder; President Bush has blocked federal money from supporting new lines of embryonic stem-cell research.
Scientists at the Massachusetts Institute of Technology were able to extract stem cells from eggs that were gene-blocked from developing into an embryo. Dr. William Hurlbut, a member of the President's Council of Bioethics, has endorsed this method because the eggs cannot produce an embryo that will develop.
A study at Advanced Cell Technology, a Worcester, Mass., company, adapted a fertility clinic technique of removing a single cell from an embryo. While clinics use the cell to test for genetic disorders, the company used it to establish a stem-cell line. In both instances, the embryo goes on to develop.
Another breakthrough of sorts occurred in August, when a Harvard University team of scientists were able to fuse an embryonic stem cell and an adult skin cell. The stem cell reprogrammed the adult cell to revert to a stem cell. If scientists can learn how the stem cell changed the adult cell, it may be possible to reprogram adult cells without using stem cells. That goal, those involved said, may be five to 10 years away.
Privately funded embryonic stem-cell research is being done here as well as overseas. Research in adult stem cells is also being conducted. Some scientists contend that embryonic stem cells have better potential for medical treatments than adult cells.
If science can extract those cells without destruction of the embryo, that potential could be realized without the moral and ethical doubts that now hinder research. Posted by QuestSolver on :
"I think scientists would be far better to concentrate on other areas of stem cell research such as amniotic and adult stem cells which show far more promise" Posted by QuestSolver on :
Stem-cell researchers debate ethics of new methods
BY JEREMY MANIER
Chicago Tribune
CHICAGO - (KRT) - When researcher Rudolf Jaenisch started work earlier this year on a method of producing embryonic stem cells that would avoid ethical objections, one of his first hurdles was not scientific but personal: He did not believe there was any moral problem in the first place.
But practical considerations led Jaenisch and his team at the Massachusetts Institute of Technology to attempt the new stem cell extraction method, which they described in the journal Nature this week.
The need to destroy embryos to obtain stem cells has aroused powerful opposition to federal funding of such work. But Jaenisch thought if he could extract the cells without destroying a viable embryo, it might satisfy the opponents. And less controversy could mean more money for the field.
"I don't really have the objections that many people do have," Jaenisch said. "But you realize the realities in this country ... I think we need a compromise in this debate."
Jaenisch's report is one of two new studies in Nature that outline ways of making embryonic stem cells without destroying a viable embryo. Jaenisch harvested stem cells from a mouse embryo that was not viable: It was genetically altered so it could not develop in the womb. A separate group at Massachusetts-based Advanced Cell Technology was able to take cells from a normal mouse embryo without destroying it.
Some ethicists believe the work could help quell the uproar over federal funding of stem cell research, though others say the new methods are no better ethically than the techniques that caused the original objections.
That even the researchers involved are ambivalent illustrates the keen difficulty of finding common ground on the issue. William Hurlbut, a Stanford University bioethicist who first proposed the method that Jaenisch used, said the researchers are sincere in seeking a solution, though he acknowledged the irony of the situation.
"This is a strange moment in science, because scientists are trying to solve a problem that they don't feel is a problem," Hurlbut said.
In fact, Jaenisch voiced skepticism about the ethical merits of Hurlbut's idea during an interview with the Chicago Tribune in May. At that moment, Jaenisch now says, his own team already was trying to make the technique work.
The process involves altering a method of stem cell extraction called nuclear transfer, or therapeutic cloning.
In the original technique, researchers make an embryo by placing the nucleus of an adult cell in an egg cell that has been emptied of DNA. After an electric jolt, the egg begins dividing like an embryo, eventually forming a ball of cells that contains stem cells. Such cells can form any kind of tissue, offering the potential of new treatments for conditions such as Parkinson's disease and diabetes.
Hurlbut proposed altering this technique so that the ball of cells, called a blastocyst, cannot form a full-fledged person. Jaenisch's team did that in mice by silencing a gene called cdx2, which helps form the embryo's outer wall and, eventually, the placenta that keeps a fetus alive.
Such deficiencies, applied to human cells, would result in an entity with "a dramatically different developmental potential than a human embryo," Hurlbut said. Skeptics contend it would still be an embryo, albeit a damaged one.
In May, when the President's Council on Bioethics issued a report that contained some praise and criticism of Hurlbut's technique, Jaenisch agreed with many of the critics.
"Does being human or not depend on the state of one particular gene? That doesn't make sense," Jaenisch said.
Jaenisch still doesn't agree with the moral basis of the new technique, he said. But he said it was an interesting experiment that could provide a practical foundation for advancing the field.
The method doesn't solve any moral problem for Richard Doerflinger, deputy director of pro-life activities for the U.S. Conference of Catholic Bishops. In an e-mail response to questions, Doerflinger said taking out the cdx2 gene "seems to make a very damaged human embryo that cannot survive past a few days of development (instead of making a new entity that is not an embryo)."
Like Jaenisch, Robert Lanza, leader of the research team at Advanced Cell Technology, has long argued that embryonic stem cell research is morally acceptable as is.
Still, he said, "I regard the embryo with respect. If we can do this without offending anyone, fine."
A new project has been launched to discover whether a patient's own stem cells can be used to treat heart disease.
The study, funded by the Heart Cells Foundation, is being undertaken at the Barts and The London NHS Trust, where researchers will conduct a four-year study examining 700 patients.
Experts will use three different types of stem cell therapy techniques on three randomised control groups – the first made up of patients whose hearts are failing due to a previous heart attack; a group of patients suffering from dilated cardiomyopathy; and a group made up of patients who had just suffered a heart attack.
Doctors will extract stem cells from bone marrow in some patients' hips to inject into their major coronary artery or into their heart in a minimally invasive operation, while other patients will receive growth factor drugs to encourage their stem cells to spill out into the blood stream.
Lead researcher Dr Anthony Mathur said: "This is one of the biggest and most comprehensive trials of its kind in the world.
"Our studies will tell us if adult stem cells in bone marrow can repair damaged hearts and if so how these cells should be administered to patients.
"There is growing evidence to suggest that stem cells may benefit people with serious heart conditions, such as heart failure or those who have had heart attacks."
The Heart Cells foundation was set up by Ian Rosenberg, who suffered from such severe heart disease he was given months to live, until he received stem cell therapy in Germany.
"Stem cell therapy has given me years I never thought I would have," he said.
"I set up the Heart Cells Foundation so that others may benefit from this new and exciting science."
Posted by QuestSolver on :
a lot of focus is being put into adult stem cell issues and CLBE is right in the midst of it among other things (gotta a feeling we will be getting news involving the companies DNA research soon,a completely differant division)
Posted by johnny14511 on :
im goignt ot keep on buying at days low
Posted by QuestSolver on :
good morning all.....
looks like the MM's are lining up early,only 8 MM's from .055 to .09 and then they are all .12 and above.
1 at .055 and 2 at .057
1 each at .06-.07-.08
and 2 at .09
Posted by QuestSolver on :
looks like the MM's are going to get jiggy early.I would like to see an early dip but so far don't see it,got some freed up cash now to buy another small block.
Posted by QuestSolver on :
flat open,looks like minor trading between .05 and .055,come on walk it up slowly!
Posted by QuestSolver on :
well people everyone have a great day! I am heading over to Daytona for a while and hopefully be back to see an ALL TIME HIGH! (LOL...hey I can wish right?)
Posted by QuestSolver on :
BTW I believe this will close the week out at .08
Posted by QuestSolver on :
Good Morning all,I see we were slightly down yesterday but bid is strong in the low .05's now.Just thing where its going to be when they announce they are in the black and showing profit this year!!
Posted by QuestSolver on :
from the last 10-k,2 major points of interest that many keep forgetting about.
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients." Posted by QuestSolver on :
LOL...I can't believe my lil 2000 share tester just now went thru at the ask....just 2000 shares!
Posted by QuestSolver on :
got another 3k tester just to see how fast and it took quick this time.
Posted by QuestSolver on :
the closer we get to the end of this month and into next I think CLBE and also AMEP both will get real active.Per the 10-k it clearly shows the direction they intend on taking this stock.It takes balls to include a statement in an SEC filing claiming "The company believes that it will report a net profit for 2005." and also "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."...these are bold statements imo.This stock is not going to continue trading within these ranges for much longer.
Posted by johnny14511 on :
this makes me think it will get in the dollars $$$$$ range
Posted by QuestSolver on :
johnny...I honestly beieve it will over time,this is why I am loading now at these levels when opportunity permits,even have a 5k buy in now for .051,I did the same with BIPH under a dime when no one wanted it...now look.I am in no hurry at all,this is a mid to long play (within 12 months from last August)
Posted by QuestSolver on :
LifeStem, Inc., is close to completion of its plans to offer a stem cell collection and storage service in selected markets. The stem cell market has developed sufficiently to a point that now offers vast opportunities. Potential consumers are becoming more knowledgeable about the possible benefits of stem cells and are more ready than ever to embrace new stem cell related services. "LifeStem has researched this market and believes that it has developed a novel approach to serve this rapidly growing market. We are anticipating launching our collection service no later than the first quarter of 2006, and possibly as soon as the fourth quarter of this year," said Dan Fulkerson, President of LifeStem Inc. LifeStem continues to maintain a focus on developing a novel approach to providing quality stem cells to researchers in California and believes that both its services will work in tandem. Future details will be provided after LifeStem completes patent and trademark protection. LifeStem is solely concentrating its efforts on autologous adult stem cells. Stem cells are the body's "master" cells that have the ability to grow into new healthy tissue. As a result, stem cells may have the potential to cure diabetes, heart disease, Alzheimer's disease, spinal cord injuries and many other medical conditions. Adult stem cells have shown great promise as a regenerative therapy and are free of the issues that complicate the use of embryonic stem cells.
About CalbaTech CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About LifeStem LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Posted by prefect on :
something tells me we won't be seing .08 today.
not that I was expecting too...
Posted by mmalone on :
Doesn't take much to move this thing. $20,000 could move this up 15 to 20%.
Posted by johnny14511 on :
just a little volume and up we go
Posted by breadwinner on :
MACD crossing into the positive moving averages. Chart drawing out nice indicators. Positive convergences forming and staying close to 50 day moving average. Usually a nice breakout to a higher high awaits a chart forming an ascending MACD. Short term candles indicates that with a little support at these levels, we keep posibility of making new short term highs alive.
Holding nicely at these levels and the fundamentals of this company dont look decent for a penny stock. Company forecast puts out that numbers are only getting better as time progresses.
I like your picks Questsolver. You always post competent plays. Of course every penny stock involves risk, but yours seem to be risk managed. : )
Bright future awaits is. At these levels, getting filled on your orders brings a good feeling. Clever investors know what theyre holding on to. GLTA this week, and lets not forget, small term fluctuations can be deceiving.
Posted by QuestSolver on :
The one thing about high quality penny stocks is that they rarely ever run high and fast at the same time.Most are slow growth but strong investments to certain levels. As science progress anyone can see that stem cell technology is going to be a major contributor but many here may believe that is all CalbaTech does and thats not true. I posted the link above for anyone to check out just what they do.They are really deep into DNA and molecular research also.Lets clear one thing up now though,this stock will not make you rich over night or even in a week or two,this is not a penny flip play.The OS is tight and trading shares even tighter so don't expect it to be an easy flipper unless MOMO is behind it. BTW I just got back from Florida,left a day early just in case the hurricane causes any evacuation traffic jambs.I hope all down there remain safe and get out if they can,I have a bad feeling about the new tropical storm (ALPHA) that is parallel to Wilma and just on the other side of Cuba,if they connect it could be bad and it will be right over Florida according to the maps.
GLTA and lets hope for a great week with news!
Q
Posted by ecko13 on :
I'm not doubting anything you post questsolver, and i'm not being negative, just being lazy and curious. Haven't done my DD on this so i wanted to ask you, looking at the 2 and 3 year chart this has not done anything, just wondering if there is any news or anything on this, and why you feel that this company is a good long term investment? TIA for any reply and answers to my questions. Posted by QuestSolver on :
ecko...this is complete differant then it was 3 years ago and even using the chart it shows that CLBE should be trading back in the normal range over .20,the lasy 10-K pretty much gave great guidance.Heres just 2 parts.
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients." Posted by QuestSolver on :
looking like a lazy day in the market so far.
Posted by QuestSolver on :
got a partial fill for my .045 buy,they still owe me 1623 shares out of 10k
Posted by johnny14511 on :
i was trying to get filled at .041 but didnt happen
Posted by STOCKMOVER on :
Quest,
All these shareholders bailing out are killing my portfolio. I am trying to hold on here but it takes a lot of strength of to look at all this red.
Posted by QuestSolver on :
Stockmover...I recommend you do whatever you feel comfortable with,as for bailing out...I don't consider the volume today as bailing at all,hell I bought more shares in 2 days last week then all of todays volume.As I have been saying though shares are held tight here with an extremely low OS to boot! I totally expect them to announce profitability before year end and that will get some major attention,especially from the penny stock watchers.I won't be surprised at all to see them apply for AMEX or even the NAS in the near future.Patience will be required here though,its going to be a gradual climber and not a fast buck that many want.
either way you must decide what you need to do and personally I will respect your decision whether its to sell and move on or hold until year end at least,its your money and there are some fast movers out here for a quick buck thats why I never tie all my money up just in case I need to play some flippers!
GLTY Q
Posted by QuestSolver on :
for new eyes getting to know what CalbaTech is really about.
CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
Molecula Research Laboratories, LLC
Molecula Research Laboratories, LLC ("Molecula"), located in Sterling, Virginia, is dedicated to meeting the needs of research scientists in the pharmaceutical, biotech, medical and academic research sectors by providing cell and molecular biology reagents and associated consumables. Molecula, a wholly owned subsidiary of the Company, is actively expanding its product range in siRNA. This builds upon its well-established reputation as a designer, manufacturer and supplier of active antisense oligonucleotides.
Molecula is focused on gene function solutions using RNAi technology. Their proprietary computer algorithm - T.A.R.G.E.T.? (The Advanced RNAi Guidance Evaluation Technology) system and 10 years of gene silencing experience, allows Molecula to consistently deliver active RNA duplexes for specific target gene silencing.
Molecula also develops and sells numerous research reagents for cell transfection, DNA and RNA purification, protein expression, gene expression analysis and other innovative and fundamental products. Molecula also sells transfection reagents, a novel IPTG replacement for increased protein expression, neuropeptides and biochemicals. Please see www.molecula.com.
KD Medical, Inc
CTI's first acquisition within the research reagent market was Molecula. Molecula has excellent design and manufacturing capabilities and is seeking opportunities to market its products on a larger scale.
After acquiring Molecula, the next step was to establish a more competitive entity capable of comprehensively supplying the specialist media and reagent needs of cell and molecular biology researchers. The product ranges of KD and Molecula are highly complementary, with little overlap. One of KD's greatest strengths is in the supply of specialized media for culture of model research organisms such as bacteria, yeast, insects and mammalian cell lines. It also supplies products to approximately 300 National Institutes of Health ("NIH") laboratories, contracts invaluable for establishing new products in a favorable government setting. Its secondary products are related to molecular biology reagents. Conversely, Molecula's primary focus is in the design and supply of high value molecular biology reagents such as siRNA and DNA antisense oligonucleotides. It also has reagents such as IPTG that are complementary to customized media. A large proportion of such research depends upon culture of a model organism (bacteria, fruit fly, etc.), which is genetically manipulated by transfection of customized oligonucleotides (siRNA). Thus, an alliance of KD and Molecula will be well placed to provide a competitive single source for these culture media transfection reagents and specialized modifier molecules such as siRNA. Further, as explained above, KD's long standing and trusted position, as a major in-house supplier to NIH will greatly ease entry of Molecula's siRNA into that major market. Please see www.kdmedical.com.
THE CELLULAR THERAPIES DIVISION
Strategy
The Cellular Therapies Division was created to house CalbaTech's emerging interests in cellular applications, particularly those relating to the use of adult stem cells. The Company believes this is an emerging market in which there are major opportunities for new entrants to establish new standards through novel stem cell research techniques and business models. The Company is positioning itself through strategic alliances to identify and take advantage of such opportunities as they emerge from the interaction between fundamental research and an evolving regulatory environment.
To this end, CalbaTech has incorporated LifeStem, Inc., to take advantage of this rapidly expanding market. In addition to advancing its business model for stem cell banking and the provision of purified stem cells to researchers, CalbaTech has filed a patent application for intellectual property relating to the efficient and effective delivery of stem cells to diseased or dead areas of the heart. This device should allow for effective and efficient delivery of stem cells to heart tissue to promote regeneration post myocardial infarction (heart attack). CalbaTech is currently seeking collaborative partners for this innovative device
LifeStem, Inc.
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 (Source DMD). This is projected due to the growth of new cellular therapeutics based on embryonic and adult stem cells, as well as clinical applications to compete with, or complement, existing drug based therapeutics. LifeStem's strategy is to leverage the CalbaTech infrastructure of companies to obtain a leadership position in the fast emerging stem cells arena and become the preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services. In time, it is anticipated that elements of LifeStem's services will become standard practice in mainstream clinical applications, thus opening a much larger market to LifeStem as a cellular logistics services company.
LifeStem is positioning itself to become a leading supplier of "Cellular Logistics" in this large new market. The company is focused on the following: (1) Providing a stem cell banking service to affluent individuals; (2) Providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells to the research market; (3) Developing delivery devices for clinical applications; and (4) Developing clinical applications of specific stem cell based therapies.
Stem Cell Banking
The opportunity to collect and preserve healthy adult stem cells on a pre-disease basis is certain to revolutionize the practice of medicine. The power and promise of stem cell therapies is just beginning to be known but the development of new clinical applications and therapies is imminent.
Posted by QuestSolver on :
looks like another low volume boring day.
Posted by mmalone on :
Huge spread on this thing.
Posted by QuestSolver on :
I put in multiple buys above the bid but just under the ask and they are not showing up yet,the bid should be showing .044 now or .043 at least.
Posted by QuestSolver on :
I just contacted the company and waiting a response now over something I know they have in the works and just want to know when they plan on a PR concerning some issues.
Posted by johnny14511 on :
hey quest any runners for tommorow?
Posted by Superbee383 on :
Quest, I'm still holding, but wow, it's getting tough! I hope you get some solid information from them soon. I want to buy more, but I need to see a solid PR before I put more $$ into it.
Posted by QuestSolver on :
just got a 7500 buy tester at .042 and it took within seconds this time.
still waiting for a response and yes we do need a PR soon.
Posted by QuestSolver on :
off topic
The Pentagon announced today the formation of a new 500-man elite fighting unit called the U. S. REDNECK SPECIAL FORCES (USRSF).
These 500 Kentucky, West Virginia, Mississippi, Louisiana, Missouri, Arkansas, Alabama, Georgia, Texas, Tennessee and North & South Carolina boys will be dropped into Iraq and have been given only the following five facts about terrorists:
1. The season opened today. 2. There ain't no limit. 3. Tastes like chicken. 4. They don't like beer, pickups, country music, or Jesus. 5. They are responsible for the death of Dale Earnhardt.
The mess in Iraq is expected to be over in about a week.
Posted by johnny14511 on :
hope so ....lol
Posted by Superbee383 on :
LMAO Quest! Good one :-)
Posted by QuestSolver on :
I don't see any news yet and I believe the 10-Q is due by mid November...that filing I can't wait to see! Following up from the 10-k they should show a profit or damn near and also projections in the $100 million area over the next 36/48 months for one division involving stem cells.
Posted by QuestSolver on :
I think the 10-q is due on the 16th
Posted by QuestSolver on :
best buying range OP now between .041 and .043
Posted by QuestSolver on :
WASHINGTON (MarketWatch) - The Senate won't act until early next year on legislation to loosen restrictions on federally funded research on embryonic stem cells, a top senator announced Friday.
In an announcement on the Senate floor, Sen. Arlen Specter, R-Pa., said that Senate Majority Leader Bill Frist, R-Tenn., "has committed to bringing it up as one of the first items next year," the Associated Press reported.
The deal eliminates a potential roadblock for a key spending bill. Specter had previously threatened to attach the legislation to the appropriations bill funding the departments of Labor and Health and Human Services - a move that was expected to delay action on the underlying legislation.
The agreement also releases Frist from a pledge to bring the stem-cell legislation to the floor this year. In July, Frist broke with President Bush and conservative Republicans by calling for an increase in federal funding.
The administration has placed strict limits on the use of federal money to fund research involving embryonic stem cells. The White House has said Bush would likely veto legislation that loosens those limits.
Frist's endorsement puts him at odds with anti-abortion advocates within his own party, who contend that embryonic stem-cell research destroys potential human life.
Advocates of expanded funding contend that the administration's restrictions have slowed the development of treatments for a range of diseases, including Alzheimer's disease, Parkinson's disease and diabetes.
The House has already passed similar legislation and backers believe they have the votes needed to achieve passage in the Senate.
Posted by prefect on :
this is really starting to get old...
Posted by QuestSolver on :
yeah but it looks like they needed to hit the .03's,it won't stay here long imo.Anywhere in this range is a great entry even for a short term double or triple within a few weeks.November will be good for this one and AMEP as I have stated before.
Posted by BULListic on :
They lowered the spread to 37x38 and I swooped in from another 50k....averaging down, usually the cardinal sin, but not if you believe in the longer term prospects.
Posted by buckstalker on :
It appears that ARCA has an unlimited amount of shares to sell....
Posted by prefect on :
I thought about picking more up at these levels but I really don't want to throw any more money at this...
The fricken thing loses me ~$200 a DAY!
Posted by BULListic on :
I see that ARCA is usually the one that wants to crash the party. Might as well be ORCA, the giant killer whale, who gobbles up all the shares and doesn't play fair. Will sit and wait for the next blockbuster news to send this back north of .06
Posted by QuestSolver on :
ARCA with unlimited shares? Hell the volume is not even 2 mill yet and all itlooks like is market makers flipping shares.I want to buy another 40,000 shares before the week is over to round off a block,today might be the best time but they still could shake it down to .035 or so.I'll be watchin closely,I pulled all my current buys and even the testers for now and hopefully will be able to get them all in one buy.
Posted by QuestSolver on :
check out level 2,theres very few shares down at these levels and the next step is well back into the .04's.Wonder of ARCA could be just consolidating before the run up.
Posted by johnny14511 on :
can anybody post the level 2
Posted by QuestSolver on :
I cannot post the Etrade screen here,guess I should figure it out huh?..LOL
Posted by QuestSolver on :
I am only showing about 120k between here and .08!
Posted by BULListic on :
Quest, looking for some Level 2 101 lessons here and I know 80% on about how to read, but where can you get a sense of available shares (I son't think just the bid size tells one anything?) at each level? I see each MM at their price, but is it possible to calculate X number of shares between point A and point B? Thanks!
Posted by QuestSolver on :
actually Bull you should be able to see the bid and ask depth that shows the exact quanity of shares sitting at each level,what L2 do you have?
I am tellin ya,this is trading identical to the patterns BIPH did back in the day! Did ya look at level 2 when I mentioned it? did you see what happened? It now looks like they were concealing buys to keep the ask and bid low and tight,see the 600k after hours that moved the ask up .042?
Quest, I don't have live L2 so I use the 15-20 minute delayed ones when I do look at them. I use the delayed at OTCBB.com and investorhub, etc. They are all pretty much the same. Is what you are seeing only for those that have a live service and pay for it. All I see is a size of 50 on all the MM's, which I don't think tells anyone how many shares they have until the next level. If I were to get into live L2, who would you recommend, or where do you get your extended info...Thanks, BULL
P.S. Time to turn this thing around....6 down days in a row and 10 of 12....now that is oversold!
Posted by QuestSolver on :
actually I think on the OTC site if you bring up level 2 and look all the way to the right it does give you the depth (there should be 3 columbs)
Posted by johnny14511 on :
Right, but all that 3rd column is is the time and sales data showing trade by trade, it doesn't show how many shares each MM has available in their inventory, and I think that's what we're talking about, the inventory of each MM. Oh yeah, that 50,000 at 14:41:22 at .038 was mine! The ones in green are buys that raised the price, the pink are sales that lowered the price and the ones in white are where the price stayed the same, ot at least that's how I decipher it. We can see NITE is at .042 and SCHB is next at .048, but what I'm trying to get at is how many shares does NITE have in their inventory before we blow by him and get to SCHB, etc. etc. Almost all of them have a "size" of 50 but what does that really mean? That doesn't tell anyone whether they have 50,000 shares in their inventory of 5 million. I know that later one at the bottom where MAXM has a size of 25 that he has less to offer than the others at 50, and that's about all I know. Can anyone shed light on this?
Posted by prefect on :
Quest I still don't see where you are getting this...
I have live L2 quotes and I am looking on the OTC site and there is nothing like what you speak of. Here is a grab from the Depth/Level II page on OTC.
-------------------------------------- Level II Quotebook
First column is the bid, second is the ask and the third is Time & Sales.
So where is this "depth?"
Posted by QuestSolver on :
your right that site only shows the shares that passed,let me see if I can work this out and post a link.
Posted by buckstalker on :
You guys don't really believe that the MM's are going to show you how many shares they have available...do you?
Posted by imakmony2005 on :
Sorry they dont show there hand man if they did it would be to easy.to bad
Posted by QuestSolver on :
I do believe CLBE is going to be a gapper tomorrow,I hope many took advantage fo the dip today.
Posted by breadwinner on :
Well, I don't view my portfolio on a daily basis, but today I happen to notice the chunk of capital that CLBE absorbed. So I decided to share with this very optimistic board that I'll more than likely be averaging down as the week comes to an end. In a way, I sort of want CLBE at these levels. Gives us a chance to average down for a greater return later.
I'm in no way looking for short-term gains here as I got in this stock for 2 reasons. First, I'm constantly reading tremendous facts on the progress that stem cell researches are making. CalbaTech plays a small but vital role in all this. Secondly, the chart looks like this is an ideal entry point for a stock that's about to make a huge recovery. All just my opinion. Won't be surprised to see it trading in the dollars as early as next year. The company has already forecasted great revenues for 06 and they have'nt been around for that long. Companies in this industry usually take 5+ years before earning any profit. Take that into consideration and that fact the ClabaTech only has 39 mil in SO and you got a stock that's setting up for a colossal run up to new highs. Mark this thread. GLTA
Posted by QuestSolver on :
looks like we are thinking along the same line breadwinner.When I first posted on this stock my projections have been mid to long term,they have so much going on right now that once they all fall into place this will surely be considered an investment and not a trading stock.
Posted by nattty04 on :
I would love to get in on this stock, but my money is tied up at the time. What a price at .04ish. MMMM. 6 months from now, an easy 10 fold. Have fun all those who have this.
Posted by QuestSolver on :
might want to loosen up a couple of bucks nattty,even short term this one will make money for many.
Posted by JL on :
What happened to this one? Ran a lil last month...now its back in the Dumpster?
Posted by QuestSolver on :
got my tester at .04 and have a REAL buy sitting at .037 but doubt it executes
Posted by BULListic on :
32 x 34 Quest, I think you got your price.
Posted by Superbee383 on :
I'm trying to buy at the ask, and they aren't taking it.. yet .032x.034
Posted by Superbee383 on :
Got 10k at .034. Bringing my average down anyway!
Posted by JL on :
Looks like its dying.....
Posted by QuestSolver on :
just got just under another 10k at .034,i am totally taking advantage of this right now,this is going to be an outstanding mid to long term investment!
Posted by QuestSolver on :
adult stem cell (ethical and uncontroversal),Biotech R&D,DNA,Molecular research,cell banking.
10-q will be out around the 16th,the 10-k says they expect to be profitable THIS year.
Buy and hold and put it away for a month or two and see what happens.These levels will be gone for good soon.
Posted by BULListic on :
OK, back to the size thing (where bigger isn't always better )....ARCA is at 150 on size....still looking for what that means....does that mean we'll be here for awhile at .034 because of him?
Posted by QuestSolver on :
back to .038 and the clock is ticking,no way this continues to be a bottom feeder play.
Posted by QuestSolver on :
lunchtime lull effect,should restart around 2 or so. ;D
Posted by BULListic on :
ARCA has taken a lunch break as well. Not on the bid or ask...and that's a good thing from what I've seen.
Posted by johnny14511 on :
YES LETS SEE NEXT WEEK Posted by QuestSolver on :
went into idle for now it seems.
Posted by QuestSolver on :
come on baby wake up into close!!
Posted by prefect on :
another day another $120 gone...
Posted by MeanGreen on :
What was with that huge buy after the bell? 1.3 million???
Posted by QuestSolver on :
someone took a dump!!! they really have been beating us up the last 2 weeks pretty much!! wish they would back off a bit to give us a breather!
Posted by QuestSolver on :
16:00:48 0.032 1360000 OTCBB 15:59:48 0.034 50000 OTCBB 15:59:05 0.034 75000 OTCBB at Ask 15:58:59 0.034 75000 OTCBB at Ask 15:58:33 0.034 9000 OTCBB 15:57:27 0.034 25000 OTCBB 15:57:25 0.034 10000 OTCBB 15:57:24 0.034 25000 OTCBB 15:54:49 0.035 40000 OTCBB at Ask 15:54:48 0.035 10000 OTCBB at Ask
Posted by QuestSolver on :
I would like to know where those shares came from? were they held out of site for the close? I don't see any 1.3 mill even consolidated!
Q, I dont know what you think your seeing but i have three L2s screens and none will show me how many shares a MM has just that he is there and most of the time it says 50 are 2500 are 1500, but they can sit all day if they have the shares, thats why i like seeing them jump around thats good sitting thats bad.
Posted by JimSC on :
Great entry points for 4 high-growth stocks at bottom:
CLBE, VTLV, VMHVF, and PMED.
Posted by QuestSolver on :
definitely CLBE and PMED (can't give an opinion on the other two since I know nothing about them)
Posted by QuestSolver on :
looks like L2 getting confused!! yes move up,thats the right direction!!LOL
Posted by QuestSolver on :
news out on STEM today...one day we will be right there with them!!
Posted by QuestSolver on :
gotta feeling we see news on Nov 1st,now is the time to make an entry for anyone out of CLBE.
Posted by QuestSolver on :
ask holding tight.
Posted by QuestSolver on :
ask heading north now
Posted by QuestSolver on :
CLBE and PMED both are a steal now if you are looking for a good mid to long play!!
Posted by trader_adam on :
I am holding TWOG OMOG AMEP CLBE PMED. When can I expect these to grow? I'm holding these for the long term...
Posted by QuestSolver on :
per CNBC--Bears rule October,all stocks selling into rallies..."GET US OUT OF OCTOBER" per analyst!
Posted by QuestSolver on :
NOVEMBER is going to be a great month for CLBE!
gapper Monday watch and see.
Posted by QuestSolver on :
IMO getten in before close would be wise today.
Posted by johnny14511 on :
ALL SET FOR NEXT WEEK
Posted by JimSC on :
Status of 4 high-growth stocks:
CLBE: up 21%; news expected next week. VTLV: up 13%; quarter report expected next week. VMHVF: up 10%; news expected next week. PMED: down 12%; great entry point.
Posted by QuestSolver on :
nice close all,at least they did not sell a block after hours and that is a good sign,it may actually be over.News is overdue now so we should get a PR early next week and the quartery is due within 3 weeks now.
everyone have a great and safe weekend and lets look forward to a great November starting Tuesday!
Q
Posted by prefect on :
Definitely a better day today!
Still have a long way to go though, hope there is some goooooood news next week.
Posted by QuestSolver on :
Doctors: Adult stem cells, cord blood hold most promise By Jim Shea Correspondent
At the 18th bi-annual interfaith Breakfast for Life Oct. 26 at Rutgers University, New Brunswick, approximately 150 doctors, students, clergy, members of the professional community and other pro-life advocates heard from one of the leading experts on the topic of ethics and stem cell research.
Speaker Dr. David Prentice is a founding member of Do No Harm: The Coalition of Americans for Research Ethics and a fellow of the Wilberforce Forum Council for Biotechnology Policy, both in Washington, D.C., and an advisory board member for the Institute on Biotechnology and the Human Future, Chicago.
“We keep hearing about the promise of embryonic stem cells, but the claims are simply unsubstantiated,” he said. “At this point in time there is little evidence of the effectiveness of embryonic stem cells. Proponents have yet to take even one dish of embryonic stem cells and have these cells change into one specific cell, i.e. a heart cell or brain cell. Based on experiments to date, it’s not safe to even try and apply them to patients.
“The bottom line,” continued Dr. Prentice, “is that our real promise lies not in the use of embryonic stem cells but with adult stem cells. Adult stem cells are today already at work in patients. I can document, through published scientific papers, with over 65 human diseases, where patients are better already, having been effectively treated through adult stem cells.”
“Some scientists admit there are ethical concerns in the use of embryonic stem cells,” Dr. Prentice said. “But, these same scientists continue to ignore the success in patients and the use of adult stem cells. The debate is ongoing. We face a lot of challenges, but the key question remains, ‘What does it mean to be human, and what kind of values do we give to any human life, whether it be a little embryo, a fetus in the womb, a newborn or someone at the other end of their life with advanced Alzheimer’s?’
“We must value every human life,” he added. “We need to push ethical science. We have an ethical problem in one sense, to make sure that everyone knows the real facts about the stem cell debate. The ethical question is that you have to kill a human embryo, a young human life, in order to obtain an embryonic stem cell. What we are dealing with is a human being at its earliest stage of life. We need to make sure we know the full facts and get out and talk about them with our friends, family and people at work. We have to write letters to the editor and to our legislators.”
Dr. Prentice also referred to a push in the U.S. Senate for a national cord blood bank, “Where we can do the kinds of magic we need to do in order to treat patients. There are thousands of patients already better, thanks to the use of cord blood alone.”
“Yesterday, (Oct. 18) Acting Gov. Richard Codey signed an executive order to establish a cord blood bank for umbilical cord blood,” said Marie Tasy, executive director of New Jersey Right to Life, adding to Dr. Prentice’s comments. “Umbilical cord blood is ethical stem cell research, and is already providing cures for people with sickle cell anemia and leukemia.”
Tasy also discussed issues that could be addressed by the legislature after the November election. “One would use $150 million in funds to construct the New Jersey Stem Cell Institute in New Brunswick,” she said. “There are also two legislative measures that would place a question on the ballot to have voters approve millions of dollars in public bond money. One measure would use $230 million and the other calls for $500 million.”
Fellow guest speaker Dr. Gary Friedman, medical director of the Center for Regenerative Medicine, Morristown Memorial Hospital, and trustee for the New Jersey Stem Cell Research and Education Foundation, agreed with Dr. Prentice’s assessment. “As of 6 p.m. last night, there were over 141 approvals for human clinical trials, utilizing human umbilical cord stem cells,” he said. “Going back 10 or 15 years, there were probably only five or 10 such cases. At the current rate, use of adult stem cells is exploding.”
“What I have learned,” Dr. Friedman said, “is that life is precious. I get to see people giving life to other people, day in, day out. People volunteer to donate their organs to a friend or family member. This shows the great giving capacity of human beings. We also understand, through the process of arranging for organ transplants, that we cannot forcibly take a life from another human being.”
Those who attended the breakfast felt it provided them with vital information that often isn’t discussed in regard to stem cell research.
“I didn’t know how effective adult stem cell research was,” said Nicole Czarnecki, a Rutgers University student. “I had no idea adult stem cells worked so well and that embryonic stem cells were not as effective.”
Shannon Varga, a student from St. Peter the Apostle High School, New Brunswick, expressed gratitude for the opportunity to attend the breakfast.
“I’m so glad I came today, to find out the importance of adult stem cell research,” she said. “I’m convinced embryonic stem cell research is wrong.”
CAMDEN Acting Gov. Richard J. Codey and Democratic gubernatorial candidate Sen. Jon Corzine reaffirmed their support for stem-cell research Thursday afternoon with a tour of the Coriell Institute for Medical Research.
"It's essential that public policy be supportive of stem-cell research in all of its forms," Corzine said. "This is fundamental for our state and all of mankind."
Codey has begun a series of initiatives to fund stem-cell research. Last week, he named Coriell, in Camden, as one of two public umbilical cord and placental blood banks in the state.
The stem cells are harvested from the blood in placentas and umbilical cords that would be discarded after a normal birth.
The institute stores the stem cells, which are made available to researchers looking to cure diseases like diabetes, AIDS, multiple sclerosis, Parkinson's and Alzheimer's.
Stem cells can also take the place of bone marrow in transplants for people with leukemia and sickle-cell anemia. Since last week's announcement, the institute has already received two placenta donations, Codey said.
"Hopefully, some human being will have their life saved by that placenta," Codey said.
Republican candidate Doug Forrester has said he said he favors adult stem-cell research but does not support research on embryonic stem cells.
As the second state to legalize embryonic stem-cell research, New Jersey must remain a leader in the biomedical research, Corzine and Codey said.
For the Liebermans, a Mount Laurel family of four, the issue is personal. "It's about me getting well," said Barbara Lieberman, who has suffered from multiple sclerosis since 1985. "My kids, they don't understand why it's not being funded, why cells have more rights than their mom."
The children were so outraged that they decided to do something about it.
Ten-year-old Ellie Lieberman, a fifth-grader at the Hartford School, raised thousands of dollars for the National Multiple Sclerosis Society selling "garden goodies" -- mostly plants, seeds and decorative bricks made by her 12-year-old brother Ben.
Scientists should focus on proven adult stem-cell research
JESSICA RODGERS
October 30, 2005
One of my favorite television shows is the science-fiction drama "Stargate Atlantis," mainly because of its smart writing and fast-paced action. A recent episode, however, reminded me of the distortion of facts surrounding a current and real issue.
The writers were talking about stem cells. Embryonic stem cells, to be exact.
Before I continue, allow me to give a summary of what stem cells are, and why they are considered to be so valuable. In the case of embryonic stem cells, they are taken from a 5- to 7-day-old embryo. In adult bodies, cells have specific jobs -- blood cells, brain cells, skin cells, etc. However, in an embryo, these systems are not finished developing and easily can be given a different purpose by scientists.
Many scientists think that they can use this to their advantage by taking the cells and shaping them into whatever may be needed for any given treatment. Great numbers of people, myself included, see a huge moral issue with this, however. The cells cannot be harvested without the destruction of a growing baby. A small baby, yes, but it cannot be confused with anything else. It is not a baby fish or a baby cat; it is, inarguably, a baby human.
All moral issues aside, though, the fact is that embryonic stem cells, for all the hype surrounding them, offer no benefits. Not one single treatment, much less a cure, has come from these studies. There haven't even been human tests with them.
Conversely, adult stem cells have provided more than 100 types of treatment for diseases, including numerous types of cancer, leukemia, multiple sclerosis and Parkinson's disease. That is only a small sampling of what adult stem cells have been able to treat with success.
It seems that it should be a common-sense issue that we invest our research dollars into a study that has real promise, not one that is a flop. Shouldn't all of our resources be going toward a study that can treat dying people?
The science behind adult stem cells is similar to that of embryonic cells. Yes, the cells already have specified "jobs," but researchers are able to simply take the cells and change their purpose. Even better, by using adult stem cells, patients receive cells from their own body, taking away the risk of reacting to a separate DNA pattern -- a risk that is real with stem cells from embryos.
President Bush has received much criticism for his policies regarding embryonic-stem-cell research, but unfortunately, those who favor using those cells are woefully misinformed of the truth. The truth is, as science has discovered, embryonic stem cells simply don't work. In many cases, they can make a situation worse by taking on the characteristics of cancerous cells. As someone who has experienced cancer in my family, I find that to be no small risk.
What with the moral issues, scientific problems and health risks involved in using embryonic cells, there is no need to hold out hope for what these cells could do for our future. Scientists already have a solution that is producing real results in the treatment of diseases. With adult stem cells, the future is now.
Jessica Rodgers, 16, is a home-schooled senior. Reach her through education reporter Sarah Evans at sevans*StatesmanJournal.com or (503) 399-6856.
Posted by QuestSolver on :
although this PR is focused more on embryonic stem cells the unethical and controversal method is being pushed aside for a better method of adult stem cell usage.
October 30, 2005
Scientists turn stem cells into cancer killers Research on federally approved embryonic line offers hope of creating tumor treatment
By David Shaffer Minneapolis Star Tribune MINNEAPOLIS, Minn. -- University of Minnesota researchers have turned embryonic stem cells into cancer-fighting cells in the lab. The research at the Stem Cell Institute doesn't offer an immediate cancer treatment, but the findings suggest that stem cells eventually could be used to boost the body's ability to fight tumors.
Using one of the federally approved embryonic stem cell lines, scientists first coaxed the cells to turn into blood cells, including "natural killer cells." These naturally occurring cells produce proteins that attack tumors. Then the research team mixed the killer cells with cancer cells in a culture dish and watched as the cancer cells died, according to a report in the Journal of Immunology. "This is really the first evidence that we can harness human embryonic stem cells to make a cell population that is able to kill tumor cells," said Dr. Dan Kaufman, an assistant professor at the institute and co-author of the report. Researchers next plan to test whether stem cell-derived killer cells will attack tumors in mice, he said. Similar studies elsewhere using adult stem cells have successfully attacked cancer cells in lab animals, Kaufman said. In theory, boosting the body's natural killer cells should help battle cancers. It remains unclear whether adult or embryonic stems cells will be more promising in such efforts. Kaufman said researchers eventually may be able to target natural killer cells to attack tumor cells. For that to work, more embryonic cell lines may be needed, he said. Government rules now limit the number of such stem cell lines available for federally funded research.
Posted by QuestSolver on :
October 27, 2005 Ethicists Say New Stem Cell Study Deserves Closer Look WASHINGTON (BP)–One of two new techniques aimed at producing stem cells without harming a human embryo is worthy of further study through research on animals, some pro-life bioethicists are cautiously saying. In one study, a team from the Massachusetts Institute of Technology used a version of cloning known as altered nuclear transfer (ANT). In the process, a gene in a mouse skin cell is turned off before the nucleus is placed in a fertilized egg, which develops to a stage in which stem cells can be extracted. By switching off the gene, however, the researchers make the embryo incapable of implantation in the uterus. The question in this procedure appears to be whether an embryo has truly been produced.
Pro-life bioethicists are not as inclined to endorse another new method reported on by a team from Advanced Cell Technology in Worchester, Mass. The researchers took single cells from eight-cell mouse embryos. They derived stem cell lines from those individual cells, and the embryos seemingly developed into healthy mice. The procedure is similar to preimplantation genetic diagnosis (PGD), a technique utilized in in vitro fertilization. In PGD, an individual cell is removed from an eight-cell embryo for genetic testing before the tiny human being is implanted.
The new techniques were outlined Oct. 16 in the online version of Nature, a science journal.
(see Calbatechs new extraction techniques)
While some ethicists said both methods pass ethical scrutiny, others who have led the opposition to destructive embryonic research offered qualified support only for experiments using the ANT technique.
“The quest for ethical ways to retrieve stem cells is genuinely encouraging, and animal studies should certainly go forward expeditiously,” bioethicist C. Ben Mitchell told Baptist Press, “but it’s too early to tell whether the [ANT] technique can be applied to human embryos without harm to the embryos. We should remain open to the possibility.”
Even so, one thing that must be avoided “is the view that human beings – whether embryos or adults – are natural resources we can strip mine,” said Mitchell, associate professor of bioethics at Trinity Evangelical Divinity School in suburban Chicago and a consultant for the Southern Baptist Ethics & Religious Liberty Commission. “Human beings deserve respect, not commodification.”
There were questions about each of the methods from two members of the President’s Council on Bioethics.
William Hurlbut, a consulting professor at Stanford University and a proponent of the ANT technique, told Nature concerning the PGD-like method that removes a single cell, “You are getting a live birth, but are you getting the same child you would otherwise get? It is uncomfortable to me to endorse such a strategy.”
just lurking on a few other boards and ran across some interesting post.
concerning adult stem cells and extract by: nobodysfool62 Long-Term Sentiment: Strong Buy 10/30/05 08:10 am Msg: 283950 of 284028
Although I no longer hold GERN I do own STEM and ASTM but after some serious and indepth DD and checking many varibles including current PPS compared to potential PPS I believe CLBE is by far the best investment in this sector now.Dig thru the 10-K and look at the rev increase that will be even higher this quarter and are expected to close this year profitable,its obvious that the current entry price will not last much longer.With 3 patents pending,FDA approval for new extraction methods and they even have their own division for stem cell banking.All this just from one division and does not include the DNA and molecular R&D divisions.I feel quite confident CLBE and its divisions will be measure in dollars per share in the very near future,your simple DD will uncover this.
Posted by QuestSolver on :
Plan adds stem cell coverage
October 30 2005
CHAROEN KITTIKANYA
With the rate of blood diseases such as leukaemia or thalassemia increasing among the Thai population, Thai Life Insurance is now offering coverage for stem cell therapy treatments.
According to Preedee Kwan-ngam, an executive vice-president, the new plan is the first of its kind in the world, covering medical expenses for stem cell transplants.
Stem cells are cells that have the potential to develop into many different cell types in the body.
The ethics of using stem cells for research have been hotly debated as most are found at the embryonic stage. To avoid controversy, some scientists have turned to studying adult stem cells derived from blood and bones.
In Thailand, the best known case of the benefits of stem cell technology is that of Dokrak Pethprasert, a 47-year-old woman,who had a limbal stem cell transplant after going blind following treatment at a hospital.
According to Mr Preedee, the new stem cell treatment will be available as an added rider to existing health insurance policies under the Health Insurance Plus Plan.
The coverage will not include cosmetic surgery and physical rehabilitation.
Due to be introduced on Dec 1, the coverage will be available under seven plans with the amounts insured ranging from 300,000 to one million baht.
The annual premium for 300,000 baht in coverage, for instance, will be around 2,700 baht for men and 3,400 baht for women.The coverage is available for those aged from one month to 65 years.
should be working its way back up to the .20 to .25 range very soon.
Posted by QuestSolver on :
gapping up now,at .044
Posted by QuestSolver on :
I have an AON buy that has not been touched at the ask,shares are still pretty tight it seems.No buying or selling.
Posted by QuestSolver on :
got 2500 as a tester
Posted by QuestSolver on :
I think we are starting to begin the reversal and uptrending now,hopefully we get back to where CLBE normally traded at .20 to .25 and don't forget the 10-Q will be out very soon (around the 16th)and we should get a completely new view of where this puppy is heading!
Posted by QuestSolver on :
31 Oct 2005, 11:06 AM EST
Jump to msg. # CLBE-CalbaTech inc.
this stock will be trading over a dollar within 6 months.
also from another board.
CLBE-major biotech play coming by: wickedclownicp2003 Long-Term Sentiment: Buy 10/31/05 09:56 am Msg: 1178939 of 1178970
remember buying BIPH at .09? Now try CLBE under .05,from last 10-k they expect to be profitable this year,the 10-q is due around the 16th.They are into Adult stem cell research and also molecular and DNA R&D.Just chart it and you will see that its heading back to .20 to .25 on current fundamentals. Analyst project this to hit $1 to $1.20 within 6 to 12 months.DD it and you will see why they are projecting that figure!OS at 39mill.
Posted by QuestSolver on :
now in the .05's,very low buying this could easily hit .08 by looking at level 2.
Posted by trader_adam on :
Quest- do you think this will retrace again, or is .51 a good place to buy some more?
Posted by QuestSolver on :
trader--thats a decision you need to make,it could retrace after lunch or it could blast off to .08 since theres little resistance between there and here.If you are holding this mid to long term you will see that anywhere under a dime now is a great opportunity.
Posted by QuestSolver on :
lunchtime is about over....many stocks are quiet for the moment.
Posted by QuestSolver on :
Adult stem cell news and info really getting noticed,heres another penny stem cell stock,soon we will be right there with them imo.
BrainStorm Announces Significant Preclinical Benefit of Its GDNF Producing Stem Cells in Animal Models of Parkinson's 10/31/2005 9:00:00 AM EST
BrainStorm Cell Therapeutics (OTCBB:BCLI), today announced that the company's scientific collaborators at Tel Aviv University had successfully implanted human bone marrow derived stem cells into animal models of Parkinson's disease and observed improved motor function within just two weeks of implantation. The beneficial effect was retained for over three months. Worldwide rights to the development and commercialization of the new technology are exclusively licensed to BrainStorm.
The differentiated cells were previously shown to produce a unique protein required for brain cell survival and growth, glial cell line derived neurotrophic factor (GDNF). The GDNF expressing cells, known as astrocytes, were derived by differentiation of human bone marrow stem cells, using the proprietary NurOwn(TM) technology that has been developed by the Company based on discoveries made by Prof. Eldad Melamed and Dr. Daniel Offen of Tel-Aviv University. This technology is exclusively licensed to the Company. In the current study, the cells were transplanted into Parkinson's disease rats, generated by specifically damaging their dopaminergic cells. Within weeks of the transplantation, there was significant improvement in their characteristic disease behavior, including more than 50% reduction in rotational movement and enhancement in their paw reaching capacity.
GDNF capacity to protect a variety of neurons and induce neural sprouting holds great promise for treatment of many neurodegenerative diseases, including Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and even Alzheimer's disease. GDNF has been shown efficacious in restoration of neural function in multiple disease models and its use for human disease is currently being evaluated in clinical trials.
Unfortunately the delivery of GDNF to the disease site is difficult. GDNF is a protein and, as such, has limited stability and brain penetration. Attempts made to deliver the protein directly into the brain have met with limited success. An alternative approach, to deliver GDNF by genetic therapy, suffers the limitations and risks of using viral vectors. Moreover, cell therapeutic approach using either genetically engineered or differentiated embryonic and neural stem cells are limited by issues of graft rejection and potential tumorogenic risk.
Posted by QuestSolver on :
setting up for an EOD rally it looks like! News before open would be nice tomorrow!
Posted by QuestSolver on :
bid support looking stronger now!
Posted by QuestSolver on :
got some momo kickin in on low volume to! EOD run up a bit!
Posted by QuestSolver on :
this is a strong buy and hold!!
Posted by QuestSolver on :
Great day all!! remember...patience is most important when playing high quality penny stocks,they really do pay off in the end! I was very pleased selling BIPH over $2 when I bought it at .09 thru .20! I hope to do the same here!
have a great night all,getting ready for Halloween!
Posted by OFFROAD on :
This seems to be agreat stock
Posted by QuestSolver on :
I was just re-reading the last PR and the more I look into this company the more I like it,take some time and really read this press release,it gives you a good idea where they will be heading!
CalbaTech Featured in Drug Discovery News Article
IRVINE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, recently was featured in Drug Discovery News (http://www.drugdiscoverynews.com), which is a newspaper on the Internet for the pharmaceutical industry. The story follows in full:
In announcing plans by its Columbia, Md.-based subsidiary K-D Medical to acquire a new facility with two validated, class 100 clean rooms, CalbaTech not only had expanded manufacture of products on its mind, but also the opportunity to profit by leasing part of the new space to other companies -- some of whom could be engaged in drug discovery efforts.
Previously, K-D Medical's facilities consisted solely of a 7,000 square foot operation located between Baltimore and Washington, D.C., near the National Institutes of Health (NIH)-- for which K-D Medical is a "primary vendor," according to CalbaTech. That facility, like the new one, has two clean rooms for sterile production, as well as a room for contract medical packaging, a warehouse and a walk-in cold box.
Of direct and primary interest to K-D Medical and its parent company, CalbaTech, is that the additional space will provide for expanding the current custom product offerings and better serving the needs of both existing and new customers, including drug discovery companies, drug production operations, universities, government agencies and others in the pharmaceutical market.
K-D Medical's founder, John Powers, adds that the new clean rooms -- along with a complete quality control laboratory at the new facility -- will also allow the company to manufacture higher quality products.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers says.
In addition to expanding its manufacturing and client service capabilities, K-D Medical is also looking forward to leasing opportunities. One of the new clean rooms will be used solely by K-D, while the other one will be usable by contract customers.
"These new facilities allow K-D Medical to open new manufacturing and clean room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," says James DeOlden, chairman and chief executive officer of CalbaTech. "We are very bullish on our subsidiary's future."
"There are two types of potential customers for K-D through the new facility," Powers reports. "First, the incubator company who needs clean room operation capability and second, the large pharmaceutical company who may want to run prototype or small batch productions for research use only."
K-D will offer the opportunity for companies to utilize the approximately 1,000 square feet of available class 100 clean room, along with the adjacent 4,000 square feet of fully furnished and fitted laboratory space, Powers says, adding that the facility is ISO 9002 certified and FDA compliant.
"K-D is of the belief that a need exists for various companies who cannot afford the capital expense of approximately $100,000 to establish this type of high-end clean room and laboratory," Powers explains, "or who believe that such space rental at the K-D facility would allow them to maximize their existing production facilities, and to do so in our facility on a daily, monthly or annual basis."
CalbaTech provides products and platforms to the biotech and pharmaceutical research market and to academic institutions, while K-D Medical is focused on manufacturing bacterial and yeast growth media, microbiological biological buffers and reagents. As of the filing of its 10KSB documentation in May, K-D Medical's production was more than a half million liters of molecular biology reagents and buffers and nearly three quarters of a million bacterial and yeast biological media products yearly -- which were sold to "every major pharmaceutical company" in the United States, according to CalbaTech.
The announcement of the new facility acquisition was followed a day later by CalbaTech's announcement that its overall corporate revenues for the six months ended June 30 totaled $625,345, up from $58,217 for the same period in 2004.
That announcement also had good things to say about K-D Medical, particularly in relation to another CalbaTech subsidiary, Molecula, which provides antisense oligonucleotides to researchers worldwide.
"We are confident that Molecula and K-D Medical will continue to complement each other and that our cross-marketing plans will allow these two subsidiaries to generate $1.5 million in revenues in the current fiscal year," DeOlden noted in the revenue announcement.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About K-D Medical, Inc.
K-D Medical, located in the heart of the Maryland Biotech Corridor, is one of the nation's leading manufacturers of microbiological culture media and other research reagents. K-D Medical's products are used in drug discovery, microbiology labs and biopharmaceutical production. The company is headquartered in Columbia, Maryland.
Posted by QuestSolver on :
QUESTION BY A POSTER--I read in a new article recently that the current value of the stem cell industry in the year 2005 is about 500 million dollars. They estimate that the industry by the year 2010 only five years from now will be worth 30 Billion dollars a year...
1) With a 60 times the revenue in 2010..how will this affect the value of stem cell stocks...
Does this mean the Stocks in Stem cells will be worth more...
How will this affect the stock
ANSWER--Absolutely it would effect probably all good stem cell related companies especially those that are focused on adult stem cells because by the embryonic stem cells will be no more.Between stem cell extraction and banking many good penny stem cell stocks like CLBE will increase PPS multiple times and I feel quite confident saying that!As for you numbers I believe they are quite accurate and will find supporting info,I to read how they expect that increase and its massive!
that link takes you to many other infomative press releases and various info,the adult stem cell industry is going to be measure in the hundreds of billions without any doubt in my mind.CLBE is linked up with just about all of the major pharm companies and when you read some of the links you will see why that is so important. These companies are throwing around tens of millions of dollars into stem cell related companies,trust me,they know exactly what they are doing.Heres just a few examples THIS WEEK
U of MN researchers awarded more than $20 million for stem cell and natural killer cell research 31 Oct 2005 17:36 GMT ... researchers awarded more than $20 million for stem cell and natural killer cell research University of ... over five years to conduct research on stem cells and natural killer cells for treatment of ...
CA Stem Cell Institute Must Allow Taxpayers, Patients to Have a Controlling Interest in New Medical Breakthroughs; Consumer Group Calls on Regulators to Protect $3 Billion Investment 31 Oct 2005 17:35 GMT ... CA Stem Cell Institute Must Allow Taxpayers, Patients to Have ... with the use of adult cord blood stem cells. Prop 71 stem cell research grants could ...
A*Star to invest S$70m over 3 years to boost stem cell research 31 Oct 2005 15:35 GMT ... : A*Star's Biomedical Research Council has earmarked S$70 million over three years to support stem cell research collaborations. The move is one of four proposals aimed at bringing scientific research ...
Soaring Biomedical Research Funding a Boon to Innovators and Investors; Investment Grows 154% to Estimated $94 Billion in Last Decade, Strengthening R&D Pipeline for Emerging Growth Biotech Companies 31 Oct 2005 14:35 GMT ... company's scientific collaborators at Tel Aviv University had successfully implanted human bone marrow derived stem cells into animal models of Parkinson's disease and observed improved motor function within just two ...
Dr. Reddy's Reports Q2 FY06 Revenue of Rs. 5,803 million; YoY Growth of 7%; Net Income Increases by 72% to Rs. 890 Million 31 Oct 2005 14:35 GMT ...
Posted by QuestSolver on :
bringing some info up front for any newbies.
CalbaTech (CLBE) is definitely a great mid to long term investment imo.(3 to 12 months or more)
reading the most recent 10K, thought I'd share some of my favorite quotes:
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
3. Officers and Directors:
James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.
Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.
John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.
4. Scientific Advisory Board:
Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.
Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.
in a new article recently that the current value of the stem cell industry in the year 2005 is about 500 million dollars. They estimate that the industry by the year 2010 only five years from now will be worth 30 Billion dollars a year...
Catholic Church Funds Adult Stem Cell Research
The Catholic Church in Korea has decided to donate money for adult stem cell research. The move comes amid strong Vatican opposition to embryonic stem cell research and is reflects support for research into an alternative. The Church has been among the most vocal opponents of embryonic stem cell research based on the belief that embryos are human beings. In Korea, a country leading that field of science, the Catholic Church is donating millions of dollars to aid research involving adult stem cells in the hope of reducing the increasing reliance on embryonic stem cells to treat hard-to-cure diseases.
"The research harms the integrity of life, and that's why we cannot accept the use of embryos," the church said. It wants to fund research on adult stem cells derived from bone marrow or umbilical cords that would otherwise be discarded after a baby is born. They say this is more practical and does not cause ethical controversy.
CalbaTech now looks to build a portfolio by buying companies that develop new technologies to sell or license; it also targets universities that are planning to license technology developed in academic labs. The firm is interested in products that will generate sales or licensing revenue within two years and need less than $1 million. Among its acquisitions are MolecularWare and iStem Technologies
Pro-Life Congressman and Dr. J Seek Adult Stem Cell Research Bill
Washington, DC (LifeNews.com) -- A leading pro-life congressman and former Philadelphia 76ers basketball star Julius "Dr. J" Erving teamed up at a press conference Thursday to ask the Senate to pass a House-approved bill that would promote adult stem cell research using umbilical cord blood. The bill provides funding to use stem cells from umbilical cord blood, which have proven to be the most effective and the House approved HR 2520 434-1 in May.
interesting info posted by Umpolung on another board...
Kary Mullis is an "interesting" read:
"Sometimes a good idea comes to you when you are not looking for it. Through an improbable combination of coincidence, naiveté and lucky mistakes ..." Kary B. Mullis (The Unusual Origin of the Polymerase Chain Reaction, Sci. Amer., April 1990, p. 445).
He testified for the defence (against PCR) at the trial of OJ Simpson.
He also believes that HIV does not cause AIDS.
He's the head of the CLBE scientific advisory board.
With the withdrawl of Vioxx and other COX-2 inhibitors, IMHO, we have seen the first of a series of failures of so-called "selective" drugs. Coupled with drug failures for other reasons (patient compliance, resistance, etc.) stem cell therapies will undoutedly play a major role in the future of medicine perhaps replacing these front-line drug treatments; however, as has been indicated, edumacation is the key...err, education and effective stem cell treatments. CLBE is money well spent but the road will be rocky (i.e., a day/swing-traders dream).
Posted by breadwinner on :
The chart should not be the reason to buy this stock but it sure does looking nice: )
- The stock just crossed 50 day moving average.
-The MACD is forming an outstanding positive divergence. (A common trait in breakout stocks)
-The MACD is also getting ready to make a bullish centerline crossover.
-RSI is rising and pointing north
With these indicators and more forming, plus promising earnings being forecasted, I don't see how this is not a strong buy. JUST FACTS people. CalbaTech is compelled to have an enduring run. JMHO. Do some research. The pps is a steal under a dime.
Posted by Zygore on :
CALBATECH INC Quick Quote: CLBE 0.05 (Even)
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent Application for Stem Cell Microbank and to Trademark 'Stem Cell Microbank' 11/1/2005
IRVINE, Calif., Nov 01, 2005 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., filed for US Trademark protection for the name of its stem cell collection service, Stem Cell Microbank, and filed a provisional patent application on the process of the Stem Cell Microbank for its process of stem cell banking. LifeStem believes that it will be the first company to focus on the micro-collection and banking of two different types of stem cells from one client.
"LifeStem's approach is based on the model that it may not be necessary to harvest a regenerative therapeutic amount of stem cells at the time of collection," said CalbaTech CEO James DeOlden. "Our collection service is unique in that stem cells will be collected in non-invasive, micro-quantities and cryo-preserved for cellular expansion at the time of use."
LifeStem, in addition to being the first company to focus on the micro-collection of stem cells, will also be the first company to offer a collection service that collects and stores two different types of stem cells for autologous use. "We believe that it is in the client's best interest to store stem cells from two tissue sources," added LifeStem President Dan Fulkerson. "By preserving two different types of stem cells on a pre-disease basis and making the cells available to the client, the client is afforded two distinct and different stem cell lineages to better suit their particular situation. The benefit to the client is that LifeStem's Microbank storage service allows the client to select the best cell source to be expanded based on the future need."
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and plans to launch its Stem Cell Microbank in the first quarter of 2006.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc. http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
Posted by Zygore on :
Wow, collecting two different types of stem cells while your healthy, storing them for future autologous use, should you become ill, and being able to have a choice of which of the two to expand that will be best suited for your particular future need.
This sure beats freezing your body until science can figure out to fix you. Posted by QuestSolver on :
OUTSTANDING!!!!!!!!!!!!!!!!!
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent Application for Stem Cell Microbank and to Trademark 'Stem Cell Microbank'
IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., filed for US Trademark protection for the name of its stem cell collection service, Stem Cell Microbank, and filed a provisional patent application on the process of the Stem Cell Microbank for its process of stem cell banking. LifeStem believes that it will be the first company to focus on the micro-collection and banking of two different types of stem cells from one client.
"LifeStem's approach is based on the model that it may not be necessary to harvest a regenerative therapeutic amount of stem cells at the time of collection," said CalbaTech CEO James DeOlden. "Our collection service is unique in that stem cells will be collected in non-invasive, micro-quantities and cryo-preserved for cellular expansion at the time of use."
LifeStem, in addition to being the first company to focus on the micro-collection of stem cells, will also be the first company to offer a collection service that collects and stores two different types of stem cells for autologous use. "We believe that it is in the client's best interest to store stem cells from two tissue sources," added LifeStem President Dan Fulkerson. "By preserving two different types of stem cells on a pre-disease basis and making the cells available to the client, the client is afforded two distinct and different stem cell lineages to better suit their particular situation. The benefit to the client is that LifeStem's Microbank storage service allows the client to select the best cell source to be expanded based on the future need."
Posted by QuestSolver on :
smart money will be buying on this news,anyone can see the upcoming sequence of events that should continue to increase the value of this company. The DT's and flippers will probably scalp it for tenths of a cent but I am sure someone will be standing by ready to accumulate their shares.This is a mid to long play and should make many here wealthy if they play it right.Anyone who sells on this news is foolish
Posted by QuestSolver on :
should be a nice open,this patent application should be approved rather quickly since it does not involve any major trial like most drug patents.
Posted by QuestSolver on :
This patent will surely protect CLBE for this first time technique where as other stem cell companies will probably have to purchase a license agreement to use this technique.
Posted by QuestSolver on :
looks like no sellers lined up...ETRD moved up to .15...LOL wouldn't that be nice!
Posted by QuestSolver on :
post from another board....
CalbaTech-CLBE--this PR is just one of 3 expected concerning patents.This is a buy and hold for massive gains.For those of you who bought BIPH under a dime (thanks makingbiggdough)then you know what I mean.CLBE will be trading at or over a dollar within 6 months imo.Other stem cell companies will have to purchase Calbatechs license agreement to use this new method.
Posted by prefect on :
jeez that was sort of short....
why can't these mms just let this go!
Posted by QuestSolver on :
its just a dip for consolidation no biggie,the lack of sellers will force them to move it.I had a 10k buy sit on .055 for a while before it took.
Posted by QuestSolver on :
I hope the west coast interest builds,I don't see any major resistance until .08,the high .05's is slight and very little buying pressure would break in imo.I think most simply don't realize what an opportunity this is.
Posted by QuestSolver on :
"plans to launch its Stem Cell Microbank in the first quarter of 2006"
" it will be the first company to focus on the micro-collection and banking of two different types of stem cells from one client"
"Our collection service is unique in that stem cells will be collected in non-invasive, micro-quantities and cryo-preserved for cellular expansion at the time of use."
filed for US Trademark protection and filed a provisional patent application on the process
Posted by QuestSolver on :
check out level 2 again..only 2 MM's in the .05's and thats NITE and SHWB,all others but one at or above .08
Posted by QuestSolver on :
all I can say is be in a good stem cell stock long before the first quarter of next year.
WASHINGTON (MarketWatch) - The Senate won't act until early next year on legislation to loosen restrictions on federally funded research on embryonic stem cells, a top senator announced Friday.
In an announcement on the Senate floor, Sen. Arlen Specter, R-Pa., said that Senate Majority Leader Bill Frist, R-Tenn., "has committed to bringing it up as one of the first items next year," the Associated Press reported.
The deal eliminates a potential roadblock for a key spending bill. Specter had previously threatened to attach the legislation to the appropriations bill funding the departments of Labor and Health and Human Services - a move that was expected to delay action on the underlying legislation.
The agreement also releases Frist from a pledge to bring the stem-cell legislation to the floor this year. In July, Frist broke with President Bush and conservative Republicans by calling for an increase in federal funding.
The administration has placed strict limits on the use of federal money to fund research involving embryonic stem cells. (they will all focus on auldt stem cells imo) The White House has said Bush would likely veto legislation that loosens those limits.
Frist's endorsement puts him at odds with anti-abortion advocates within his own party, who contend that embryonic stem-cell research destroys potential human life.
Advocates of expanded funding contend that the administration's restrictions have slowed the development of treatments for a range of diseases, including Alzheimer's disease, Parkinson's disease and diabetes.
The House has already passed similar legislation and backers believe they have the votes needed to achieve passage in the Senate.
Posted by Forrestgump on :
Quest it is just a matter of time now because the chart look very strong
Posted by QuestSolver on :
Plan adds stem cell coverage
CHAROEN KITTIKANYA
With the rate of blood diseases such as leukaemia or thalassemia increasing among the Thai population, Thai Life Insurance is now offering coverage for stem cell therapy treatments.
According to Preedee Kwan-ngam, an executive vice-president, the new plan is the first of its kind in the world, covering medical expenses for stem cell transplants.
Stem cells are cells that have the potential to develop into many different cell types in the body.
The ethics of using stem cells for research have been hotly debated as most are found at the embryonic stage. To avoid controversy, some scientists have turned to studying adult stem cells derived from blood and bones.
In Thailand, the best known case of the benefits of stem cell technology is that of Dokrak Pethprasert, a 47-year-old woman,who had a limbal stem cell transplant after going blind following treatment at a hospital.
According to Mr Preedee, the new stem cell treatment will be available as an added rider to existing health insurance policies under the Health Insurance Plus Plan.
The coverage will not include cosmetic surgery and physical rehabilitation.
Due to be introduced on Dec 1, the coverage will be available under seven plans with the amounts insured ranging from 300,000 to one million baht.
The annual premium for 300,000 baht in coverage, for instance, will be around 2,700 baht for men and 3,400 baht for women.The coverage is available for those aged from one month to 65 years.
I will say this much, this is one of the most illiquid stocks I've ever seen. NITE on the bid at .0515, I put in a small order to see a few shares at .051, it executes a whole 444 shares (yes, a whopping $22 worth!!!!) and the bid drops from .0515 to .05 flat. Quest, I still say going back to the conversation late last week, there is no way to know the inventory by MM. If NITE can't get me more than 444 shares, then screw 'em all.
Posted by QuestSolver on :
many will be waking up to stem cell knowledge soon especially since its going to be a $30 billion dollar industry in the next 5 years...thats a big jump from only $500 mill now.
don't worry...it will get in a real fluid state before the end of year!
Posted by QuestSolver on :
looks like its prepping for and EOD rally CLBE has a habit of releasing back to back PR's if I remember correctly.
Posted by QuestSolver on :
not bad so far into closing...like to see a follow up PR about profits!!
Posted by QuestSolver on :
I think this is just the beginning,November is going to be a good month.
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent ... PR Newswire (press release), NY - 12 hours ago IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ --
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http ... CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent ... PharmaLive.com (press release)
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent ... Yahoo! News (press release) all 6 related »
CalbaTech Featured in Drug Discovery News Article PR Newswire (press release), NY - Oct 12, 2005 IRVINE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company ...
CalbaTech Advisory Member Contributes Stem Cell Intellectual ... PR Newswire (press release), NY - Oct 6, 2005 6 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... "We're pleased to have the support and contribution of Dr. Van Tassel," said CalbaTech CEO James DeOlden. ...
CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of ... PR Newswire (press release), NY - Oct 5, 2005 IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board ... stem cells. About CalbaTech CalbaTech, Inc. (OTC ...
CalbaTech's Subsidiary, KD Medical, Inc., Contracts With ... PR Newswire (press release), NY - Oct 10, 2005 IRVINE, Calif. and COLUMBIA, Md., Oct. 10 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... The contract is for two years. About CalbaTech CalbaTech, Inc. ...
CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of ... Biotech Intelligence (press release), France - Oct 5, 2005 IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (BULLETIN BOARD: CLBE) , an ... CalbaTech, Inc. (BULLETIN BOARD: CLBE) is ...
(PRN) - Major Youth Football Tournament Will Kick Off in Qatar ... ... Bolsamania.com, Spain - 11 hours ago ... [+]. (PRN) - CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent Application for Stem Cell Microbank and to Trademark 'Stem Cell Microbank' ... [. ...
CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of ... Yahoo! News (press release) - Oct 5, 2005 IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE ... CalbaTech, Inc. (OTC Bulletin Board: CLBE ...
CalbaTech's Subsidiary, KD Medical, Inc., Contracts With ... Yahoo! News (press release) - Oct 10, 2005 IRVINE, Calif. and COLUMBIA, Md., Oct. 10 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... The contract is for two years. CalbaTech, Inc. ...
CalbaTech's Subsidiary, KD Medical, Inc., Contracts With ... PharmaLive.com (press release), PA - Oct 10, 2005 IRVINE, Calif. and COLUMBIA, Md., October 10, 2005 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... The contract is for two years. CalbaTech, Inc. ...
This could be the one that hits.... and selling for only five cents.......
Get the word out...
mizzou7
Posted by QuestSolver on :
mizzou7...of course I agree and BTW the short term rating just went to buy and hopefully mid and long follows today,the uptrend has been confirmed and this should be moving back into its normal trading range soon which is in the low .20's and imo will move much much higher pending at least to other announcements one of which is the announement of profitability this year.
Composite Indicator -- Signal -- -- Strength -- -- Direction -- Trend Spotter (TM) Buy Minimum Strongest
Short Term Indicators 7 Day Average Directional Indicator Buy Weak Strongest 10 - 8 Day Moving Average Hilo Channel Buy Minimum Strongest 20 Day Moving Average vs Price Buy Minimum Strongest 20 - 50 Day MACD Oscillator Buy Minimum Strongest 20 Day Bollinger Bands Hold Bullish
Short Term Indicators Average: 80% - Buy
Posted by QuestSolver on :
take advantage of these dips if you can,they are getting fewer and fewer.
Posted by trader_adam on :
What causes these massive dips? .45 back to .5 in seconds?
Posted by QuestSolver on :
it takes very few shares to drop it like that,looks like typical games.I seen them drop it a half cent on 2500 shares.Things are getting wound up tight now it looks like.It took me 10 minutes to get 10k at the ask.This is setting up for a mini spike it looks like.
Posted by QuestSolver on :
this is the best time to buy CLBE...during the lunchtime slow down and look at the tight spread!
Posted by johnny14511 on :
ive seen a pattern right hwen the market opens it gaps and the it goes down like at 9:45
Posted by Katrina7 on :
Hi all. New to board. Old with CLBE--been playing since before the run. Wondering why she is trading so tight these past few days? Are we seeing a new level of support? Also, I read here or on RB that people are waiting for news. Was thet the patent release? Thanks Kat
Posted by prefect on :
they really won't just let this go will they...
i have about had it with this crap.
Posted by Superbee383 on :
Where's Quest when we need him to keep digging up info about stem cell research and posting the info? Why the heck is this one falling? There's nothing but good news in its' future.
Posted by OFFROAD on :
QUEST IS SOMEWHERE WORKING ON THIS TRUST ME
Posted by MeanGreen on :
stem cell bank in S. Korea inundated w/ applications
Posted by OFFROAD on :
THANKS MEANGREEN, THAT WAS VERY INTERESTING AND GOOD TO KNOW
Posted by STOCKMOVER on :
Just got in and all I have to say is "WOW". I did not think we would be down today.
Posted by johnny14511 on :
this is nothing to worry about ill be back to five again
Posted by sportsguy on :
.038 OUCH!
What gives?
Posted by JimSC on :
It cleared up the preferred stock piles today. When the quarter-report gets out, CLBE should fly.
Also check this out: SSVG -- a sleeping giant could wake up soon; up 30% today.
Posted by newpenny on :
what is this stuff I am reading on other boards about the os being much larger than we think..200 not 93 and something about the finance company they hired doing "naked shorting" I am still pretty new to all this and am getting worried Is there going to be news in the report on the 16th regarding their os as well? because if it has increased a lot that could overwhelm the good news....any thoughts..or any more info on what all this means
Posted by Superbee383 on :
Personally I'll believe what's in their SEC filings over 'rumors on other boards' Go read it. It seems alot more reliable than rumors.
Posted by mizzou7 on :
1st LESSON...
Never believe anything you read on these boards... Do your own DD... I lost a lot of money listening to people on these boards when I first started out...
Most of these people are just novice investors... THEY ARE NOT PROFESSIONALS...
Most of the time when you see a new stock appear on one of these boards it's usually to late... After you do your own DD if you feel you have a winner invest on the dips and never hold long-term in these types of investments.
Get the word out...
mizzou7
quote:Originally posted by Superbee383: Personally I'll believe what's in their SEC filings over 'rumors on other boards' Go read it. It seems alot more reliable than rumors.
Posted by prefect on :
any CLBErs alive out there?
Posted by Superbee383 on :
Yup.. still here, and still waiting.. lol. btw, where's Quest been? I haven't heard a peep from him in a few days now.
Posted by johnny14511 on :
right here brother??
quest should be here any minute now
Posted by MeanGreen on :
So is this the calm before the storm, or what?
Posted by Persia on :
CalbaTech Subsidiary, K-D Medical, Inc., Contracts With Global Defense Company for Work on Anthrax Detection System Wednesday November 9, 5:00 am ET
IRVINE, Calif. and COLUMBIA, Md., Nov. 9 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, has contracted with a global defense company to provide products and services for an anthrax detection system sold by the defense company to the United States Postal Service. ADVERTISEMENT
K-D Medical, a primary vendor to the National Institutes of Health, also currently sells its full line of molecular biology products to Universities, Research Centers and major Pharmaceutical companies nationwide. K-D Medical will provide and assemble components used in the anthrax detection units. Two U.S. Postal workers died due to the inhalation of microscopic spores of anthrax that was sent to Congress in 2001.
"This contract is worth approximately $100,000 and will provide favorable margins," said John Powers, President of K-D Medical. "We see this as an opportunity to expand our business into component manufacturing for various bio-terrorist threat detection systems. This contract, in addition to our new facility with over 2,000 square feet of Class 100 Clean Room capabilities, will enable us to aggressively pursue other opportunities in this line of business," he added.
"This is an excellent example of the diversity K-D Medical can bring to our Company and we are very bullish on our subsidiary's business strategy," said James DeOlden, CEO of CalbaTech.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About K-D Medical, Inc.
K-D Medical, located in the heart of the Maryland Biotech Corridor, is one of the nation's leading manufacturers of microbiological culture media and other research reagents. K-D Medical's products are used in drug discovery, microbiology labs and biopharmaceutical production. The company is headquartered in Columbia, Maryland.
Posted by QuestSolver on :
LOL...yeah super I am here and not going anywhere,I been tied up on a few real estate deals going on that limits my time on the boards.I see the news is fair,not really high value but I am sure theres more to come!
Posted by EverGreen on :
great news - should move to previous high
Posted by prefect on :
or the previous low...jesus....
My patience is wearing thin with this one...
Posted by QuestSolver on :
Feds Give OK for Safety Test of Adult Stem Cells in Patients With Heart Disease
And then from calbatech.com
CalbaTech acquired iStem technologies, which is developing intellectual property relating to the efficient and effective deliver of stem cells to diseased or dead areas of the heart.
Looks like good news for them.
by RealAmerican on the HSM board
Posted by JimSC on :
JNJ, leading indicator of bio-tek sector stocks, fonnd it's bottom last Friday and ended a 4-month downward trend; this is the best time to enter bio-tek stocks, like BANY, CLBE, and PMED -- they will follow JNJ to a new upward trend.
Posted by JimSC on :
Questsolver wrote:
talked to Paul from CLBE,the 10-Q will be on time and he would not comment on whether they are profitable or not,I think CLBE has all their ducks in a row and we should see some big things happening soon. _________________ QuestSolver
Posted by servant_350 on :
when u excepect the news to be out?
Posted by hazel1401 on :
I am about to give up with this one I think, maybe something will happen later next week.
When is PMED going to do something great?
Posted by strike1 on :
is this dilution or what is going on? large vol on a slow day and before earnings? Somebody knows something or it is arca diluting it
Posted by Forrestgump on :
Consolidation...dont' see ARCA on L2... .031-.034 = resistance. Moving up next week.
Posted by prefect on :
Posted by j160e on :
Strike, I've seen ARCA on the ask several times today. I saw him (it?) at .034, disappear, return at .035 where I bought more then return at .034 again a little later.
quote:Originally posted by strike1: is this dilution or what is going on? large vol on a slow day and before earnings? Somebody knows something or it is arca diluting it
Posted by buckstalker on :
Been wondering the same thing....ARCA...now that is one market monkey that I am starting to dislike alot...lol
quote:Originally posted by strike1: is this dilution or what is going on? large vol on a slow day and before earnings? Somebody knows something or it is arca diluting it
Posted by EverGreen on :
... and after ARCA there is DOMS
must keep 03 support (like october)
Posted by JimSC on :
Watch the charts and volums of BANY and CLBE, they are designed by the MMs to indicate that a rally is ready!
Posted by QuestSolver on :
I agree jim,especially with CLBE,I expect the 10-q on Wednesday of next week.
Posted by Zygore on :
10/14/05 LOW .031 10/18/05 HIGH .057
10/27/05 LOW .032 11/01/05 HIGH .057
11/11/05 LOW .031 11/??/05 HIGH .???
Where are you gonna set your sell point?
Something else to consider! Look back two years on the charts and see what happened to this stock between OCT and DEC of 2004.
I guess it really wouldn't be a day without losing another $100 on this POS.
Posted by new_guy on :
Posted by new_guy on :
I hear ya, I'm down too, but I'm holding until we see the reports this week. good luck
Posted by Tooka56 on :
I think you all should be aware-great prospect with this one-However, there is the most trading volume ever on this company these last three months which could be a sign that more shares were sold onto the market by the company. It has definitely as of October doubled the share count since the end of last year according to the reports.
Posted by Tooka56 on :
It looks like these might or might not have happened-someone give some info if they've been following this one well.
Posted by Superbee383 on :
According to the last 10-QSB that was filed, the # of shares is exactly what Quest wrote on the 1st page of this thread. To me, the volume just sounds like there are alot more people buying AND selling on a daily basis, NOT that there are more shares on the market. I know I've bought/sold a couple of times myself.
Posted by Persia on :
CalbaTech Announces 2005 Nine-Month Revenue Increase Tuesday November 15, 8:58 am ET
IRVINE, Calif., Nov. 15 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC BB: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, today announced revenues for the nine months ended June 30, 2005 totaled $952,312, up from $128,940 for the same period in 2004. Revenues for the third quarter totaled $326,967, compared to revenues of $70,723 for the same period in 2004. The Company announced a gross profit of $650,817 for the first nine months of the fiscal year and $227,298 for the third quarter.
"We believe that revenues will continue to increase significantly from operations in the coming year," said James DeOlden, CalbaTech Chairman and CEO.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Posted by QuestSolver on :
IRVINE, Calif., Nov. 15 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC BB: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, today announced revenues for the nine months ended June 30, 2005 totaled $952,312, up from $128,940 for the same period in 2004.
Revenues for the third quarter totaled $326,967, compared to revenues of $70,723 for the same period in 2004. The Company announced a gross profit of $650,817 for the first nine months of the fiscal year and $227,298 for the third quarter.
"We believe that revenues will continue to increase significantly from operations in the coming year," said James DeOlden, CalbaTech Chairman and CEO.
Posted by prefect on :
ok clbe, show me what you got.
Posted by kywee on :
shes finally going
Posted by kywee on :
anyone else wathcing this? we need .04 to fall and were good
Posted by prefect on :
maybe we need a new thread Posted by kywee on :
we broke it .04x.041
Posted by prefect on :
jeez NITE jumped from 4 to 8!!!
Posted by STOCKMOVER on :
Kywee,
I'm with you watching this also. Looks like we are going to get a significant increase today.
Posted by kywee on :
a new thread would be good, up to quest or whoever
.041x.043
Posted by kywee on :
looks like it. im watching to see what this can do, im happy right now
Posted by prefect on :
man, people are soooo anal around here...
Posted by kywee on :
guess were staying here. anyways bid is up. .042x.043
Posted by kywee on :
well, im out. dont like to hold these things to long, plus its at HOD atm. gl if you are going to hold
Posted by rider3160 on :
im holding until it goes over .05
Posted by Lucas Brachish on :
I bought this one too high.... So I'll need to hold until over .065 at least. Hope we make it there... Whaddaya think? I feel kinda good about it... Posted by prefect on :
I am looking for .08 Posted by hazel1401 on :
Its not too late to buy more at .043 if it will lower your other purchases we should see a slight increase tomorrow as well
Posted by Lucas Brachish on :
quote:Originally posted by prefect: I am looking for .08
Yeah, my PPS average was over 8 before, too, but I managed to average down. Still, I'm well into the red right now... hope we can keep climbing to at least 9, although I'll probably sell before 8 unless things are really looking great.
Sell point, anyone? What does Quest think?
Posted by hazel1401 on :
this will hit over .05 close to close (imo)
Posted by Zygore on :
www.****************: Market Gainer Releases Profile for Calbatech Incorporated 11/15/05
Nov 15, 2005 (M2 PRESSWIRE via COMTEX) -- **************** strives to find dynamic issues that are unknown but because of their technology, approach, executive team, recent discoveries or other key factors, could advance in the market. **************** has identified the following company based on these issues. Calbatech Incorporated (OTCBB:CLBE) is an emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Calbatech Incorporated experienced an increase in value this morning as shares elevated 30 percent. While rising up $0.01 from the previous close of $0.03, the current value presently resides at $0.043. The volume of Calbatech is trading well over 700,000 shares, which is in fact slightly under the average of 1.3 million. In accordance to the 5 day chart, this company is up in value from yesterday, while actually recouping from a minor dip, that may have come contradictory to positive news. As revealed in announcement on November 9, 2005, Calbatech Incorporated had acquired new contracts, and equally dealt with an increase in share value. Today more good news of this company comes as they announce a 9 month revenue increase.
Today, Calbatech announced revenues for the nine months ended June 30, 2005 totaled $952,312, up from $128,940 for the same period in 2004.
Revenues for the third quarter totaled $326,967, compared to revenues of $70,723 for the same period in 2004. The Company announced a gross profit of $650,817 for the first nine months of the fiscal year and $227,298 for the third quarter.
James DeOlden, CalbaTech Chairman and CEO notes, "We believe that revenues will continue to increase significantly from operations in the coming year."
Market Gainer will continue to provide coverage on Calbatech Incorporated as they continue stepping forward into the next quarter. As more opportunities arise in a growing market place, investors could find solace in future trading.
To view other Market Gainer reports, please visit www.**************** for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed.
The Financial Information and Financial Content provided by **************** is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by ****************. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by **************** to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. **************** does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.
All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Market Gainer may receive compensation in cash or shares from independent third parties or from the companies mentioned.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info*m2.com.
(C)1994-2005 M2 COMMUNICATIONS LTD
Posted by prefect on :
MMs are all over the place...
This is setup for a nice EOD run IMHO.
Posted by prefect on :
Already got three bullish indicators on chart. And these are miniscule indicators compared to ones that will start lighting off soon as they make proper filings and this thing shoots up. Many are a little wary and dont want to get in at these levels. They want to see positive earnings but then it will be too late as traders will be jumping over the bid. I like my chances to double, perhaps even tripple my money at these levels. This stock had not seen .10 since September. Now that earnings release date nears us, shorts are on their toes preparing to cover. We'll see this trading in the .20's soon. Watch closely..
Posted by QuestSolver on :
watch what happens when they announce 3 patent approvals.Read past PR's and compare it to this...
this should run over .055 today
Posted by STOCKMOVER on :
breadwinner,
Which other filings are we waiting on now? I see the 10KSB/A but that is for the year end and we will not receive it until September 06. Is this correct?
Thanks,
Posted by Zygore on :
What happened this AM?
MM pullback or profit takers? Anybody know?
Posted by trader_adam on :
Can someone explain how this can dive down to .036 and then back to .045 so quickly? This just seems a little unsettling to me. I am trying to understand...
Posted by Superbee383 on :
Is it possibly people that bought it yesterday before it spiked up? And sold today at a profit? That's my thoughts on it, but it definitely got me nervous for awhile!
Posted by STOCKMOVER on :
I agree, it seems it was the people who bought yesterday, now its back up, we still need to fully break the .04 range.
Posted by QuestSolver on :
In our continuing pro-active efforts to keep investors apprised of the most relevant and timely information on CalbaTech Inc. and its target markets, AGORA is pleased to present you with this latest Industry Update.
Researchers at Florida State University, has developed a device which could significantly enhance the research of adult stem cells. We find the following article beneficial to you as this opens more avenues for adult stem cell research.
Tallahassee, FL (LifeNews.com) -- A new device developed by researchers at Florida State University could significantly expand the amount of cells scientists can use in adult stem cell research. The device could make the more effective form of stem cell research even better than the embryonic version.
The Florida State team reports it has designed a biomedical device that will allow stem cells derived from adult bone marrow to be grown in sufficient quantities to permit far more research. The device also allows faster growth of tissues that can be transplanted into patients.
Posted by Persia on :
CalbaTech's Subsidiary, LifeStem, Inc., Signs Letter of Intent to Offer Its Stem Cell MicroBank Collection Service Through Solana MedSpas 11/17/05
IRVINE, Calif., Nov 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary LifeStem, Inc., has signed a Letter of Intent (LOI) with Solana MedSpas, http://www.solanamedspas.com, the nation's foremost developer and syndicator of medical spas, to offer LifeStem's unique Stem Cell MicroBank Service through the Solana MedSpa network.
LifeStem President, Dan Fulkerson states, "As we reviewed our business plan, we realized that selecting the right distribution channel was an essential element to its overall success. Our model for collecting and storing adult stem cells through our Stem Cell MicroBank Service is a perfect fit with the medspa market. The demographic that we're targeting is almost identical to the Solana MedSpa's client base and by joining forces, we will have access to the nation's largest distribution channel into the rapidly growing medspa market. We envision our relationship with Solana MedSpas generating substantial results for both companies," Fulkerson notes.
Solana CEO and co-founder John Buckingham adds, "As the medspa industry leader, part of our overall strategy is to continually evaluate new technologies and services that will deliver the best results for our clients. Adding LifeStem's Stem Cell MicroBank Service to our locations not only positions Solana MedSpas as unique vis-a-vis the competition, but it represents the next logical step with regard to our vision and mission." Solana MedSpas has opened medspas throughout the United States and plans to have 70 in operation by the end of 2006.
"We view this as a significant step for LifeStem," says James DeOlden, CEO of LifeStem's parent company CalbaTech. "We are extremely pleased to be working toward a definitive relationship with Solana MedSpas and their network of medspa owners," DeOlden remarks.
Terms of the LOI were not released. Both companies seek to have a definitive agreement in place by November 30, 2005.
Posted by blacklab669 on :
Our model for collecting and storing adult stem cells though our stem cell microbank service is a perfect fit with the medspa market.Excellent news,on to the next level...
Posted by QuestSolver on :
told ya....November is the beginning of big things to come....strong buy and hold here and in AMEP and in DIAAF....watch and see.
Posted by servant_350 on :
hey guys ...u think it will have quick run in first 20 min ?
Posted by Zygore on :
Ask at .05
Posted by kywee on :
this should go up nicely
Posted by prefect on :
yeah if orca would get his fat ass out of the way!
Posted by trader_adam on :
wow .08 jump
Posted by prefect on :
ummm where do you see that?
Posted by prefect on :
really movin now...
Posted by Tooka56 on :
don't get too upset this morning guys-it should be back up by this afternoon-looks like a setup by the MMs-too much of a gap.
Posted by hazel1401 on :
are you sure CLBE is not going to screw all of us and stay at these levels for a while Im starting to fell like we might be here for a while (imo)I hope im wrong
Posted by servant_350 on :
what's going on? !!!
Posted by prefect on :
quote:Originally posted by servant_350: what's going on? !!!
Ummm the stock is garbage?
Posted by prefect on :
oh a 1,000,000 share sell waaaay below the bid...
That makes sense...
What is the thinking there? Genius...
Posted by mizzou7 on :
I got suckered in at .055........
Never listen to anyone on these boards.... all of these penny stocks are just short term holds... in and out... Here's what I have discovered over the last few years... when people start pumping a stock it has usually already peaked and they are trying to profit out on someone elses money.
Now I'm stuck with this and again my money is tied up... NO MORE!!!
Get the word out...
mizzou7
Posted by Forrestgump on :
You are wrong Mizzou. May I tell you why? Let me tell you first that QuestSolver did a VERY GREAT JOB on this one. He did alot of DD but he cannot control the market and MMs manipulation.
In order to invest in a stock, you need to do you own DD. If you invest base on someone theory or assumption or enthousiasm...You better leave the market because your not ready for it. May I suggest you to read this book: "A beginner's guide for daytrading online".
This book should help you to understand how to play with the market. This thread has been update for a while now. Stock like people need to rest sometime.
Don't blame someone else except yourself if you didn't do correctly your DD and put your buy order in bad entry point.
CBLE will rebound but not before STO hit 20 I think.
CBLE has a great potentiel like CBAI, CNCN, CYBL, CTUM, DIAAF, SYCI,WWBP, (Stock I recommended).
Do you own DD, learn to read and understand Chart, Read PR, Read book, filling, LEARN LEARN AND NEVER STOP TO NEVER...THIS IS THE KEY OF SUCCESS IN STOCK MARKET.
Thanks andd have a nive day.
Posted by mizzou7 on :
I totally disagree...
People are out there to get other people to buy into stocks just like this one... I have seen this over and over....
You are correct however, I have never lost money on any stocks that I did proper DD... only on the ones that I purchased during a pump...I consider myself a savvy investor and have been doing it now for 5 years... but, like many others I find myself caught-up in stocks that appear to be the real thing only to find out it was another pump and dump investment.
No one should hold one of these stocks thinking it will go from .03 to .20... it absolutley makes 'NO' sense. 1% or 2% of these companies might be for real but the other 98% to 99% are simply pump and dump scams ( not saying this one is... I totally agree this company has a good future)...
2006 I will leave the penny market for good and invest only in real brick and mortar companies...
GL2Y...
Get the word out...
mizzou7
quote:Originally posted by Forrestgump: You are wrong Mizzou. May I tell you why? Let me tell you first that QuestSolver did a VERY GREAT JOB on this one. He did alot of DD but he cannot control the market and MMs manipulation.
In order to invest in a stock, you need to do you own DD. If you invest base on someone theory or assumption or enthousiasm...You better leave the market because your not ready for it. May I suggest you to read this book: "A beginner's guide for daytrading online".
This book should help you to understand how to play with the market. This thread has been update for a while now. Stock like people need to rest sometime.
Don't blame someone else except yourself if you didn't do correctly your DD and put your buy order in bad entry point.
CBLE will rebound but not before STO hit 20 I think.
CBLE has a great potentiel like CBAI, CNCN, CYBL, CTUM, DIAAF, SYCI,WWBP, (Stock I recommended).
Do you own DD, learn to read and understand Chart, Read PR, Read book, filling, LEARN LEARN AND NEVER STOP TO NEVER...THIS IS THE KEY OF SUCCESS IN STOCK MARKET.
Thanks andd have a nive day.
Posted by Forrestgump on :
Mizzou7
Your first sentence is sage
Posted by Forrestgump on :
Mizzou7
CYBL went in June from .03 to 20 cents. CNCN went in october from .03 cent to 15 cents CBAI wnet in June from .19 to .85... and son on.
LEARN TO READ CHART and playing momo. However I do like the way you think. I believe that you have a wise market approach.
And I am sure you make alot of money. GLTY.
Thanks
Posted by Tooka56 on :
quote:Originally posted by hazel1401: are you sure CLBE is not going to screw all of us and stay at these levels for a while Im starting to fell like we might be here for a while (imo)I hope im wrong
Of course I can't guarantee that. You should know that. There are so many times when I have lost money on one I thought was a sure deal. However, I love that they at least have positive gross profits, patents filed, a discounted chart, and a new LOI with Solana Medspas for skin stem cell therapy. It just seems like it has a lot of great characteristics and therefore, I'm in.
Posted by Zygore on :
I get so sick of everyone calling every d**n stock a pump and dump just because they start losing money and don't play it right.
An example of a P&D would be like GRYF who had a bulls**t business, put out bogus PRs, got the chat groups to hype it up, sold off, and now it is a dead stock at .0001
CLBE is a real stock, real business, real potential, real people, and a great future. Yes it is still a penny stock so you should be leary of long term holds. For me, and for now, I play it short term.
This is just another fine example of us spoiled americans wanting instant gratification.
Posted by EverGreen on :
often SB2 shares go in big blocks when the diluter sell to another MM (even below bid)
then this MM sell retail to us
don't worry (be happy)
quote:Originally posted by prefect: oh a 1,000,000 share sell waaaay below the bid...
That makes sense...
What is the thinking there? Genius...
Posted by Tooka56 on :
Looks like we're back in above .04, barely! But maybe it will keep on chugging...
Posted by Zygore on :
UP 22%
On no news or financials to boot...hhmmmmm
Posted by breadwinner on :
Lets not forget the lucrative business that CLBE is in..
About CalbaTech
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute innovation in areas of biological discovery.
Posted by matto on :
CalbaTech's Subsidiary, LifeStem, Inc., Selects Leading Physician as Chief Medical Officer 11/22/2005
IRVINE, Calif., Nov 22, 2005 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary LifeStem, Inc., has selected Dr. Jason R. Van Tassel as its Chief Medical Officer.
Los Angeles based physician, Dr. Jason R. Van Tassel M.D., was selected to become LifeStem's Chief Medical Officer. In this new position, Dr. Van Tassel will direct all of the company's medical technologies related to its Stem Cell MicroBank service and provide advisory, consulting and technical services to the company. He will also be directly involved in the rollout of LifeStem's MicroBanking Stem Cell collection and storage service with Solana MedSpas which the company announced on November 17th.
"We're very fortunate to have Dr. Van Tassel as part of our management team," said LifeStem President Dan Fulkerson. "Dr. Van Tassel has been with our parent company, CalbaTech, as an advisory board member for the past year so he knows our business and as is well qualified to fill this important role," Mr. Fulkerson added.
According to Dr. Van Tassel, the timing of his appointment was ideal. "The stem cell market is quickly expanding and the benefits of adult stem cells as a regenerative therapy are rapidly becoming evident. With the addition of the Solana MedSpa network, I am convinced that LifeStem's MicroBank service will be an essential component to an overall stem cell therapy."
Dr. Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in Los Angeles, CA. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California at Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery. He is an Associate Clinical Professor at UCLA in the Department of Surgery, in the Division of Otolaryngology Head and Neck Surgery. Prior to practicing medicine in Los Angeles, Dr. Van Tassel worked at Hybritech Inc., a subsidiary of Eli Lilly, where he performed research investigating manufacturing processes related to monoclonal antibody test assays. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Dept. of Neurosciences at San Diego State University.
Posted by QuestSolver on :
cool!!!
Posted by EverGreen on :
i'm happy ... and you?
quote:Originally posted by EverGreen: often SB2 shares go in big blocks when the diluter sell to another MM (even below bid)
then this MM sell retail to us
don't worry (be happy)
quote:Originally posted by prefect: oh a 1,000,000 share sell waaaay below the bid...
That makes sense...
What is the thinking there? Genius...
Posted by prefect on :
I am happy and I am OUT!!!
FREE AT LAST FREE AT LAST....FREE...AT...LAST!!!
WOOHOO!
Posted by trader_adam on :
I finally played this right. Was in at .049 and out at .057 today on the run. This thing seems like it always returns to lower levels again. I will buy in again if we hit the low 40s or even 30s and do it again... no more holding through these spikes unless we get BIG news.
Posted by BULListic on :
I got a hat trick going on CLBE. I have bought 100k at .033 three times in the last 6 weeks and sold between .042 and .048, may have missed out on some upside, but it's been nice dependable cashflow. So there you have it, look for .033!!
Posted by EverGreen on :
very good
maybe next time watch big blocs (price-time and IF there is any influence on the trades that follow)
good luck
quote:Originally posted by prefect: I am happy and I am OUT!!!
FREE AT LAST FREE AT LAST....FREE...AT...LAST!!!
WOOHOO!
Posted by QuestSolver on :
thats what trading is all about but on good companies I don't like unloading totally,playing will half is a little safer since sooner or later there will be no or very little retrace.
Posted by hazel1401 on :
am i the only one that didnt sell (I wish i did but a lot happened while i was away for two hours) any thought on where this might be tommorow?
Posted by trader_adam on :
My guess is it will hover around .04, weak finish today.
Posted by STOCKMOVER on :
hazel1401,
Don't feel bad, I did not get a chance to sell today either, I was really shocked to see that high of .058
Posted by breadwinner on :
From another board:
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 due to the growth of new cellular therapeutics as well as clinical applications. LifeStem's strategy is to leverage CalbaTech's infrastructure of companies to obtain a leadership position in the emerging stem cells arena and become a preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services.
The one thing about high quality penny stocks is that they rarely ever run high and fast at the same time. Most are slow growth but strong investments to certain levels. As science progress anyone can see that stem cell technology is going to be a major contributor but many here may believe that is all CalbaTech does and that’s not true. They are really deep into DNA and molecular research also.
Posted by QuestSolver on :
keep an eye on this one now until the end of year.
from the most recent 10K, thought I'd share some of my favorite quotes that makes a good reminder.
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
3. Officers and Directors:
James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.
Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.
John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.
4. Scientific Advisory Board:
Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.
Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.
Posted by Lucas Brachish on :
Pretty quite 'round these parts. Is there a newer thread for CLBE or has discussion just run dry since the company hasn't released any PR lately?
Quest, et al.:
CLBE and PMEd have sunk by nearly 50% since I bought 'em a while back... I'm still pretty confident they'll go back up (especially CLBE, at this point), but will we actually see a 100%+ run in the near future for either of 'em, I wonder, or should I unload before 2006, so I can write it all off as losses?
Is everyone still feeling good about CLBE?
Hmmmm... Posted by Superbee383 on :
I still believe in this company 100%! I'm not happy about the price, but in my opinion, she'll turn around soon! I'd like to hear Quests comments on this one too though! Posted by STOCKMOVER on :
Lucas,
I am stil confident in CLBE also, but the dips are hard to stomach. I am down about 25%. I do not think we will see a run until after the new year.
Posted by JimSC on :
At 0.033 it's a great time to add a new position. The chart shows it moves with cycle and it will be in the 0.05s next week. This dip is part of the MMs' game plan to collect cheap shares. Wait and see.
Posted by Lucas Brachish on :
Thanks everyone for the input.
Sounds good.
I bought a chunk at 0.034 this morning, which has allowed me to average down to the low 5s, finally... It feels good not to see that negative 55% on my chart anymore, even though I'm still in the red. Of course, just my luck that CLBE seems to now be dropping even lower than the 0.034 I thought would be the support, but if JimSC's chart prediction is correct then I'll be back above break-even by next week...
Good luck to all!
Posted by iiiqqqeg on :
Level II looks good to enter at .033... i'm in
Posted by iiiqqqeg on :
SCHB dilluting?
Posted by JimSC on :
If you understand the MMs' agenda, you will be more confortable with the dips, when they bring down the pps to collect cheap shares. After they collect enough, they wil raise the pps. Just wait and see.
Posted by Tooka56 on :
I'm still holding and averaging down also for whatever that's worth! I watched the MM's do exactly what JimSC is talking about with MBAH sveral times so I just ride the wave with them!
Posted by JimSC on :
Hey, Tooka56, sooner or later you might become an assistant to the MMs. Good luck on your riding the waves with the MMs. JimSc
Posted by iiiqqqeg on :
thought is has good support at .03 ... now it may keep diving
Posted by JimSC on :
This is part of the MMs game plan -- creating feat to get cheap shares. I will buy more.
******** Buy when the MMs are buying and sell when the MMs are selling. imho ******** The MMs have tons of inventory between 0.032 to 0.038 from last few cycles; they are preparing for a long rally for this stock, so they want to get more by lowering the pps. So hold your shares tight. When they finish collecting, they will raise the pps to unload their inventory to the investors. Check the charts, and you will find their tricks and take advantage of them.
Posted by Paramedic81 on :
anyone think .03 is a good entry? cause that is where I loaded up today, and brought a large amount of shares
Medic
Posted by JimSC on :
Congratulations, you are doing better than the MMs. My average is 0.034.
Posted by gemseeker on :
This apprears to go down. Major support at 0.027 and it it gets broken, it goes down to 0.022. I will wait for it to go down further.
Posted by strike1 on :
When O/S get to 97 million you will know dilution is over as far as their toxic financing... then it should pop, but until then just trade it...
quote:Originally posted by iiiqqqeg: SCHB dilluting?
Posted by BornAndBred on :
Huge clbe news!
I have a hot tip from a friend that works with biotech companies. Notice the abnormal clbe volume? Expect a major PR concerning their patents either tomorrow or thursday the latest. My advice is to be in this before close tomorrow otherwise you will be stuck chasing. The pr is expected to be overwhelmingly positive with several biotech companies showing interest in clbes patent. I have a set buy to buy 1 million shares of clbe at .03 tomorrow. That's how confident I am in this. If it doesn't fill I'm just going to grab whatever I can at whatever price it is at.
From my source the conservative estimate is ten cents by friday, THATS RIGHT TEN CENTS! And continuing higher next week. POSITIVE PATENT NEWS IS HUGE!
Posted by JimSC on :
Thanks for the great news, Bornandbred.
Posted by trader_adam on :
This thing is a steal at these levels... If there is a chance to buy around .03 tomorrow, it won't be for long.
Posted by gemseeker on :
The chart says that we go Lower tomorrow. They may not move until next year or until they give a Solid PR. I will wait and watch.
Posted by strike1 on :
charts do look very horrible... somebody on another board is almost guaranteed major news today or tomorrow and .10cents possible... He seems to be right most of the time... insider?
Posted by podcaster on :
i'm having one heck of a time getting a fill today. tried for 20 mins at 031, been waiting now almost an hour for fill at 0325 ... placing AON-- anybody else having problems like this??
Posted by Thorn on :
That's AON for ya.
Posted by strike1 on :
sometimes if you take off the AON they will give it to you anyway..jmho
Posted by podcaster on :
thanks- just didn't wanna get nagged to death with small fills
Posted by Tooka56 on :
I hope there is news. I'm not liking this high volume/possible dilution, but that's the game I spose. JimSC careful with your comments-mighty big insult around here to call someone an assistant the MM's...but I'll let it slide b/c I don't think you REALLY meant it.
Posted by podcaster on :
that 100k fat finger buy at .05 is really gonna mess with the TA after close-- might wanna be careful how we interpret today's stoch
Posted by JimSC on :
Hi, Tooka56. There is an misunderstang about the term. When I said assistant to the MMs -- I meant you are a top rated trader. I was impressed that you could trade MBAH many cycles. I tried it, but it's very hard to get in and I missed a few cycles. I hope this will clear things up. Thank you for your tolerance.
Posted by podcaster on :
quote:Originally posted by podcaster: that 100k fat finger buy at .05 is really gonna mess with the TA after close-- might wanna be careful how we interpret today's stoch
on second thought, maybe that wasn't a fat finger. i had problems getting a fill (finally got one) and the fat finger maybe wanted in real bad and one way to do that in low liquidity is to bid 'way over ask. i just can't see an "accident" like this tho i guess anything's possible...
Posted by Lucas Brachish on :
Is there a newer thread for this joker or has everyone just given up and stopped talkin' 'bout it? Weren't we supposed to make a mint off of CLBE and PMED before 2006? Where'd QuestSolver go? Guess I'm playin' long...
Posted by breadwinner on :
No worries Lucas, we longs are holding tight to our shares. Calbatech is poised to emerge ahead of its current condition starting early next year. The stock has been depreciated this past year due to poor net income for 2004. This year however, they have reported positive record earning statements and are projecting even greater earnings growth for 2006. They hold numerous patents on all of its proprietary technologies. Their subsidiary, Lifestem, Inc. is acquiring more contracts to whom they can offer their Stem Cell Microbank. Calbatech has opened the doors for great opportunities for 2006. Here are some of their key numbers.This year should look a lot better:
Fiscal Year-End December 2004 Sales (mil.)-- $0.3 1-Year Sales Growth-- 2,408.3% 2004 Net Income (mil.)-- ($2.7) 2004 Employees-- 19 1-Year Employee Growth-- 137.5%
Posted by breadwinner on :
CLBE has gotten a fair amount of PR in the last 15 days. Now, none of it is revolutionary news -- most of it is just boilerplate blurbs in the SessionsIR.com newsletter thing, probably a paid spot -- but I'm still surprised that the stock keeps going down down down when things are kinda looking up (or, at least, they aren't looking down, as far as we know)....
Below is a list of the latest PR in which CLBE is mentioned. The standard SessionsIR blurb always says something like "LifeStem, a wholly owned subsidiary of CalbaTech, Inc. (CLBE) is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service."
12/28/2005 SessionsIR.com: Regeneron Shares Up After Lehman Analyst Sees Improving Prospects for Experimental Drug: CLBE, ASTM, REGN, BMY
12/28/2005 SessionsIR.com: Health Management to buy hospital in Augusta, Georgia for undisclosed amount
12/28/2005 SessionsIR.com: Guidant gets FDA warning letter on facility
12/21/2005 SessionsIR.com: CalbaTech subsidiary contracts to exclusively offer its Stem Cell Microbank(TM) to bank adult stem cells nationally: CLBE, VIAC, ASTM, DNA
12/20/2005 CalbaTech's Subsidiary, LifeStem, Inc., Contracts With Solana MedSpas to Exclusively Offer Its Stem Cell Microbank(TM) to Bank Adult Stem Cells Through Solana MedSpas' National Network - PR Newswire
12/13/2005 Solana MedSpas Signs Letter of Intent With CalbaTech Subsidiary to Offer Adult Stem Cell Microbank Collection Service - PR Newswire
----------------
So why is CLBE's stock tanking so bad? I mean, it's bad. Very bad. Lots of red. I know that the end of December can be a bad time for stocks as people sell of before the end of the fiscal year for tax reasons.... but still... CLBE's current price is just nasty low. And not for any good reason that I can tell.
Posted by JimSC on :
Watch the charts of GLIF and CLBE -- they are ready for hard rebounce. Trust the MMs -- they have played the games several times. They need lots of shares to make a run, so it's taken down and up several times.
Posted by Persia on :
Trust the MM's ? LOL Jimmy! Posted by buckstalker on :
That's the funniest thing that I've heard all year...It is moving though.
quote:Originally posted by Persia: Trust the MM's ? LOL Jimmy!
Posted by TruthLiesWithin on :
MM's....
yeah let's send them fine chocolates and wish them a happy new year.
Would they be effective without us?
Posted by JimSC on :
Persia wrote: Trust the MM's ? LOL Jimmy!
****** JimSc wrote: Hi, Persia. I used to hate MMs, they always worked againt me. After studying a lot of charts, I decided to change myself and follow the MMs -- when they pulled down the pps below the support level, I would get in; when they raise the pps to unload their inventory, I would take a profit. For example, see what they did it to SSSU yesterday and today,I even posted it in another thread -- UHV List (12/28). Yes, MMs are great -- if you find out their agenda to a particular stock. So, next time when you find they pull down the pps of a stock, please post it. I even trust their aboility to control the pps -- they always pull down the pps to collect cheap shares, after they got the majority of the shares, they always raise the pps -- and I like it. So, if you are not happy with the system, try to learn from my mistake and change yourself to follow the MMs. I belive that one day you would say, "The MMs are great, and I trust them." Happy new year to all who are reading this msg, and thanks to the MMs who have made my trades profitable.
Posted by JimSC on :
CLBE: up 21%. This is the year-end tax selling time, and CLBE jumped 21% -- it's a proof that MMs have full control of the pps -- as soon as they get all the cheap shares, they will always raise the pps. Wait and see what they are going to do next week. The pps is completely manipulated by the MMs and the only way to win the game is to follow the MMs, not to work against them. If your mood is a function of the swing of the pps, you are a victium of the manipulations of the MMs. The simple fact is that the pps is down when the MMs want your shares for cheap; the pps will be up when they want to sell for a profit. Our job is to identify when the MMs are buying or selling. The buying point is UHV (unusual high volume), a term coined by Will. which is often at or below the support level; the top is not easy to identiry, but if set your goal at 35%, you wll get hit most of the time. This is what I said about following the MMs. You must understand that the pps must be changed in order to get the investors, but not you, to buy or sell. Please read the charts of CLBE and GLIF, then compare them with my points of view. Also keep track of your mood at different pss level -- so next time when the pps changes, you will say, "The pps is changed because the MMs want to do this or that."
Posted by strike1 on :
Resistence Levels... strong resistence at .03 then we will trade to the .05 level rather easily...then not much resistence upwards and that will be later this year or depending on how fast they get operations going especially with the agressive promoting of the LifeStem Stem Cell MicroBank service...GLTA
Good info strike1. Calbatech, Inc. (CLBE) is poised to emerge ahead of its current condition starting early next year. The stock has been depreciated this past year due to poor net income for 2004. This year however, they have reported positive record earning statements and are projecting even greater earnings growth for 2006.
They hold numerous patents on all of its proprietary technologies. There are rumors spredding on the yahoo boards illustrating that CLBE is ready to make a run for it. I'm in at .03 and holding regardless but watch closely because this stock is liable to breakout any day now.
Posted by breadwinner on :
Slowly gaining momentum this morning. Bids are hiked up and strong hands are holding. Watch for eod day. Could close above .03
Posted by trader_adam on :
should gap... up over 20%
Posted by MARKIT on :
GOOD FINISH TODAY AT.034
Posted by breadwinner on :
Yup. This has not even gotten started. It closed strong and forward momentum should continue next week. The chart has set up beautifully and now its time to get CLBE back to an appreciated trading range. IMO, this could see .10 by early Febuary. Should have an execellent 2006 for those holding long.
Posted by JimSC on :
HO HO HO! CLBE up 20%. The MMs deserve a bottle of wine. Don't you think so? Happy New Year!
Posted by j160e on :
Seems like the slightest buying pressure moves CLBE up fast. Looking good now heading into the new year. Any kind of patent news or insider buying would send this flying, imo. For anyone not familiar, CalbaTech contains four wholly owned subsidiaries that combine products and technologies and have filed two patent applications in the last two years.
Molecula, Inc. - Focused on gene function solutions using RNAi technology.
KD Medical, Inc. - Manufactures and distributes microbiological culture medias and other research reagents.
LifeStem, Inc. - Positioning itself to become a leading supplier of "Cellular Logistics" by providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies.
Molecularware, Inc. - Offers bioinformatics software and other products to integrate the volumes of data produced from high throughput screening, combinatorial synthesis, and other methods of genomics research.
"Device and methods for processing sample and detecting analytes at low concentration" is a provisional application 60/536,044 filed 01/13/04 by James Zoval, Ph.D. This application describes a novel concept for the isolation and purification of DNA and other biological molecules.
"Cardiac Stem Cell Delivery Apparatus" application number 60/571,510 filed 06/10/2004 inventor Jason Van Tassel, M.D., that describes a modification of endoscope technology which will facilitate the targeted delivery of adult stem cells to specific tissues.
Posted by strike1 on :
broke .03 resistence HOD .034... Looking good going into next year... no tax selling/selling of any kind last 2 days. GLTA
Posted by strike1 on :
Microbank contracts will come from all over if they promote agressivily as they stated they will... I can't make projections but the way it is set up there could be dosens of deals just on microbank alone...This doesn't even include their other products and patents... CLBE was about the only stem cell stock up the past 2 days... I look for great news coming very soon and a continous flow...Numbers for 2005 mark a distinct turnaround year for CLBE and 20006 is 10 times more promising with the groundwork laid...GLTA
Posted by strike1 on :
Website Updated... also check out thier Molecula & KD Medical website's.
Just a newbie question here strike. I was planning to get this when it was in .02* but due to the nature of my work, I couldn't get in on time. Do you think .034 is still a good entry?
Posted by strike1 on :
amer12ca... I am still holding... but not adding any more at this time since my average is .02325 from wen. last week... I am going to hold 1/2 and trade the other half of my position so as not to miss out on news or a big run... It ran great into the new year and this could be do to upcoming news? My target to strat trading is .05 real soon but that is be subject to change... Just my opinion but I would wait an see how the clbe opens up in the morning and buy any dips... with your job I would take a 1/3 buy strategy and maybe buy 1/3 on monday and 1/3 in a day or two and the same with the other 1/3 so to get an average price... you may end up with a higher pps if the stock goes up but if there is any profit taking you will have a lower average... or, you can just take a position all at once in case we really start to run or get news...It is totally up to you though... I think we will see a run into the .20+ cent area by spring but this depends on the company and how many new microbank deals they do and other things also.. this will be the year for clbe as all the groundwork is pretty much laid.. I have almost 2% of the o/s now from wen. so I am betting it will be one of the bigger gainer's this year...GLTY with whatever you decide and hope this helps you out...charts are turning very bullish right now also...
Posted by amer12ca on :
Thanks strike. It sure helps.
Posted by strike1 on :
PR from the 20th
CalbaTech's Subsidiary, LifeStem, Inc., Contracts With Solana MedSpas to Exclusively Offer Its Stem Cell Microbank(TM) to Bank Adult Stem Cells Through Solana MedSpas' National Network Tuesday December 20, 5:00 am ET
IRVINE, Calif., Dec. 20 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, today announced that its wholly owned subsidiary, LifeStem, Inc., has reached an agreement with Solana MedSpas (http://www.solanamedspas.com), the nation's foremost developer and syndicator of medical spas, to exclusively offer LifeStem's Stem Cell MicroBank(TM) Service through Solana MedSpas' national network. ADVERTISEMENT
In the definitive agreement, LifeStem's Stem Cell MicroBank(TM) will initially be offered in six Solana MedSpas network locations in Southern California. Solana MedSpas expects to have as many as 70 locations open by the end of 2006 and intends to offer the Stem Cell Microbank Service at all locations. "We are extremely pleased that we have formalized an agreement with Solana MedSpas," says LifeStem President Dan Fulkerson, "and are confident that many individuals within the Solana MedSpas client base will take advantage of our Stem Cell MicroBank(TM) Service."
Fulkerson continued, "By beginning with six locations and by adding new locations as Solana MedSpas debuts them, our conservative estimates over the first 12 months of operations project revenues in excess of $3 million, with the potential to exceed $25 million in the next couple of years. We're looking forward to expanding our microbanking model into the growing Solana MedSpas network."
In addition to serving the Solana MedSpas client base, LifeStem is planning an aggressive marketing program of its Stem Cell Microbank(TM) Service, outside of Solana's efforts, which will reach more potential clients.
"We are delighted to finalize our agreement with LifeStem," says John Buckingham, CEO and co-founder of Irvine, Calif.-based Solana MedSpas. "We are now ready to move to the beta test phase at selected medspa locations," Buckingham adds, noting that Solana MedSpas will the first medspa network to offer an adult stem cell collection service. "As Solana MedSpas continue to orchestrate the marriage of healthcare product innovation with our ever expanding medspa distribution channel, the addition of LifeStem's Stem Cell MicroBank(TM) Service to our locations, not only positions Solana MedSpas as unique vis-a-vis the competition, but it represents the next logical step in the realization of our vision and mission as a syndicator of medical spas."
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE - News) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service.
Posted by strike1 on :
""LifeStem is planning an aggressive marketing program of its Stem Cell Microbank(TM) Service, outside of Solana's efforts, which will reach more potential clients.""
This was already planned way before this PR. We should start to see new contracts very soon. GLTA
Posted by strike1 on :
clbe Gapping up
Posted by strike1 on :
Holding strong today on still higher volume.
Posted by Rbreb13 on :
Got in today. Finally saw a good entry point at .03 and had some cash freed up.
Posted by Raptorsrule on :
quote:Originally posted by strike1: Holding strong today on still higher volume.
you are actually advocating buying this???
Look at the chart!.....PALEEEZE....quit pumping garbage.
Posted by breadwinner on :
Garbage? lol. I'll put this in simple terms raptor..BUY THIS STOCK!
This has great potential to at least triple by the end of the first quarter. News is expected soon and I have a really good feeling tight holders will be grateful after this stock makes its run. Watch closely and mark this thread! WE WILL SEE .10+ THIS YEAR.
Posted by STOCKMOVER on :
10/10/2005
quote:Originally posted by QuestSolver: I am tellin ya,this has another "BIPH" written all over it,just look at the other stem cell companies now! Don't be surprised to see this at .20 this week imo!
It sure would be nice to see this at .20 right now. I hope we get news soon. This needs to run to reach a respectable PPS again.
Posted by mizzou7 on :
don't be fooled with this stock... buy low and get out... this is just another pump and dump stock!!!
Posted by EverGreen on :
nice close today with NITE pushing the bid
low volume but chart appear to be close to a reversal
Posted by OO7 on :
Pump and dump or long term, this stock has great potential to go back above $1 this year!!! Im in and holding.
Posted by STOCKMOVER on :
Why did the price drop to .025? Is everyone selling?
Posted by Persia on :
Good time to buy now imo.
Posted by OhhhYeah on :
I got in at .0244. I think this is an easy 30%
Posted by trader_adam on :
This is a high volume day... I'm willing to bet this is about to pop!
Posted by man4apenny on :
Pop? guess not! But still looks to have stabilized and with any news then ....
Posted by STOCKMOVER on :
Does anyone know when we can expect more financial news? Thanks.
Posted by breadwinner on :
Rumor has it that theres news coming out soon. As I've mentioned on another board, this is a great mid-long term invesment, wether news is do out soon or not. The Company believes that adult stem cells have tremendous potential to promote the regeneration of dead or diseased cardiac tissue. They have filed patent applications for its Stem Cell Delivery Device. If, approved, the patents will allow for the Device and Methods for Treatment of Necrotic Tissue using Stem Cells.This is a not another junky catchpenny. They sell products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. They are engaged in a business that will play a huge roll in stem cell developments this year. IMO, anything under a nickle is a bargain. Those holding on tight to their shares will see appreciation in due time.
Posted by STOCKMOVER on :
The trades this morning look very strange, with this I would suspect that news is right around the corner. Maybe the MM's are playing with the trading. What do you guys think?
Posted by EverGreen on :
crazy trades - i tried a sell at .031 and gone in 5 sec
sure some short covering
btw - now that i sold it will fly!!!
Posted by STOCKMOVER on :
Does anyone know what is going on today with this stock? It has dropped pretty low. Maybe someone is trying to shake cheap shares out of the hands of holders....I have no idea.
Posted by MDP5754 on :
Well I heard rumors of a pr this week and then I also noticed that it looked like a possible MM shake for cheap shares, so I grabbed 50k more. CLBE has a knack for closing close to or in the green on days like this. Just my opinion of course. GLTA
Posted by STOCKMOVER on :
Thanks MDP5754,
I grabbed a few more shares myself, because this usually happened before news. It will be interesting to see where the close is today. Good luck to you.
Posted by j160e on :
CLBE moving up B/A 0.032/0.033
Posted by OhhhYeah on :
CLBE moving up B/A 0.0345/0.035
Posted by STOCKMOVER on :
This is GREAT, I made a nice flip from when I got in around the .02's early this week. I think HUGE news is around the corner, we could see .08 again.
Posted by j160e on :
Nice! .039 last trade
Posted by STOCKMOVER on :
whats causing the volume and pps increase?
Posted by OhhhYeah on :
RUMOR OF HUGE NEWS
Posted by TruthLiesWithin on :
Looking at buys and price climb I only saw one big sell that actually effected the price, but the rest has been nothing but up...
I had a personal target of .15 does that sound rediculous?
Posted by STOCKMOVER on :
Not ridiculous at all. That sounds reasonable, it may take a few months. I am looking for this to reach the .30's this year.
Posted by STOCKMOVER on :
THIS IS UP 54% for the day, WITH NO NEWS! KEEP A WATCH FOR THIS TO HAVE HUGE GAINS IN THE NEXT WEEK OR SO.
Posted by j160e on :
Wow! .043/.044 If it closes high of day, should gap tomorrow. I'd love to see news before the open.
Posted by STOCKMOVER on :
What are you guys doing? selling or holding? I sold some earlier at .03, I did not know it would get this high today. I was in the red with this for months.
Posted by Superbee383 on :
I've been in the red for months with CLBE, but wow! It's a sight of beauty today! I'm actually even right now! Was there news? Or just pending news? And no, not selling anything yet. I still have all my shares.
Posted by j160e on :
Stockmover, I'm doing both.
Posted by jmichael7 on :
yeeeeeaahh RSI now entering the PowerHouse 70 Zone on Huge Volume!! ;0) Posted by STOCKMOVER on :
There was no public news made, but whatever news is coming it must be good because the volume today is through the roof and its up quite a bit.
I think insiders know something we don't yet.
I am holding for now, I wonder what tomm. will bring. ???
Posted by STOCKMOVER on :
Just HIT .051!!!!!!
Posted by Superbee383 on :
Glad to see I'm not the only one holding.. obviously something is up! Oh and Jmichael.. thanks for that chart!!! Well, Quest always did say to buy and put it out of site till 2006!
Posted by kywee on :
just jumped in w/o a day trade.. hope it stays up
Posted by kywee on :
damn this thing is flying. must be good news
Posted by STOCKMOVER on :
I may have to sell (at least some). I was in the red too long. I will let you know what I decide.
Posted by STOCKMOVER on :
Everyone is getting in, we are approaching 21 million in volume!!!!
Congrats to everyone.
Posted by Superbee383 on :
I can't believe this volume! It is HUGE !!! Did you sell any Stockmover? I'm still holding all my shares. No doubt there'll be profit taking now, but I still believe it's heading north again tomorrow. It's amazing!
Posted by STOCKMOVER on :
I got greedy...lol, I did not sell....I just wonder how high it can go in short term because this was originally a long term hold, I was looking to free the funds so....I will wait until tomm and see, if it goes to .10, its sold.
Posted by STOCKMOVER on :
I would advise anyone to get in now while they are lower because its obvious that someone knows something and this is going to soar on the next PR. IMO.
Posted by STOCKMOVER on :
up 128%
Posted by kywee on :
what was the bid/ask at close? i see a close of .069 and a bid of .062 and an ask of .065. did they just go down because the mms left? thanks
Posted by OhhhYeah on :
I sold 1/2 my lot to make up for some other stocks.. I still have the other half though!
who pointed out this stock last week... This was a GREAT find!
Posted by EverGreen on :
as usual
quote:Originally posted by EverGreen: crazy trades - i tried a sell at .031 and gone in 5 sec
sure some short covering
btw - now that i sold it will fly!!!
Posted by blacklab669 on :
Somebody knows something you dont, expect news thursday.If you must sell get your original investment back and let the rest ride.Congrates to everyone!!!
Posted by j160e on :
Congrats everyone, great gains today!
Posted by TruthLiesWithin on :
Things really took off late yesterday..
looking for this news...
Posted by STOCKMOVER on :
It may gap this morning, may reach .10 around mid day, getting in around .06 would be decent. Nice $ to be made here.
Good Luck To All,
Posted by TruthLiesWithin on :
I saw a NOON push and a 3-4 oclock push.
Are people adding to their holdings or are new people jumping in?
Volume was half the O/S, probably 3/4 the float. I have a feeling this is going gangbusters today,,, I hate when someones knows something ahead of time, and I have to play guess.........
I did just see the ask drop to .056 Like usual, after the sell, the bigger run up happens... I will wait...
Posted by STOCKMOVER on :
I would wait, I am watching CLOSE, that .056 was someone who just noticed this morning. The ask is back to .062
It should soar today also.
Posted by pennnies on :
lol this one is a toss up without any news. Either it will stall or tank if it was a group run.
Posted by TruthLiesWithin on :
.07 real soon
Posted by TruthLiesWithin on :
Funny when you see those 056 bids suddenly start going up...
Especially when people are sitting on the ASK.
I'm assuming the chase is on.
Posted by pennnies on :
looks like I was wrong.. lol
Something is up for sure. Solid play!
Get in while you still can. Has to be news coming today or tomorrow!
Posted by STOCKMOVER on :
Yep .069 was last, should be flying by 11am.
Posted by TruthLiesWithin on :
.07 seconds away
Posted by pennnies on :
I was looking at the chart and when this thing runs it runs. One run went from .09 to .20 I do believe in a span of two days.
Could be good for us!
Posted by STOCKMOVER on :
Pennies,
People are just sitting on the ask, no budge, this has always been a quality stock, mostly for long term. I know of a lot of holders in on this.
Posted by TruthLiesWithin on :
Level 2 is crazy...
.08 is the next waiting point after a couple .075's
Gonna blast right to it...
The bids are constantly trying to catch up with the ask... seriously is this a chase?
Posted by gloomiath on :
Im in 22500 at .069
Gl to us!
Posted by STOCKMOVER on :
I picked up some more shares.
Posted by pennnies on :
quote:Originally posted by STOCKMOVER: Pennies,
People are just sitting on the ask, no budge, this has always been a quality stock, mostly for long term. I know of a lot of holders in on this.
I am starting to be a believer... lol The year chart looks like it is a long holder. Could be sitting back at .30 any month now.
Posted by STOCKMOVER on :
GET IN PEOPLE, THIS IS RUNNING, NOW!
Posted by pennnies on :
the thing that gets me peeing my pants is the O/S is only 49 million!
Take about a rocket in waiting of a easy 1000% gainer!
Posted by STOCKMOVER on :
Pennies,
What did you get in at?
Posted by pennnies on :
quote:Originally posted by STOCKMOVER: Pennies,
What did you get in at?
today at .066. I plan on holding until .2+
So many turd plays right now this looks like the best hold out of them all.
Posted by pennnies on :
shake shake shake...............
Posted by TruthLiesWithin on :
someone is screwing around...
Posted by STOCKMOVER on :
yeah, whats going on? I think the MM's are shaking shares out. No one would be selling this low.
Posted by kywee on :
quote:Originally posted by STOCKMOVER: yeah, whats going on? I think the MM's are shaking shares out. No one would be selling this low.
why not? they are up over 100%
Posted by STOCKMOVER on :
no they are not, the low today was .06
Posted by TruthLiesWithin on :
When things settle in, it will move up.
For a second, it looked like everyone was trying to out do each other with an ASK...
Posted by gloomiath on :
165,000 share block just shot this sucker up again
woohoo!
hope everyone held on tight!
Posted by kywee on :
yes. yesterdays open was below .03 and it closed at .069, thats more then 100% gain
Posted by TruthLiesWithin on :
Pretty funny aint it???
.071
Posted by gloomiath on :
I'm hearing the 200 day is .10
a break of that could be big!
just my opinion
Posted by pennnies on :
JUST HOLD ON STRONG CATS. SOMETHING BIG IS COMING.
Posted by TruthLiesWithin on :
If there were any news, imagine what would happen now..
Posted by gloomiath on :
how many shares is everyone holding?
22500 * .069
better late than never!
Posted by TruthLiesWithin on :
.09? did that really happen.
Posted by STOCKMOVER on :
Personally I am waiting for .10, this stock will reach .30 by the end of the year. I don't want to let any shares go, do the research on the company. Stemcells are a hot market right now.
Posted by STOCKMOVER on :
75000sh
25000 at .06
the rest I had since September.
I saw that .09 also
Posted by Superbee383 on :
I'm with you Stockmover!! Posted by gloomiath on :
GL To everyone. Seems to be some resistance here .07-.075
I'm holding tight
Posted by STOCKMOVER on :
Everyone should hold tight, we saw .08 easily and .09 actually once. I think we should see .10 around 2pm.
What do you guys think?
Posted by Superbee383 on :
Are you planning on selling at .10? I think I might still hold. I have 75k shs too, averaged at .0419.. and maybe if it hit .10.. I MAY sell half, but first we have to see if it even hits that today! LOL
Posted by STOCKMOVER on :
Usually, its good for a 2-3 day run. Today normally would reach higher than yesterday. I am waiting for .10
I was in this so long ago, its hard to decide but based on what the company is and does, its really worth .10.
Many people are playing it right now but if you can see the .08 block is large. There are 6 waiting for that.
Posted by pennnies on :
I am holding until we get news.
Posted by STOCKMOVER on :
I got out guys, I have to leave so I will not be here to watch the LII. Cannot wait for the .10
Good Luck To All,
Posted by j160e on :
I'm out for now. I've held shares for 2 months so a good profit said it's time to go. Good luck to all!
Posted by pennnies on :
Holdin up strong. Could be a slow riser for a few days or month.
Posted by Wall St. on :
There's a lot of benjamins to be made in those bio-techs.....you know what I'm talking about Greg.
[ January 26, 2006, 13:05: Message edited by: Wall St. ]
Posted by pennnies on :
IDK how long any of you have been trading, but when the MM's sit on the bid and eat shares. It means the price is going up. They have to make money on all those shares they are eating.
Posted by OhhhYeah on :
I sold 1/2 of my shares and I am running on free shares right now.. I think I will hold until the news comes out...What do they say??? Buy on rumor... sell on news :-)
Posted by Rbreb13 on :
quote:Originally posted by OhhhYeah: I sold 1/2 of my shares and I am running on free shares right now.. I think I will hold until the news comes out...What do they say??? Buy on rumor... sell on news :-)
Ditto on that. Took some profit and holding 13k shares of freebies for now.
Posted by blacklab669 on :
Third Day is a Charm for Green.Playing with mad money after a sell Friday *.09.We should hear something Friday.Iheard something on CNBC this morning about a cure for Diabetes using adult stemcells producing insulin.Imagine the clients around the world that would be donating and storing adult stemcells with us in the meda spas.They wouldnt be able to build the spas fast enough
Posted by OhhhYeah on :
Nice job pumping!
Posted by blacklab669 on :
5 years for approval on adult stemcell producing isulin.No more injections of insulin for diabetes.
Posted by pennnies on :
MA hasn't even crossed yet! Look at the potential ppl!
Posted by pennnies on :
this baby is on fire today!
Posted by OhhhYeah on :
CLBE moving up B/A 0.091/0.092
Posted by pennnies on :
if this can break 10 which I don't see why it wouldn't we should see huge gains then.
Once we break .10 its nothing but sky!!!
Posted by blacklab669 on :
70 Medaspas by the end of 2006 oh yea!!!Heres to .70
Posted by breadwinner on :
HAHA! Congrats to all that held. IMO, this still has MUCH room to grow. Company is in early stages of development in a sector that will be very profitable in the future. SHould only go one way from here.
Posted by pennnies on :
oh I think this is going to .30+ before we see another drop. Something major is in the works. MM's are eating shares and driving it higher.
Best part is only like 5 five of us from allstocks are in it; won't drop like a rock on any sells.
Most of thses cats on allstocks have no idea how to make money. It makes me sick to see stocks like this that can bring in a boat load and no one cares, but some turd they will pump a month for a 10% gain.
lol
[ January 28, 2006, 13:45: Message edited by: pennnies ]
Posted by KillaKmetz on :
I've gone over my watch lists here and I've decided this is Deff a stock I am going to get into this week. From looking over its history itv is way overdue for a PR. I've been making a lot of huge gains flipping PECB (they seem to get a nice PR every week, and it keeps heading up) and I have the feeling I will be able to play this much the same way.
Anyone know of any expected PR's?
OH, and this week I am going to get into KLGE again, probably back into some GZFX by the end of the week. I'll sell some of my PECB if we get another PR and I also will be loading up on CLBE here.
Any other opinions or suggestions?
Posted by ShadowLurker on :
I started watching CLBE last Monday and all it has done is go up. Have my funds locked up in other stocks but thinking about cutting my loses on them and try to make up for it on CLBE.
Do you think it is too late to get in on CLBE, should I wait for the sell off and the price comes down a bit.
I ALSO bought some KLGE last week. Got in at 1.58 Waiting for their sponsering of 'The Contender' on ESPN following the ProBowl. I would expect it should go up some more after that.
I too have PECB. Waiting for that $2.10 PPS
Posted by KillaKmetz on :
quote:Originally posted by ShadowLurker: I started watching CLBE last Monday and all it has done is go up. Have my funds locked up in other stocks but thinking about cutting my loses on them and try to make up for it on CLBE.
Do you think it is too late to get in on CLBE, should I wait for the sell off and the price comes down a bit.
I ALSO bought some KLGE last week. Got in at 1.58 Waiting for their sponsering of 'The Contender' on ESPN following the ProBowl. I would expect it should go up some more after that.
I too have PECB. Waiting for that $2.10 PPS
CLBE was in a very strong uptrend at the end of the week last week, so I do expect some profit taking on or about Monday or Tuesday. Of course the strong up trend could because someone knows something about an upcoming PR that we don't know about. I would say it would be safe to get in at or around $.087 - $.091 on CLBE. I get these numbers from this chart:
Forget the 'Support levels', they don't really apply on penny stocks. On penny stocks the number that you should look more closer at is the 'Pivot Point' (which is $.0863) as from my experience stocks tend to drop down to that level as people do some profit taking, then the next uptrend begeins.
Also, PECB is going to be a GREAT stock to play all year (IMO) as you can buy in when its low, and unload it shortly after their next nice PR. KLGE is in the same boat, but it is trading in the $1.50 - $2 range, so it is much less volatile, but it is an excellent stock, and we'll be able to make some money.
Glad to see someone else is following the same stocks I am, makes me feel like I am on the right track Posted by BuyTex on :
nice find, D (ya could always PM yer old palz... )
Posted by TruthLiesWithin on :
I got in at .029 awhile ago, and thought a double would be nice....it was just moving to quick to get rid of....
Did dump half at .07 only because the volume compared to what looked like a new round of investors, who were in it at around .05 or higher...
Thinking they might opt for a sell after 2 nice gains...
Right now it is tricky,,,,the stock looks like it wants to go gangbusters, and start climbing by 5's, let's see how the new people view this...
Posted by kairos on :
i'm in here also, since .029. Nice ride. sold some at .07 and then .093. have half my shares left. it will be interesting to see where this thing finally levels off. think it should be a great play all year as this is a solid company.
Posted by mizzou7 on :
Good call people... I missed it... GL2A...
Posted by gloomiath on :
still holding 25k from .069 gl to all
Posted by The Bigfoot on :
Shoot!
I thought I knew what I wanted to do this week but you guys are making me waver. I might have to put my plans off for a bit. I'll be watching what happens Monday.
The Bigfoot
Posted by KillaKmetz on :
I'd hold on this until it gets close to $.090's... and I doubt we will get that on Monday. I'm thinking Tuesday would be the day to jump onboard here, prolly right before noon'ish, it seems to be low around then every day.
I just hope we don't get a PR before then, I am looking to get onboard myself, and if a PR comes out before when I plan on getting in (Tuesday morning) I am out of luck. So is life.
Posted by pennnies on :
well we closed at .097. I look for a open at .10 and then a dip. Then back up. Everyday this dips hard and then goes right back up to the HOD.
Don't get fooled when you see this drop. It comes back before you can even get back in!
Posted by TruthLiesWithin on :
Wasn't there supposed to be some news or something?
The volume didn't just happen for no reason.
Posted by The Bigfoot on :
That's why I'm seriously looking at it. Volume like this doesn't just happen even with a group play.
Could be someone knows something and is stocking up.
The large dips make me believe that the MM's are making the same bet and stocking up themselves.
I don't know, but could be a big deal.
Could also have already played itself out and will fizzle so look before you leap.
The Bigfoot
Posted by blacklab669 on :
CLBE will be trading in a different section after today.Stocks above .10 on this board.
Posted by TruthLiesWithin on :
Wow Optimism.
Quick, make a section for stocks over $10 Posted by STOCKMOVER on :
I would like to extend my experience with CLBE for others.
Back on 10/3/05 the stock had a low of .015
It started to run for a few days, I got in at .08 on 10/10/05, there was a high of .10 during this run. Immediately after that it went down to around .03 over the next few months. I averaged down and sold during this last run, last Thursday-Friday.
Posted by pennnies on :
this run tried to drop, but the MM's held up meaning something is in the works and this isn't a pump and dump!!!
Posted by STOCKMOVER on :
pennies,
I cannot recall exactly what was going on at the last time I bought, in October, I really joined based on quick DD, only mistake was that I bought in during the last day of a run.
Its still a extremely nice stock that I believe will reach .30 by the end of the year.
Posted by trader_adam on :
profit taking
Posted by BULListic on :
3,423,000 share buy at .094, they jumped the b/a up a whole .015 on that one trade, then dropped the bid back to .08 and left the ask at .094. Will be interesting to see where this goes from here.
Posted by pennnies on :
yeah I think something big might be up...... lol
that was one big ass buy!!!!!!
Posted by pennnies on :
hold on!!!!!!!!!!!!!!!!!!!!!!!! lets explode baby!!!
Posted by pennnies on :
lol this is crazy!!!!!!!!!!!!!!!!!!!!! PR the news already!!!!! lol
Posted by pennnies on :
If your on the fence jump in!!!
Lets run for a 100% day baby!!!!!!!!
Posted by pennnies on :
should see a nice afternoon rebound with a dip then run til close. Usually is what it does.
Posted by pennnies on :
have you guys realized this is the real deal yet??????????????????????????
lol
Posted by pennnies on :
EOD run coming. Should blow by the 12's....
Posted by daveinSD on :
I hope so
Posted by pennnies on :
Big news coming out tomorrow!!!!!!!!!!
Posted by daveinSD on :
pennies, how do you know or is that just a speculation?
Posted by pennnies on :
call investor relations!
Posted by pennnies on :
upticking!!!!!!!!
Posted by pennnies on :
Going to be a great day!!!
Muhahahahaha!!!!!!!
Posted by nattty04 on :
Im stuck in MOTG currently, wish i could play with you guys. Those L2's are going to be crazy if it can push past .12, should be an interesting day.
Posted by nattty04 on :
Holy Crap, 200,000 buy. Woo thats 20K
Posted by pennnies on :
there was a 3.5 million share buy yesturday!
Posted by STOCKMOVER on :
Nice entry spot for some, .085 as of now. Maybe the low of the day?
Posted by pennnies on :
Hopin' for some news or we will see lower. Can't hold this run forver.
Posted by KillaKmetz on :
quote:Originally posted by KillaKmetz: I'd hold on this until it gets close to $.090's... and I doubt we will get that on Monday. I'm thinking Tuesday would be the day to jump onboard here, prolly right before noon'ish, it seems to be low around then every day.
I just hope we don't get a PR before then, I am looking to get onboard myself, and if a PR comes out before when I plan on getting in (Tuesday morning) I am out of luck. So is life.
OK, it is Tuesday morning, and it is trading at $.088... looks like a GREAT time to get in to me Posted by daveinSD on :
I just got an email from Paul...he knows nothing of a PR today.
Posted by OhhhYeah on :
is anyone watching this????
Posted by OhhhYeah on :
volume has doubled in past 20 minutes with mostly buys...
Posted by Wall St. on :
I'm watching and I'm liking what I see
Posted by daveinSD on :
.115
Posted by daveinSD on :
something is definitely going on. This ones been running for over a week now
Posted by BULListic on :
700k at .13 printed....
Posted by OverDose on :
No PR and the price continues to rise...I can't figure this one out. Any ideas here?
Posted by STOCKMOVER on :
This is really strange, I wonder how high it can go?
Posted by Rbreb13 on :
quote:Originally posted by STOCKMOVER: This is really strange, I wonder how high it can go?
To da moon!
No, seriously though. My original target was .14-.15 but that was WITH news. With no news I may ride this for a lot longer. I'm riding free shares right now anyways.
Posted by Wall St. on :
Just my opinion, but I think that CLBE is undervalued and it is heading back up to where it should be. My target is back to the 25-30 cent range within the next couple of months. Do your own DD and look at all that Calbatech has going for it. Posted by OverDose on :
I got in this at .0235 and sold at .069..oops! I've been waiting it out thinking with no news the pps would drop and I would add then but it's not dropping??
I reloaded today and made more than I did in the last two months holding it.
Something is going on here...wish I new. LOL
Posted by OhhhYeah on :
Same Here.. I got in at .0224 and then sold at .087.. You cant really think about those what ifs... just like when you are playing poker and you fold a 2-3... the flop comes out and it is a 2-2-3.
Doesnt mean you should always play a 2-3. I see having a penny stock is like holding a 2-3 :-)
Should never complain with a profit!
Posted by Lucas Brachish on :
I got in at an average of .038 many moons ago (started at a higher average) and, after seeing it drop and hover for so long, I put up a big GTC sell order to unload it at .036 -- Of course, now I'm not a happy camper, since the .036 sell order got snapped up as CLBE started it's big run while I wasn't paying attention.... I shouldn't have given up on this boy! Goes to show that it's often worth it to be very patient with these pennies. Luckily I still had some CLBE left over, which I sold for a nice profit at around .078. I still don't see this breaking .1 anywhere in the short term, and it'll likely go down again, so buying in above .06 is a bit risky IMHO. However, it's nice to see this stock alive and kicking again.
It's interesting that PMED always seems to follow CLBE's trend, and vice-versa..... Are the companies connected in some way?
Posted by OhhhYeah on :
Have you not looked at the stock today??? It closed at .14 LOL... dont see it breaking .1.....that is some funny ****!
Posted by UnknownTrader on :
IMO...
CLBE's EOD price tomorrow will definitely be higher than today's EOD price and most like the next's EOD will even be higher.
The analysis shows a pretty good gap between the two lines....it's clearly in an uptrend, I see no signal for a downtrend yet (probably will have a better feel tomorrow).
Just my opinion....
Posted by KillaKmetz on :
I wish I would have been able to get in today. It hit the high $.080's just as I guessed it would. I put all my money into MMSV though, and I lucked out, It was up 76% today.
It IPO'd today, I got in at $1.80 and it closed at $2.65... The best thing is nobody knows about it yet, but they will find out about it in the next couple of days, and so the next few days will be green.
I wouldn't be shocked to see it double. If you are interested, I have started a thread on the 'Hot Stocks for All' Board for MMSV. I am hoping for a sell off on MMSV by Friday, then I will be looking to get back into PECB and CLBE.
Posted by DALE 302 on :
Does anybody have any ideas what this will do today
Posted by Wall St. on :
My guess is that it will go back up in the late afternoon. I am trying to get some more shares at or below 10 cents. Should be interesting to see what it does this afternoon.
Posted by DALE 302 on :
I gave up on it, I'm riding on freebies now, I just got 75k of MSSI
Posted by smoke420247 on :
Yes sir, 200dma support at .10 it ain't going below that. Intraday MACD poised for a bullish cross coming up. And that buying volume yesterday afternoon, trumped the previous 2 day buying volume.
Posted by MDP5754 on :
My crystal ball says "2:20est will begin the buying frenzy and close at .13...." GLTA
Posted by Wall St. on :
Mine says 2:41 cst
Posted by Lucas Brachish on :
quote:Originally posted by OhhhYeah: Have you not looked at the stock today??? It closed at .14 LOL... dont see it breaking .1.....that is some funny ****!
Did you actually sell any at .14? When ordinary traders are selling at those prices, then I'll stand corrected, but some one-off price spikes don't hold water in my book. A couple of suckers getting tricked into buying too high. Look for the true, average sell price or you'll just get disappointed in the end.
It's a great time to sell this stock right now but a very dangerous time to buy. There could be big news coming, but it's just as likely that this is a group play or MM manipulation, and things will likely not look so good a month from now. This stock has always had good potential to skyrocket... but the current run seems a bit odd to me.
Posted by MDP5754 on :
I hope yours is more accurate.
Posted by Lucas Brachish on :
Don't get me wrong -- I think the ceiling for CLBE is quite high. My original sell-point hope was to unload CLBE at around .21 or more, and .4 isn't out of the question in the future. But after the last run we saw this drop and stagger for quite a while... reaching lows of .024, etc..... And since those lows, nothing really incredible or substantial has happened that would justify the current run. So although a few lucky individuals might be able to flip this quickly and make some bucks, I'd predict that most of the people that buy in now and/or don't sell soon will likely get stuck holding the bag for a (relatively) long time -- Unless we get better info about why more faith should be put in this stock or the current PPS highs.
Long term this could still be a very good play, but in the short term I'd be very cautious about buying based on a run that may be sparked by manipulation and where the highs of the day aren't available to the average seller. And there's a good chance that there will be more opportunities to buy low in the near future, so be careful before jumping in, and be realistic about your sell-point.
Posted by ckeadle on :
does anyone know the current OS?
Posted by ckeadle on :
is anyone watching this one today?
I will be playing the bounce off these levels...
Posted by KillaKmetz on :
49,943,000 Shares Outstanding.
Posted by MDP5754 on :
ARCA is the one to watch here. Yesterday he was gobbleing up shares in the .10's and today he has been parked with 200 on the bid around .085. Nobody is giving up many shares though. We have plenty of support at .085 and hopefully we can close around .094. We need news or some more big $$ buys to keep us afloat here.
Posted by ckeadle on :
MDP you are right, I am assuming all the big buys are investors and not traders. with that assumption and only 49MM OS. shares are going to get a little tight. that is good news for longs. I do think we need some news though....
Posted by MDP5754 on :
I'm surprised to see it in the 7's but it is Friday and we have gone a week since the boom with no pr. The sells are still small. A few buys puts us right back in the green and if we get another volume push we should move up quickly. I'm holding - something is up.
Posted by MDP5754 on :
I'm surprised to see it in the 7's but it is Friday and we have gone a week since the boom with no pr. The sells are still small. A few buys puts us right back in the green and if we get another volume push we should move up quickly. I'm holding - something is up.
Posted by P_R_Rice on :
ARCA is sitting it's fat butt on the sell at .083
Posted by ckeadle on :
I am holding as well, you don't make 330k investments(ie the 3.3MM share buy a couple days ago) without knowing something is going on. there has been a lot of money put into this lately.
we should bounce off 7.5 pretty well. ARCA has been all over the place this morning
Posted by ckeadle on :
just bounced back from 7.5 to 8.3 nice little flip there...
Posted by P_R_Rice on :
arca is off the sell at .083...they had a big block sitting there
Posted by MDP5754 on :
We have some volume here. ARCA is definitely the one to watch. I agree that big money is in this play for a good reason.
Posted by ckeadle on :
a few weird trades that don't fall into the top bid ask... I saw these before the last run up. not actually sure if it means anything....
Posted by P_R_Rice on :
I agree... watch arca... the way it sits right now, this can take off with a volume surge, but that can change ofcourse
Posted by MDP5754 on :
ckeadle - recognize you from HSM. The server issue is driving me nuts. Go CLBE.
Posted by ckeadle on :
Yeah the server issue is driving me nuts as well... how hard can it be to fix?
This has been a pretty interesting run for CLBE. normally I would be pretty skeptical but the amount of money flowing into it is very promising. the buys are not small money buys but very big buys at the ask. traders would average in over time but these are just huge buys at any level. there is something going on...
Posted by MDP5754 on :
Strange trades going on - 1,000, 600, 1,100 - whats up with that?
Posted by ckeadle on :
hit has been small trades like that on the down tick and big blocks on the up ticks....
Posted by P_R_Rice on :
i'm not sure what to think... that's a big spread and no one seems to be budging really
Posted by MDP5754 on :
I agree. People are comfortable with .08 - .085 right now but not quite ready to jump on the 9's. People tend to be cautious buyers on Friday.
Posted by ckeadle on :
I wouldn't be surprised if we saw a eod run...
Posted by ckeadle on :
has been bouncing off 7.5.... watch for the eod run,
Posted by P_R_Rice on :
it could happen if arca moves it's fat butt off the ask
Posted by ckeadle on :
they will move... it should close at the .09 wall .... doubt it can break that on a friday unless it is really thin
Posted by ckeadle on :
i want it to drop down to .0765 before it runs though ... i have been sitting there since this morning and still haven't been filled... I just saw a trade go at .076 too... arghhh
Posted by P_R_Rice on :
i agree.. i see it hitting that .09 wall
Posted by ckeadle on :
pretty boring right now... but that is better than a big down day... ARCA should move off the bid around 12:45 Pacific time
Posted by ckeadle on :
buying opportunity at these levels... we should see a run again at the end of this week or early next week. This one is just breathing a bit. Remember it was up form .02 to .14 in a little over a week.
Posted by ckeadle on :
![[Frown]](frown.gif)
![[Big Grin]](biggrin.gif)
![[Smile]](smile.gif)
![[Confused]](confused.gif)
![[Wink]](wink.gif)
![[Mad]](mad.gif)
![[Razz]](tongue.gif)
![[Eek!]](eek.gif)
)....ARCA is at 150 on size....still looking for what that means....does that mean we'll be here for awhile at .034 because of him?
![[Roll Eyes]](rolleyes.gif)
